Validating MSC Identity by Flow Cytometry: A Practical Guide to ISCT Criteria and Beyond

Abstract

This article provides a comprehensive guide for researchers and drug development professionals on validating Mesenchymal Stromal Cell (MSC) identity using flow cytometry in accordance with International Society for Cell & Gene Therapy (ISCT) criteria. It covers the evolution of MSC definitions from the 2006 minimal criteria to the latest 2025 standards, which emphasize precise quantification and functional potency. The content delivers detailed methodological protocols for flow cytometry panel design and assay validation, addresses common troubleshooting scenarios, and explores advanced strategies for linking phenotypic data to therapeutic efficacy. This resource is designed to support robust MSC characterization for reproducible research and successful clinical translation.

Understanding MSC Identity: From Historical Definitions to Modern ISCT Standards

The field of regenerative medicine has witnessed a significant evolution in the understanding and classification of Mesenchymal Stem Cells (MSCs), reflecting a maturation of scientific knowledge and clinical applications. What began as a simple designation for bone marrow-derived adherent cells has transformed into a complex narrative of biological discovery and nomenclature refinement. This evolution from "stem" to "stromal" to "medicinal signaling" cells represents more than mere semantic adjustment—it signifies a fundamental shift in how the scientific community conceptualizes the primary mechanisms and therapeutic applications of these versatile cells. As the International Society for Cell & Gene Therapy (ISCT) has progressively refined its position statements, the criteria for defining and validating MSC identity have become increasingly sophisticated, moving beyond morphological characteristics toward functional immunomodulatory properties and mechanism-based therapeutic classifications. This guide examines the historical progression, current standards, and practical methodologies for MSC identification within the broader thesis of validating MSC identity through ISCT criteria, providing researchers and drug development professionals with essential frameworks for navigating this evolving landscape.

The Historical Trajectory of MSC Nomenclature

The journey of MSC nomenclature begins with foundational discoveries in the 1960s and 1970s by Soviet scientist A.J. Friedenstein and his team, who first identified adherent, colony-forming fibroblast-like cells in bone marrow with osteogenic potential [1]. These cells were initially termed "colony-forming unit fibroblasts" (CFU-Fs), reflecting their observed behavior in culture rather than any presumed developmental capacity [2]. Throughout the 1980s, these cells were variously referenced as "stromal stem cells" or "osteogenic stem cells," emphasizing their residence in bone marrow stroma and their differentiation potential [1].

A pivotal moment arrived in 1991 when Dr. Arnold Caplan at Case Western Reserve University coined the term "mesenchymal stem cells," highlighting their perceived self-renewal and multilineage differentiation capabilities [3] [2] [1]. This terminology gained rapid and widespread adoption throughout the 1990s and early 2000s as research into their multipotency expanded. The term "mesenchymal" itself references the embryonic mesenchyme from which these cells were thought to originate, though this has been subsequently debated [3].

By 2005, the scientific community recognized the need for standardization as research expanded and clinical applications emerged. The International Society for Cellular Therapy (ISCT) responded in 2006 by establishing minimal criteria for defining MSCs, which included plastic adherence, specific surface marker expression (CD73, CD90, CD105), and trilineage differentiation potential (osteogenic, adipogenic, and chondrogenic) in vitro [2] [4]. Despite this standardization, the ISCT deliberately referred to them as "multipotent mesenchymal stromal cells" while acknowledging the common usage of "mesenchymal stem cells" [2].

The most recent nomenclature evolution reflects a deeper understanding of MSC mechanisms. Dr. Caplan himself later proposed the term "medicinal signaling cells" to emphasize their therapeutic actions through paracrine factors rather than differentiation [1]. Concurrently, accumulating evidence demonstrated that MSCs exert their therapeutic effects predominantly through immunomodulatory and trophic mechanisms rather than lineage-driven regeneration [5]. This biological understanding prompted the ISCT in 2019 to officially recommend "mesenchymal stromal cells" as the preferred terminology [5], with further refinements in 2025 emphasizing immunomodulatory criteria and mechanism-aligned potency assays [5] [6].

Table 1: Historical Evolution of MSC Nomenclature

Time Period	Predominant Terminology	Key Defining Characteristics	Major Proponents/Events
1960s-1970s	Colony-Forming Unit Fibroblasts (CFU-F)	Adherent cells with osteogenic potential	Friedenstein and colleagues
1980s	Stromal Stem Cells/Osteogenic Stem Cells	Residence in stromal compartments	Owen and colleagues
1991	Mesenchymal Stem Cells	Self-renewal and multilineage differentiation	Arnold Caplan
2006	Multipotent Mesenchymal Stromal Cells	Plastic adherence, marker expression, trilineage differentiation	ISCT Standardization
2019-Present	Mesenchymal Stromal Cells/Medicinal Signaling Cells	Immunomodulatory properties and paracrine effects	ISCT and Arnold Caplan

Comparative Analysis of MSC Identification Standards

ISCT 2006 vs. 2025 Standards: A Paradigm Shift

The evolution of MSC nomenclature is concretely reflected in the changing identification standards established by the ISCT. The 2006 criteria represented a foundational framework that enabled consistency across laboratories and studies worldwide [4]. These standards focused primarily on in vitro characteristics that could be readily assessed in most research settings: plastic adherence, specific surface marker profiles, and trilineage differentiation potential [4].

The updated 2025 standards reflect a more nuanced understanding of MSC biology and therapeutic function [6]. The most striking change is the formal definition of MSCs as "mesenchymal stromal cells" instead of "mesenchymal stem cells," requiring researchers who wish to use the "stem" terminology to provide experimental evidence of genuine stem cell properties [6]. This shift acknowledges that the traditional "stemness" assays cannot reliably distinguish true stem cells from more specialized stromal cell populations.

The 2025 standards also introduce significant modifications to identification criteria. While CD73, CD90, and CD105 remain as basic positive markers, the new standards require quantitative reporting with specific thresholds via flow cytometry rather than qualitative assessment [6]. Similarly, negative markers (particularly CD45 as a hematopoietic marker) must be included with complete results reporting for each marker, including percentages of positive cells [6]. This enhanced transparency facilitates better comparability across studies and products.

Perhaps the most significant advancement in the 2025 standards is the incorporation of efficacy and functional characterization into Critical Quality Attributes (CQAs) [6]. This shift emphasizes that MSC products must not only meet phenotypic standards but also demonstrate expected therapeutic functionality, particularly immunomodulatory capacity for relevant clinical applications [5]. The standards also mandate detailed reporting of tissue origin and culture conditions, acknowledging that cells from different sources may have distinct phenotypic and functional properties [6].

Table 2: Comparison of ISCT 2006 and 2025 MSC Identification Standards

Standard Element	ISCT 2006 Standard	ISCT 2025 Standard	Significance of Change
Cell Definition	Mesenchymal Stem Cells (MSCs)	Mesenchymal Stromal Cells (MSCs)	Aligns terminology with predominant therapeutic mechanism
Stemness Requirement	Must demonstrate trilineage differentiation	Must provide evidence to use term "stem"	Reflects understanding that differentiation potential ≠ stemness
Marker Detection	Qualitative (positive/negative)	Quantitative (thresholds and percentages)	Enhances reproducibility and comparability
Tissue Origin	Not emphasized	Must be specified and considered	Acknowledges functional differences between sources
Critical Quality Attributes	Not required	Must assess efficacy and functional properties	Links product characterization to clinical mechanism
Culture Conditions	No standard reporting requirement	Detailed parameter reporting required	Recognizes impact of culture on cell function

Mechanism-Based Reclassification: MSC-Based Immunomodulatory Therapies

Recent regulatory approvals and maturing clinical evidence have catalyzed a movement toward mechanism-aligned terminology. The approved clinical applications for MSCs, including remestemcel-L for pediatric acute graft-versus-host disease (aGVHD) in the U.S. and Amimestrocel for steroid-refractory aGVHD in China, demonstrate therapeutic effects primarily through immunomodulation rather than lineage-driven regeneration [5].

This understanding has led to proposals for framing these interventions as "MSC-based immunomodulatory therapies" to improve scientific clarity, align clinical endpoints and potency assays with the mechanism of action, facilitate regulatory communication, and mitigate public misunderstanding tied to the legacy "stem cell" label [5]. This mechanism-based classification better reflects the biological reality that MSCs act predominantly as immune modulators in vivo through paracrine factors and extracellular vesicles that suppress effector T-cell activation, expand regulatory T cells, downregulate proinflammatory cytokines, and reprogram myeloid cells toward inflammation-resolving phenotypes [5].

The mechanism-based nomenclature also addresses important ethical and communication challenges. The persistence of the generic "stem cell" label has been susceptible to misuse by unregulated providers and fosters regeneration-centric expectations that may not align with the primary mechanisms of action [5]. Adopting more precise terminology serves as a corrective measure that improves informed consent and reduces ambiguity in public discourse while maintaining scientific accuracy.

Experimental Protocols for MSC Characterization

Flow Cytometry Analysis for MSC Validation

Flow cytometry remains the gold standard for validating MSC surface marker expression according to ISCT criteria. The following protocol provides a comprehensive methodology for MSC immunophenotyping:

Sample Preparation: Harvest MSCs at passage 3-5 using standard dissociation reagents (e.g., trypsin-EDTA or enzyme-free cell dissociation buffers). Wash cells twice with phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) to create a single-cell suspension. Adjust cell concentration to 1×10^7 cells/mL in flow cytometry staining buffer [4] [1].

Antibody Staining: Aliquot 100 μL of cell suspension (1×10^6 cells) into separate tubes for each marker. Add fluorochrome-conjugated antibodies according to manufacturer recommendations, typically 5-20 μL per test. Essential antibody panels must include:

• Positive markers: CD73, CD90, CD105
• Negative markers: CD45, CD34, CD11b or CD14, CD19, and HLA-DR
• Appropriate isotype controls for each antibody

Incubate stained samples for 30 minutes at 4°C in the dark. Wash cells twice with staining buffer to remove unbound antibody, then resuspend in 300-500 μL of staining buffer for analysis [4].

Data Acquisition and Analysis: Acquire data using a flow cytometer calibrated with appropriate compensation controls. Collect a minimum of 10,000 events per sample. Analyze data using flow cytometry software, establishing positive populations based on isotype control staining (typically >95% for positive markers and <2% for negative markers according to 2006 standards) [4]. The 2025 standards require reporting specific percentage positive values and the fluorescence thresholds used for determination [6].

Functional Characterization: Beyond Surface Markers

Modern MSC characterization requires functional assessment aligned with proposed mechanisms of action. The following protocols address key functional attributes:

Immunomodulatory Potency Assays: A standardized mixed lymphocyte reaction (MLR) provides a robust assessment of MSC immunomodulatory capacity [1]. Is peripheral blood mononuclear cells (PBMCs) from at least three healthy donors. Label responder PBMCs with cell division tracking dyes (e.g., CFSE). Co-culture labeled responders with irradiated stimulator PBMCs at a 1:1 ratio in the presence or absence of test MSCs at varying ratios (typically 1:10 to 1:100 MSC:PBMC). After 5-7 days, analyze T-cell proliferation by flow cytometry using CFSE dilution and measure cytokine profiles (IFN-γ, TNF-α, IL-10) in supernatants via ELISA [5].

Trilineage Differentiation Potential: While de-emphasized in the 2025 standards, trilineage differentiation remains useful for characterizing multipotency [6].

• Osteogenic Differentiation: Culture MSCs in specific induction media containing dexamethasone, ascorbate-2-phosphate, and β-glycerophosphate for 2-3 weeks. Assess mineralization via Alizarin Red S staining.
• Adipogenic Differentiation: Use induction media with dexamethasone, indomethacin, and insulin for 2-3 weeks. Visualize lipid vacuoles with Oil Red O staining.
• Chondrogenic Differentiation: Pellet culture in media with TGF-β3 for 3-4 weeks. Evaluate proteoglycan deposition with Alcian Blue or Safranin O staining.

Paracrine Factor Secretion Profiling: Quantify MSC secretome by analyzing conditioned media collections via multiplex ELISA or Luminex assays. Key factors include PGE2, IDO, IL-6, HGF, and TGF-β, which mediate immunomodulatory and trophic effects [5] [3].

Visualizing MSC Characterization Workflows

MSC Characterization Workflow

MSC Characterization Workflow: This diagram outlines the comprehensive process for validating mesenchymal stromal cell identity and function according to modern ISCT standards, highlighting essential steps from isolation through quality control.

MSC Immunomodulatory Mechanism

MSC Immunomodulatory Mechanism: This visualization depicts how activated MSCs secrete key immunomodulatory factors that alter immune cell function, ultimately creating an anti-inflammatory environment conducive to tissue repair.

The Scientist's Toolkit: Essential Reagents for MSC Research

Table 3: Essential Research Reagents for MSC Characterization

Reagent Category	Specific Examples	Research Function	Application Notes
Surface Marker Antibodies	Anti-CD73, CD90, CD105, CD45, CD34, HLA-DR	Flow cytometry immunophenotyping	Fluorochrome-conjugated; required for ISCT standards
Dissociation Reagents	Trypsin-EDTA, enzyme-free cell dissociation buffers	Cell harvesting and passaging	Enzyme-free preferred for surface marker preservation
Culture Media	DMEM/F12, α-MEM, MSC-qualified FBS, platelet lysate	Cell expansion and maintenance	Serum-free formulations available for clinical applications
Differentiation Kits	Osteogenic, adipogenic, chondrogenic induction media	Multilineage differentiation assessment	Quality control for differentiation potential
Cytokine Detection	IFN-γ, TNF-α, IL-10 ELISA kits, multiplex arrays	Secretome and functional analysis	Critical for immunomodulatory potency assessment
Flow Cytometry Supplies	Flow cytometry staining buffer, compensation beads	Instrument calibration and sample preparation	Essential for quantitative marker expression
Cell Viability Assays	7-AAD, propidium iodide, calcein AM	Viability and cytotoxicity assessment	Quality control for cell products

The evolution of MSC nomenclature from "stem" to "stromal" to potentially "medicinal signaling" cells represents the scientific community's progressing understanding of these cells' fundamental biology and therapeutic mechanisms. This terminological shift is not merely semantic but reflects a fundamental maturation of the field that aligns characterization standards with biological function and clinical application. The updated ISCT 2025 standards provide a robust framework for validating MSC identity through quantitative surface marker analysis, tissue origin specification, and functional potency assays centered on immunomodulatory capacity.

For researchers and drug development professionals, these developments underscore the importance of mechanism-aligned characterization approaches that prioritize therapeutic functionality alongside traditional phenotypic markers. The adoption of precise, mechanism-based terminology such as "MSC-based immunomodulatory therapies" enhances scientific clarity, facilitates appropriate regulatory evaluation, and supports accurate communication of therapeutic expectations. As the field continues to advance, maintaining this alignment between nomenclature, characterization standards, and biological mechanism will be essential for the responsible development and clinical translation of MSC-based therapies that fulfill their potential in regenerative medicine and immunomodulation.

In the early 2000s, the field of mesenchymal stem cell (MSC) research was burgeoning with potential but plagued by a critical problem: a lack of consensus. Investigators were using different methods for isolation, expansion, and characterization, making it nearly impossible to compare and contrast study outcomes across laboratories [7]. This heterogeneity hindered scientific progress and clinical translation. In 2006, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) addressed this challenge by proposing a set of minimal criteria to define human MSCs [7]. This position statement, which has since been cited thousands of times, established a foundational baseline that brought much-needed standardization to the field [8]. This guide provides a detailed comparison of these criteria, their implementation, and their evolution, providing researchers with the experimental context needed to navigate MSC characterization.

The Three Pillars of MSC Identity

The ISCT criteria established three mandatory properties that a cell population must possess to be defined as an MSC.

• 1. Plastic Adherence: The cells must be adherent to plastic when maintained in standard culture conditions. This functional characteristic is typically the first step in isolating MSCs from a heterogeneous cell mixture [9] [10].
• 2. Specific Surface Marker Expression: The cell population must express a defined set of surface antigens, as measured by techniques like flow cytometry.
• 3. Multipotent Differentiation Potential: The cells must possess the functional capacity to differentiate into osteoblasts, adipocytes, and chondroblasts under standard in vitro inducing conditions [7] [10].

Core Marker Profile: A Quantitative Breakdown

The flow cytometric analysis of surface markers is the most precise of the three criteria. The ISCT standard provides clear quantitative thresholds for positive and negative marker expression.

Positive Marker Requirements

The following table details the markers that must be present on ≥95% of the MSC population [9] [10]:

Marker	Common Name	Biological Role / Significance
CD105	Endoglin	Part of the TGF-β receptor complex; role in angiogenesis and cardiovascular development.
CD73	Ecto-5'-nucleotidase	Surface enzyme that catalyzes the conversion of AMP to adenosine; involved in purine metabolism and immunomodulation.
CD90	Thy-1	A glycophosphatidylinositol (GPI)-anchored protein involved in cell-cell and cell-matrix interactions.

Negative Marker Requirements

The following table details the markers that must be absent from ≤2% of the MSC population. These are primarily hematopoietic lineage markers used to exclude contaminating cells [9] [10] [11]:

Marker	Cell Type Excluded
CD45	Pan-leukocyte marker (all hematopoietic cells)
CD34	Primitive hematopoietic progenitors and endothelial cells
CD14 (or CD11b)	Monocytes and macrophages
CD19 (or CD79α)	B cells
HLA-DR	HLA Class II; antigen-presenting cells (Note: Can be expressed on MSCs under cytokine stimulation)

Experimental Protocols for Validation

Flow Cytometry for Marker Expression

Validating MSC identity according to ISCT criteria requires a robust flow cytometry protocol.

Detailed Methodology:

• Cell Preparation: Harvest MSCs at the appropriate passage (typically between passage 2-5 for human bone marrow-derived MSCs) using a standard dissociation reagent like trypsin/EDTA [12]. Wash cells with a phosphate-buffered saline (PBS) solution.
• Staining: Aliquot cells into tubes (approximately 1-5 x 10^5 cells per tube). Incubate with fluorochrome-conjugated antibodies against the positive (CD105, CD73, CD90) and negative (CD45, CD34, CD14, CD19, HLA-DR) markers. Include isotype control antibodies to set negative populations and fluorescence compensation controls for multicolor panels [10].
• Analysis: Analyze stained cells on a flow cytometer. The instrument should be calibrated using standard beads. Collect a minimum of 10,000 events per sample. The population of interest is gated based on forward and side scatter to exclude debris and dead cells [13].
• Interpretation: The MSC population is considered positive for a marker if ≥95% of gated cells show fluorescence above the isotype control for CD105, CD73, and CD90. Conversely, the population is considered negative if ≤2% of gated cells show fluorescence above the isotype control for the hematopoietic and HLA-DR markers [7] [10].

Trilineage Differentiation Assay

The functional validation of multipotency is a cornerstone of the ISCT criteria.

Detailed Methodology:

• Cell Seeding: Plate MSCs at a defined density (e.g., 8,000-20,000 cells per well in a tissue culture slide or multi-well plate) in standard growth medium and allow them to adhere [12].
• Induction: After 24-48 hours, replace the standard medium with specific differentiation media. Maintain control cells in standard growth medium.
  • Adipogenic Differentiation: Use medium supplemented with 1 mM dexamethasone, 5 μl/ml insulin, and 1 μl/ml 3-isobutyl-1-methylxanthine [12] or similar inductors like indomethacin. Differentiated adipocytes will display intracellular lipid vesicles.
  • Osteogenic Differentiation: Use medium supplemented with 100 μM dexamethasone, 0.1 mM ascorbic acid, and 10 nM β-glycerophosphate [12]. Differentiated osteoblasts will deposit mineralized matrix.
  • Chondrogenic Differentiation: This is often performed in a pellet culture system to promote cell condensation. Use medium supplemented with 100 μM dexamethasone and 0.01 μg/ml transforming growth factor-β1 (TGF-β1) [12]. Differentiated chondrocytes will produce a cartilaginous matrix rich in proteoglycans.
• Maintenance: Culture cells for 14-21 days, replacing the differentiation medium every 3-4 days.
• Staining and Detection: After the differentiation period, fix cells and use specific histological stains to confirm differentiation:
  • Adipocytes: Stain with Oil Red O to visualize lipid vacuoles [12] [10].
  • Osteoblasts: Stain with Alizarin Red S to detect calcium deposits [12] [10].
  • Chondrocytes: Stain with Toluidine Blue or Alcian Blue to detect sulfated and acidic proteoglycans in the extracellular matrix [12] [10].

Comparison with Evolving Standards

While the 2006 criteria remain the foundational baseline, the field has recognized the need for more nuanced characterization, especially for clinical applications. The following table compares the classical criteria with modern perspectives.

Feature	ISCT 2006 Minimal Criteria (Foundational Baseline)	Evolving / Advanced Considerations
Primary Purpose	Define basic MSC identity for research consistency [7].	Predict therapeutic potency and ensure batch-to-batch quality for clinical use [13] [12].
Marker Specificity	General panel for all tissue sources.	Recognition of potential marker variability by tissue source (e.g., CD34 expression in fresh adipose-derived MSCs) [9] [14].
Functional Assays	Trilineage differentiation (multipotency).	Potency assays: e.g., Immunosuppressive function via Mixed Lymphocyte Reaction (MLR) to simulate GvHD pathology [13] [15].
Nomenclature	Uses "multipotent mesenchymal stromal cells" [7].	Clarification on "Mesenchymal Stromal Cells" vs. "Mesenchymal Stem Cells"; suggestion for tissue-source abbreviations (e.g., MSC(M) for bone marrow) [9] [8].
Scope	Defines the cell population.	Provides guidelines for entire biobanking process (collection, isolation, cryopreservation) as per ISO standards [8].

A key development is the use of potency assays. For MSCs used in immunomodulatory therapies, a validated Mixed Lymphocyte Reaction (MLR) is now often required. In this assay, MSCs are co-cultured with stimulated peripheral blood mononuclear cells (PBMCs). The specific inhibition of T-cell proliferation, tracked using a dye like VPD450 and flow cytometry, serves as a quantitative measure of immunosuppressive potency [13]. Furthermore, it is now understood that the immunological function of MSCs is not static; it can be enhanced by "licensing" the cells with inflammatory cytokines like IFN-γ and TNF-α prior to testing or administration, which better mimics the in vivo environment [15].

The Scientist's Toolkit: Essential Reagents for ISCT Compliance

The following table lists key reagents and their functions for validating MSCs against the ISCT 2006 criteria.

Research Reagent / Tool	Function in MSC Validation
Fluorochrome-conjugated Antibodies (against CD105, CD73, CD90, CD45, CD34, CD14/CD11b, CD19/CD79a, HLA-DR)	Essential for flow cytometric analysis of the positive and negative marker profiles as defined by the ISCT [10] [11].
Trilineage Differentiation Media Kits (Adipogenic, Osteogenic, Chondrogenic)	Provide standardized, optimized media supplements (e.g., dexamethasone, insulin, IBMX, ascorbate, β-glycerophosphate, TGF-β) to induce and assess multipotency [12] [11].
Histological Stains (Oil Red O, Alizarin Red S, Alcian Blue/Toluidine Blue)	Used to visually confirm successful differentiation into adipocytes (lipids), osteoblasts (calcium), and chondrocytes (proteoglycans), respectively [12] [10].
Flow Cytometer	The primary instrument for quantitatively assessing the expression of cell surface markers, ensuring the population meets the ≥95% positive and ≤2% negative thresholds [13] [10].
Human Platelet Lysate (hPL)	A defined, xeno-free supplement increasingly used as an alternative to Fetal Bovine Serum (FBS) for clinical-grade MSC expansion, which can influence MSC growth and surface marker expression [14].

The ISCT 2006 minimal criteria successfully provided a critical foundational baseline for the MSC field, establishing a common language and enabling more consistent reporting and comparison of data [7] [8]. The three pillars of plastic adherence, specific surface marker expression, and trilineage differentiation remain the mandatory starting point for any research involving MSCs.

However, as the field advances toward clinical applications, it is clear that these minimal criteria are necessary but not always sufficient. They define identity but do not fully predict potency. Modern MSC research must therefore view the 2006 criteria as a solid foundation upon which to build more sophisticated characterizations. This includes adopting tissue-source-specific markers, implementing quantitative potency assays like the MLR for immunomodulation, and following evolving international standards for biobanking and manufacturing. By combining the foundational ISCT baseline with these advanced tools, researchers can better ensure the quality, efficacy, and safety of MSC-based therapies.

The field of mesenchymal stromal cell (MSC) research has reached a pivotal moment with the International Society for Cell & Gene Therapy (ISCT) releasing updated identification standards in 2025. These changes represent the most significant overhaul since the 2006 standards were established, reflecting nearly two decades of scientific advancement and clinical experience. For researchers, scientists, and drug development professionals, understanding these updates is crucial for ensuring regulatory compliance, improving experimental reproducibility, and advancing therapeutic development. This guide provides a comprehensive analysis of the key shifts in terminology and mandatory requirements, with particular focus on their implications for validating MSC identity through flow cytometry within the broader context of MSC identity research.

Unpacking the 2025 ISCT Terminology Shift: From "Stem" to "Stromal"

Redefining Fundamental Cell Identity

The most striking terminological change in the 2025 ISCT standards is the formal definition of MSCs as "Mesenchymal Stromal Cells" instead of the previously widely used "Mesenchymal Stem Cells" [6]. This represents far more than semantic nuance—it reflects an evidence-based reevaluation of the cells' fundamental biological nature based on extensive scientific research conducted over the past two decades.

The updated standards now require researchers who wish to use the term "Mesenchymal Stem Cells" to provide experimental evidence demonstrating that their cells possess actual stem cell properties, including self-renewal and multi-lineage differentiation potential [6]. This requirement addresses long-standing issues of reproducibility caused by naming confusion and reflects the scientific community's strengthened emphasis on terminological accuracy that aligns with demonstrated cellular function.

Revised Differentiation Requirements

In a significant departure from previous standards, the 2025 update no longer mandates "trilineage differentiation in vitro" (osteogenesis, adipogenesis, and chondrogenesis) as a compulsory identification criterion [6]. This adjustment acknowledges the documented limitations of traditional "stemness" assays in distinguishing true stem cells from more specialized stromal cell populations. Similarly, the requirement for "adherence to plastic under standard conditions" has been de-emphasized, recognizing that this property varies considerably based on culture conditions and may not reliably define fundamental cell identity.

Table: Comparison of ISCT 2006 vs. 2025 Terminology and Basic Requirements

Standard Element	2006 Standard	2025 Standard
Cell Definition	Mesenchymal Stem Cells (MSCs)	Mesenchymal Stromal Cells (MSCs)
Stemness Requirement	Must demonstrate trilineage differentiation	Must provide evidence to use the term "stem"
Differentiation Assays	Mandatory trilineage differentiation	No longer mandatory
Plastic Adherence	Required	No longer emphasized
Theoretical Basis	Presumed stemness	Function-based classification

Comprehensive Analysis of Updated Mandatory Requirements

Enhanced Flow Cytometry Standards

The 2025 ISCT standards introduce substantially refined requirements for flow cytometry-based characterization, moving from qualitative assessments to quantitative measurements with specific thresholds [6]. While CD73, CD90, and CD105 remain as basic positive markers, the updated standards now require researchers to specify the exact threshold percentage for positive identification via flow cytometry and report complete results for each marker, including the percentage of positive cells. This enhanced transparency enables better cross-comparison of data between different laboratories and research studies.

A critical addition to the negative marker requirements is the mandatory inclusion of CD45 (a hematopoietic marker) to ensure that the MSC population is not contaminated by hematopoietic lineages [6]. This addresses a common source of variability in MSC preparations and reinforces the importance of population purity in therapeutic applications.

New Emphasis on Tissue Origin and Critical Quality Attributes

The 2025 standards place unprecedented emphasis on specifying the tissue origin of MSCs, acknowledging that cells from different sources may exhibit distinct phenotypic and functional properties [6]. This recognition aligns with emerging single-cell omics data revealing substantive differences between MSCs derived from various tissues, including bone marrow, adipose tissue, umbilical cord, and even specialized niches like the brain.

Perhaps the most strategically significant update is the incorporation of efficacy and functional characterization into Critical Quality Attributes (CQAs) [6]. This shift demands that researchers describe these attributes to define the clinical functionality of MSCs, ensuring that MSC products not only meet phenotypic standards but also deliver the expected therapeutic outcomes. The standards now require more comprehensive quality control, including:

• Standardization of Culture Conditions: Detailed reporting on medium components, passaging methods, and culture environment parameters
• Enhanced Safety Testing: Mandated rigorous detection for microbial contamination (bacteria, fungi, mycoplasma)
• Application-Specific Functional Validation: Customized efficacy tests designed based on the intended clinical application

Updated Clinical Trial Reporting Standards

For autoimmune disease applications, the ISCT has established new minimal criteria for peer-reviewed reporting of MSC clinical trials [16]. These standards emphasize the need for greater transparency and reproducibility in research, ensuring that readers can correctly interpret data and that meta-analyses are generated from comparable datasets. The standards address key manufacturing parameters and product characterization requirements specific to autoimmune disorders, facilitating more meaningful cross-study comparisons and accelerating clinical translation.

Experimental Implementation: Validating MSC Identity with 2025 Flow Cytometry Criteria

Flow Cytometry Experimental Design and Methodology

Implementing the 2025 ISCT standards requires refined flow cytometry protocols that address both the classical and expanded marker panels. The following methodology supports compliance with the updated requirements:

Sample Preparation

• Harvest MSCs at appropriate passage number (typically P3-P5) during logarithmic growth phase
• Use standardized detachment methods (enzyme-free cell dissociation buffers preferred to preserve surface epitopes)
• Wash cells with PBS containing 1% FBS or human platelet lysate
• Adjust cell concentration to 1-5×10^6 cells/mL in staining buffer

Antibody Staining Protocol

• Primary antibody incubation: Use validated antibodies against CD73, CD90, CD105, CD45, and recommended additional markers (CD36, CD163, CD271, CD200, CD273, CD274, CD146, CD248, CD140b) [14]
• Implement viability staining (e.g., 7-AAD or DAPI) to exclude dead cells from analysis
• Include appropriate isotype controls and compensation beads for multicolor panels
• Incubation: 30 minutes at 4°C in dark, followed by two washes with staining buffer

Instrument Setup and Data Acquisition

• Perform daily calibration using standardized fluorescent beads
• Establish photomultiplier tube (PMT) voltages using unstained and single-stained controls
• Collect a minimum of 10,000 events per sample within the live cell gate
• Use automated platforms like the Accellix Cell Phenotyping Platform to reduce operator-dependent variability when available [17]

Data Analysis and Interpretation

• Analyze data using FlowJo, FCS Express, or equivalent software
• Apply consistent gating strategies: FSC-A/SSC-A for cell population, FSC-H/FSC-A for singlets, viability dye-negative for live cells, then marker-specific gates
• Report percentage positive cells for each marker relative to isotype controls
• Document fluorescence intensity (Mean Fluorescence Intensity or Geometric Mean) in addition to percentage positive

Diagram 1: Updated Flow Cytometry Workflow for MSC Characterization. The 2025 ISCT standards require comprehensive marker panels including classical positive markers (green), mandatory negative markers (red), and expanded characterization markers (blue) to fully validate MSC identity.

Reference Reagents and Standardization Tools

The World Health Organization (WHO) has developed a candidate International Reference Reagent (IRR) for MSC identity via flow cytometry to address standardization challenges [18]. In a collaborative study involving 15 participants from 9 laboratories, the reference reagent demonstrated excellent performance across different flow cytometry setups and conditions. The mean values obtained fell remarkably close to the ranges for percentage expression for each marker in the ISCT recommendations.

This reagent serves as a vital tool for validating equipment and results, though it is not a replacement for the ISCT values themselves. Laboratories can use this standardized reagent to calibrate instruments, establish baseline measurements, and ensure inter-laboratory consistency when implementing the 2025 ISCT standards.

Table: Research Reagent Solutions for MSC Flow Cytometry Validation

Reagent/Category	Specific Examples	Function in MSC Validation
Reference Standards	WHO IRR for MSC Identity [18]	Instrument calibration and inter-laboratory standardization
Core Positive Markers	CD73, CD90, CD105 Antibodies	Confirmation of classical mesenchymal phenotype
Mandatory Negative Markers	CD45 Antibodies	Exclusion of hematopoietic contamination
Expanded Characterization Panel	CD36, CD163, CD271, CD200, CD273, CD274, CD146, CD248, CD140b [14]	Functional subset identification and potency indication
Viability Indicators	7-AAD, DAPI, Propidium Iodide	Exclusion of dead cells from analysis
Instrument Calibration	Fluorescent calibration beads	Daily performance verification and standardization
Automated Platforms	Accellix Cell Phenotyping Platform [17]	Workflow standardization and reduction of operator variability

The Scientist's Toolkit: Essential Materials for 2025 Compliance

Successfully implementing the 2025 ISCT standards requires both standardized reagents and appropriate technical platforms. The following toolkit elements are essential for compliance:

Reference Standards and Controls

• WHO International Reference Reagent for MSC identity [18]
• Validated antibody panels against classical and expanded markers
• Isotype-matched control antibodies for background determination
• Standardized fluorescent beads for instrument calibration

Technical Platforms

• Flow cytometers with minimum 3-color detection capability
• Automated analysis software with batch processing capability
• Optional automated platforms (e.g., Accellix) for manufacturing environments [17]

Quality Management Components

• Documented standard operating procedures (SOPs) for all processes
• Culture media with defined components (e.g., serum-free systems)
• Detailed record-keeping systems for culture parameters and reagents

Diagram 2: Interrelationship of 2025 ISCT MSC Characterization Components. The updated standards establish an integrated framework where core markers, expanded characterization, tissue origin specification, and critical quality attributes form interconnected validation elements supported by reference reagents.

Comparative Analysis: Strategic Implications of the 2025 Updates

Impact on Research Reproducibility and Clinical Translation

The 2025 ISCT standards address fundamental challenges in MSC research reproducibility by replacing qualitative assessments with quantitative thresholds and expanding reporting requirements. The mandatory documentation of flow cytometry percentages and thresholds specifically targets the variability in MSC characterization that has plagued inter-laboratory comparisons and meta-analyses.

For clinical translation, the incorporation of Critical Quality Attributes (CQAs) directly links characterization to therapeutic functionality, potentially improving clinical trial success rates. This is particularly relevant for autoimmune disease applications, where the ISCT has established specific minimal reporting criteria for clinical trials [16]. The requirement to specify tissue origin acknowledges that MSCs from different sources may exhibit distinct functional properties, allowing for more targeted therapeutic development.

Alignment with Global Regulatory Trends

The 2025 ISCT updates align with broader regulatory evolution in the cell and gene therapy sector. In 2025, regulatory agencies worldwide have embraced more flexible approaches to balance innovation with safety, including:

• FDA draft guidance on expedited programs for regenerative medicine therapies [19]
• Increased acceptance of real-world evidence for post-approval safety monitoring [19]
• International collaborative reviews to accelerate global access [19]

The enhanced MSC standards provide a framework for developers to generate the robust manufacturing and characterization data that regulators increasingly demand. The emphasis on functional CQAs aligns with regulatory expectations for understanding mechanism of action and potency, particularly for complex biological products.

The 2025 ISCT updates represent a maturing of the MSC field, replacing presumption with evidence-based characterization. The shift from "stem" to "stromal" terminology, enhanced flow cytometry requirements, and incorporation of Critical Quality Attributes collectively address long-standing reproducibility challenges while creating a more robust foundation for therapeutic development. For researchers and drug development professionals, successful implementation requires both technical adjustments to laboratory practices and strategic reconsideration of how MSC identity is defined and validated. As the field continues to evolve, these standards provide a framework for generating comparable, reproducible data that will accelerate the development of safe and effective MSC-based therapies.

The definitive characterization of Mesenchymal Stromal Cells (MSCs) represents a critical challenge in regenerative medicine and cellular therapy. To address this, the International Society for Cellular Therapy (ISCT) established minimal criteria for defining human MSCs, creating a standardized framework for the field [1]. According to these criteria, MSCs must be plastic-adherent under standard culture conditions, possess trilineage differentiation potential (osteogenic, adipogenic, and chondrogenic), and express a specific panel of cell surface markers [20]. This article focuses on the critical positive markers (CD73, CD90, CD105) and the essential negative marker (CD45) that form the cornerstone of MSC identification. These markers serve as vital release criteria for good manufacturing practice (GMP)-compliant production, ensuring consistency and reliability in clinical-grade MSC products [14]. The proper application of this marker panel in flow cytometry is fundamental for validating MSC identity across different tissue sources and experimental applications.

Marker-Specific Profiles and Functional Significance

CD73 (Ecto-5'-Nucleotidase)

CD73, also known as ecto-5'-nucleotidase, is a glycosyl-phosphatidylinositol-(GPI)-anchored cell surface protein encoded by the NT5E gene. This enzyme catalyzes the final step in extracellular ATP metabolism, converting AMP to adenosine [20]. The adenosine produced through CD73 activity exerts potent immunomodulatory effects, primarily through suppression of T-cell activation and proliferation, positioning CD73 as a key mediator of the therapeutic immunoregulatory properties of MSCs [14]. According to ISCT standards, ≥95% of the MSC population must express CD73 [20]. Research indicates that CD73 expression remains stable (>90% positive cells) even after osteogenic differentiation, demonstrating its persistence beyond undifferentiated states [21].

CD90 (Thy-1)

CD90, or Thy-1, is a GPI-anchored glycoprotein functioning in cell-cell and cell-matrix interactions. It plays significant roles in cellular adhesion, migration, and signal transduction [20]. In MSCs, CD90 expression is associated with stemness properties, including self-renewal capacity. Studies evaluating primary cultured cells from periosteum and cartilage demonstrate near-universal expression (>95%) of CD90 in vitro [21]. Like CD73, CD90 expression is retained in >90% of cells following osteogenic induction [21]. However, recent evidence suggests that CD90 expression, along with CD73, may be acquired during in vitro culture rather than representing native in vivo expression, indicating phenotypic adaptation to culture conditions [21].

CD105 (Endoglin)

CD105, or endoglin, functions as a component of the TGF-β receptor complex, modulating cellular responses to this multifunctional cytokine [20]. This marker is particularly significant in angiogenesis and endothelial maintenance. Among the classical MSC markers, CD105 demonstrates the highest usage frequency (82.9%) in studies investigating MSCs associated with skeletal tissue [22]. The expression levels of CD105 can vary between MSC isolates from different donors and tissue sources, potentially reflecting functional heterogeneity within MSC populations [14]. During differentiation, CD105 expression patterns may change, with some studies noting reduced expression following specific lineage commitment.

CD45 (Protein Tyrosine Phosphatase Receptor Type C)

CD45, a transmembrane protein tyrosine phosphatase receptor type C, serves as a critical negative marker for MSCs [20]. As a pan-leukocyte marker expressed on all hematopoietic cells, including lymphocytes, monocytes, and granulocytes, its absence helps distinguish MSCs from hematopoietic contaminants [14]. According to ISCT criteria, ≤2% of the MSC population should express CD45, ensuring minimal hematopoietic cell contamination in the final product [20]. This exclusionary criterion is particularly important when isolating MSCs from hematopoietic tissue-rich sources like bone marrow, where careful gating strategies during flow cytometry are essential for accurate population identification.

Table 1: Essential Surface Markers for MSC Characterization

Marker	Alternative Name	Protein Function	ISCT Requirement	Expression in Other Cell Types
CD73	Ecto-5'-nucleotidase	Converts AMP to adenosine; immunoregulation	≥95% Positive [20]	Endothelial cells, lymphocytes
CD90	Thy-1	Cell adhesion, migration, signal transduction	≥95% Positive [20]	Fibroblasts, neurons, activated endothelial cells
CD105	Endoglin	TGF-β receptor complex; angiogenesis	≥95% Positive [20]	Endothelial cells, macrophages
CD45	PTPRC	Tyrosine phosphatase; leukocyte signaling	≤2% Positive [20]	All hematopoietic cells (pan-leukocyte marker)

Experimental Data and Comparative Analysis

Extensive research has validated the consistency of CD73, CD90, and CD105 expression across MSCs derived from various tissue sources while maintaining absence of CD45. A comprehensive scoping review of MSC studies related to the skeletal system revealed that CD105 represents the most consistently reported marker (82.9% of studies), followed by CD90 (75.0%) and CD73 (52.0%) [22]. This expression profile remains remarkably stable across MSCs derived from bone marrow, adipose tissue, umbilical cord, and dental pulp, despite biological variations in these sources [1]. When clinical-grade adipose-derived MSCs (AMSCs) were expanded in human platelet lysate (hPL), they demonstrated homogeneous expression of these classical markers across 15 different donors, confirming their reliability as quality control measures [14].

Impact of Culture Conditions and Differentiation

Culture conditions significantly influence marker expression patterns. Studies investigating periosteal and cartilage-derived cells found universal expression of CD73 and CD90 (>95%) regardless of extracellular matrix coatings applied to culture surfaces [21]. However, a critical finding emerged when researchers discovered that markers including CD73 and CD90 are largely acquired during in vitro culture rather than reflecting native in vivo expression, demonstrating phenotypic convergence in plastic-adherent cultures [21]. During osteogenic differentiation, MSCs typically retain CD73 and CD90 expression in >90% of cells, while other markers like CD106 and CD146 show diminished expression [21]. This differential expression pattern during lineage commitment underscores the complex regulation of surface markers throughout MSC maturation.

Table 2: Marker Expression Under Different Experimental Conditions

Experimental Condition	CD73 Expression	CD90 Expression	CD105 Expression	CD45 Expression	Research Context
Standard In Vitro Culture	>95% [21]	>95% [21]	>95% [20]	≤2% [20]	Plastic-adherent cells from various tissues
Post-Osteogenic Differentiation	>90% retained [21]	>90% retained [21]	Variable reports	Not expressed	Periosteal and cartilage cultures
With ECM Coating Variations	Minimal change [21]	Minimal change [21]	Not specified	Not specified	Collagen, fibronectin, Geltrex coatings
In Vivo Native State	Acquired in vitro [21]	Acquired in vitro [21]	Not specified	Not expressed	Freshly isolated periosteal populations

Experimental Protocols for Marker Validation

Sample Preparation and Cell Culture

Protocols begin with tissue collection approved by ethical committees, with participants providing written informed consent [21]. For skeletal tissues, periosteum is scraped off cortical bone and minced, while articular cartilage is dissected into approximately 2mm² pieces. Tissues undergo digestion with 1mg/mL collagenase P in complete medium at 37°C with agitation overnight (<15 hours) [21]. Following digestion, cells are filtered through a 70μm cell strainer and washed with phosphate-buffered saline (PBS). For bulk culture, cells are seeded in αMEM supplemented with 10% fetal bovine serum (FBS) at densities of 1.5×10⁴ cells/cm² (periosteum) or 2×10⁴ cells/cm² (cartilage) [21]. Media changes are performed on days 4 and 7, with passaging upon confluence using Accutase cell dissociation reagent.

Flow Cytometry Staining and Analysis

Single-cell suspensions of cultured cells are obtained using enzymatic dissociation, then passed through cell strainers prior to staining [21]. Staining and washes are performed in staining medium (2% FBS, 1mM EDTA in PBS). Cells are stained in 100μL antibody cocktail containing Brilliant Stain buffer for 30 minutes at 4°C in the dark prior to washing and resuspension [21]. For clinical-grade qualification, flow cytometry analysis should demonstrate ≥95% expression of CD73, CD90, and CD105, while ≤2% expression of CD45 and other hematopoietic markers (CD34, CD14, CD19, HLA-DR) [20]. Proper isotype controls and compensation standards are essential for accurate interpretation, particularly when using multi-color panels [23].

Diagram 1: Experimental workflow for MSC surface marker validation

Technical Considerations in Flow Cytometry

Conventional vs. Spectral Cytometry Approaches

The choice between conventional and spectral flow cytometry significantly impacts panel design and data quality. Conventional flow cytometers utilize optical filters (dichroic mirrors and bandpass filters) to separate and direct emitted light to appropriate detectors, following a "one detector–one fluorophore" approach [24]. This method works well for small panels of highly distinguishable fluorochromes but reaches limitations with complex panels due to spectral overlap, which is corrected mathematically through compensation [25]. In contrast, spectral cytometers collect the entire emission spectrum of each fluorophore using a prism or diffraction grating, capturing scattered light with an array of highly sensitive detectors [24]. This spectral unmixing process enables more accurate resolution of highly overlapping labels and better discrimination of cellular autofluorescence, particularly beneficial for complex MSC characterization panels [25].

Panel Design and Fluorochrome Selection

Effective panel design requires careful fluorochrome selection based on instrument capabilities and biomarker expression levels. For the essential MSC marker panel, bright fluorochromes should be paired with markers expressed at lower levels to ensure detection sensitivity [25]. When building multi-color panels, it is crucial to consider the entire spectrum of each fluorochrome, not just peak emissions, to minimize unanticipated spectral overlaps that complicate compensation [25]. For conventional cytometers, fluorochromes with distinct excitation spectra should be prioritized where possible. For example, utilizing BV421 (violet laser-excited) with FITC (blue laser-excited) and APC (red laser-excited) maximizes spectral separation [25]. The development of new dye classes, including Spark, Vio, and eFluor dyes, has expanded options for panel design, though established dyes often provide more reliable performance for critical applications like MSC qualification [24].

Diagram 2: Comparison of conventional versus spectral flow cytometry detection

Research Reagent Solutions Toolkit

Table 3: Essential Research Reagents for MSC Surface Marker Analysis

Reagent Category	Specific Examples	Research Application	Technical Considerations
Dissociation Reagents	Collagenase P, Accutase	Tissue digestion and cell harvesting	Collagenase P for primary tissue; Accutase for adherent cultures [21]
Culture Media	αMEM with 10% FBS; Serum-free specialized media	MSC expansion and maintenance	Human platelet lysate (hPL) provides GMP-compliant alternative to FBS [14]
Flow Cytometry Antibodies	Anti-CD73, CD90, CD105, CD45 clones	Surface marker detection	Validate clones for specific applications; check compatibility with fixation [20]
Staining Buffers	Brilliant Stain Buffer, FBS/EDTA/PBS	Antibody staining procedures	Brilliant Stain Buffer enhances fluorochrome stability in polychromatic panels [21]
Instrumentation Platforms	BD FACSymphony, Cytek Aurora, Beckman CytoFLEX	Flow cytometry analysis	Spectral systems (Cytek Aurora) enable higher-parameter panels [24]

The critical surface marker panel of CD73, CD90, CD105, and CD45 remains the foundation for MSC identification and characterization according to ISCT standards. While these markers provide essential criteria for defining plastic-adherent MSC populations, emerging research indicates they may represent culture-acquired phenotypes rather than native in vivo identities [21]. The consistency of CD73 and CD90 expression across different tissue sources and culture conditions reinforces their value as primary positive identifiers, while CD45 exclusion remains crucial for confirming non-hematopoietic origin. As the field advances, incorporating additional markers such as CD146, CD271, and CD200 may provide deeper insights into functional MSC subpopulations and potency characteristics [14]. The ongoing refinement of flow cytometry technologies, particularly spectral cytometry, continues to enhance resolution for detecting increasingly complex marker combinations, ultimately strengthening MSC characterization for research and clinical applications.

For decades, flow cytometry measuring surface markers like CD73, CD90, and CD105 has served as the cornerstone for identifying Mesenchymal Stromal Cells (MSCs) based on the International Society for Cell & Gene Therapy (ISCT) criteria. However, the scientific community is increasingly recognizing that this phenotypic profile, while essential for identity, is insufficient for predicting therapeutic efficacy. The growing consensus, reinforced by a 2025 ISCT update that de-emphasizes the term "stem cells" in favor of "stromal cells," underscores the critical need to supplement phenotype with robust functional potency assays. This shift acknowledges that MSCs from different donors or tissue sources can exhibit identical surface markers yet possess vastly different therapeutic capabilities. This guide objectively compares the experimental approaches and methodologies that are defining the next generation of MSC potency assessment, providing researchers with a framework for validating the true functional quality of their cellular products.

The Limits of Phenotype: Why Functional Potency is Non-Negotiable

Adherence to plastic and a defined set of surface markers remain the foundational requirements for MSC identity. Yet, several key findings highlight the severe limitations of relying on phenotype alone:

• Donor Variability Dictates Function: Research demonstrates that the secretome changes arising from MSC and peripheral blood mononuclear cell (PBMC) interactions are largely determined by the PBMC donor, highlighting that the functional response is highly context-dependent and not predictable by MSC surface markers alone [26].
• Pooling MSCs Can Mask True Potency: A 2025 study revealed that pooled MSC samples, often used to mitigate donor variation, do not accurately reflect the average of individual donors. Even pools composed of donors with similar cell fitness can become dominated by the single most potent donor within just one passage, leading to a homogenized and potentially skewed representation of functionality [27].
• New ISCT Standards Prioritize Function: The 2025 ISCT standards represent a major shift, formally redefining MSCs as "Mesenchymal Stromal Cells" and removing the mandatory requirement for in vitro trilineage differentiation. The new standards explicitly incorporate efficacy and functional characterization into Critical Quality Attributes (CQAs), demanding a direct link between quality control and clinical functionality [6].

Comparative Analysis of Functional Potency Assay Platforms

A matrix of assays is often necessary to capture the multifaceted therapeutic mechanisms of MSCs, which include immunomodulation, trophic factor secretion, and prevention of regulated cell death. The following table compares three key functional assay platforms.

Table 1: Comparison of Key Functional Potency Assay Platforms for MSCs

Assay Platform	Measured Function	Key Readouts	Correlation with In Vivo Effect	Key Advantages	Key Limitations
Immunomodulation Co-culture	Suppression of immune cell proliferation & activation	• T cell proliferation (e.g., Ki67+) [26]• Cytokine secretion (e.g., IFN-γ, TNF-α downregulation; CXCL10, GCSF upregulation) [26]	Correlated with suppression of T cell proliferation and prediction of clinical response in inflammatory diseases [26] [28].	Measures a primary MoA; Can use patient-specific PBMCs for relevance [26].	High donor-to-donor variability in responder immune cells [26].
Secretome Analysis	Paracrine factor secretion profile	• Quantification of induced soluble factors (e.g., VEGF, CCL2, CXCL9) [26]• Quantification of suppressed soluble factors (e.g., TNF-α, IL-13, CCL3) [26]	Defined cytokine signatures (e.g., TNF-α suppression, GCSF induction) correlate with T cell suppression [26].	High-throughput; Can identify specific potency biomarkers for release criteria.	Static snapshot; may not capture dynamic interactions.
Macrophage Polarization Assay	Modulation of macrophage phenotype	• IL-1RA secretion by MSCs [29]• Macrophage surface marker expression (CD80, CD36) [29]	Directly relevant for macrophage-driven diseases (e.g., GvHD, fibrotic disorders) [29].	Models a specific, clinically important immune interaction.	Narrower focus on a single immune cell pathway.

Detailed Experimental Protocols for Key Potency Assays

To ensure reproducibility and facilitate implementation, below are detailed methodologies for two critical potency assays drawn from recent literature.

Protocol 1: T Cell Immunosuppression Assay

This assay measures the ability of MSCs to suppress the proliferation of activated T cells, a cornerstone of their immunomodulatory function [26].

• PBMC Isolation and Activation: Isolate PBMCs from healthy human donors or patient blood using density gradient centrifugation.
• PBMC Labeling: Label PBMCs with a cell proliferation dye (e.g., CFSE) to track division.
• Co-culture Setup: Seed irradiated MSCs in a flat-bottom culture plate and allow them to adhere. Add SEB-activated, CFSE-labeled PBMCs to the MSC monolayer at varying MSC:PBMC ratios (e.g., 1:2 to 1:8). Include controls for activated PBMCs alone and MSCs alone.
• Culture and Harvest: Co-culture cells for 3-5 days. Harvest the non-adherent cell fraction containing the PBMCs.
• Flow Cytometry Analysis: Stain harvested cells with a fluorescent anti-CD3 antibody and a viability dye. Analyze using flow cytometry to determine the percentage of CD3+ viable cells that have undergone division (CFSE dilution) and express the proliferation marker Ki67 [26].
• Secretome Analysis (Optional): Collect supernatant from co-cultures and analyze using a multiplex cytokine array (e.g., Luminex) to quantify the upregulation of MSC-derived factors (VEGF, GCSF, CXCL10) and downregulation of PBMC-derived factors (TNF-α, IFN-γ, IL-13) [26].

The signaling pathways involved in this functional assay can be visualized as follows:

Diagram 1: T Cell Suppression Assay Workflow

Protocol 2: Macrophage Polarization Potency Assay

This assay is specifically designed to measure the potency of MSCs in modulating macrophages, which is critical for diseases like GvHD [29].

• Macrophage Differentiation and Polarization: Differentiate THP-1 monocytes into macrophages by treating with phorbol 12-myristate 13-acetate (PMA) for 48 hours. Polarize the resulting macrophages into an M1 pro-inflammatory phenotype using lipopolysaccharide (LPS) and interferon-gamma (IFN-γ).
• Validation of Polarization: Confirm M1 polarization by flow cytometry analysis of increased surface expression of CD80 and CD36, and by measuring the release of pro-inflammatory TNF-α [29].
• Co-culture with MSCs: Culture the polarized M1 macrophages with the MSCs under test. A transwell system is recommended to separate the cell types, allowing the analysis of paracrine effects without direct cell contact.
• IL-1RA Quantification: After 24-48 hours of co-culture, collect the supernatant. Quantify the concentration of human Interleukin-1 Receptor Antagonist (IL-1RA) using a validated enzyme-linked immunosorbent assay (ELISA). This MSC-secreted anti-inflammatory molecule is a key functional readout of potency in this system [29].
• Data Analysis: Calculate the amount of IL-1RA secreted per MSC to establish a quantifiable potency metric for batch release.

The Scientist's Toolkit: Essential Reagents & Materials

Successful implementation of functional potency assays requires carefully selected reagents. The following table details key solutions used in the featured experiments.

Table 2: Essential Research Reagent Solutions for Functional Potency Assays

Research Reagent	Function in Assay	Example from Featured Research
Staphylococcal Enterotoxin B (SEB)	Polyclonal T cell activator used to stimulate PBMCs in immunomodulation assays.	Used to activate PBMCs for measuring MSC-mediated suppression of T cell proliferation [26].
Human Platelet Lysate (hPL)	Xeno-free supplement for MSC culture media; supports expansion and can influence functionality.	Used as a serum supplement in GMP-compliant production of MSCs for subsequent sEV and potency studies [30].
PMA / LPS / IFN-γ	Agents for differentiating and polarizing monocytes into M1 pro-inflammatory macrophages.	Used to differentiate THP-1 cells and polarize them to an M1 phenotype for macrophage-MSC co-culture assays [29].
IL-1RA ELISA Kit	Quantitative detection of a critical anti-inflammatory protein secreted by MSCs upon macrophage interaction.	The primary analytical readout for measuring MSC potency in a macrophage-driven inflammation model [29].
Multiplex Cytokine Array	Simultaneous quantification of multiple cytokines and chemokines in cell culture supernatant.	Used for secretome analysis to identify upregulated (VEGF, GCSF) and downregulated (TNF-α, IFN-γ) signatures correlated with potency [26].

Beyond Immunomodulation: Novel Potency Paradigms

While immunomodulation is a primary MoA, a complete potency profile should consider other therapeutic functions. Emerging research highlights the importance of measuring a broader range of biological activities.

• Prevention of Regulated Cell Death (RCD): MSCs can inhibit detrimental RCD processes like pyroptosis and necroptosis in distressed cells via mitochondrial transfer and paracrine factors. Incorporating in vitro assays that measure the ability of MSCs to prevent RCD in relevant target cells (e.g., macrophages undergoing pyroptosis) is suggested as a complementary potency criterion, especially for degenerative and inflammatory disorders [28].
• Small Extracellular Vesicle (sEV) Production: The therapeutic effect of MSCs is increasingly attributed to their secreted sEVs. The potency of these sEVs is highly dependent on MSC culture conditions and isolation methods. For example, isolating sEVs using Tangential Flow Filtration (TFF) yields a higher particle number than traditional Ultracentrifugation (UC) [30]. Therefore, quantifying sEV yield and function can serve as an indirect but highly relevant potency assay for MSC products.

The relationship between MSC function, signaling pathways, and therapeutic application is complex. The following diagram outlines this logical framework for assay selection:

Diagram 2: From MSC Function to Therapeutic Application

The evolution of the ISCT criteria signals a definitive transition in the field of MSC research and therapy—from a primary focus on what these cells are to a critical emphasis on what they do. Phenotypic characterization by flow cytometry remains a necessary first step for identity, but it is no longer sufficient for predicting clinical performance. The future of robust MSC product development lies in implementing a matrix of mechanism-based functional potency assays, such as immunomodulation co-cultures and secretome profiling, tailored to the specific clinical indication. By adopting these quantitative functional measures, researchers and drug developers can ensure that their MSC products are not only correctly identified but also therapeutically potent, ultimately paving a more reliable and standardized path to clinical success.

Implementing Flow Cytometry for MSC Validation: A Step-by-Step Protocol

Within the critical field of Mesenchymal Stromal Cell (MSC) research, flow cytometry stands as an indispensable tool for validating cell identity and quality, directly impacting the safety and efficacy of cellular therapies. The International Society for Cell & Gene Therapy (ISCT) has established evolving criteria for defining MSCs, moving from "Mesenchymal Stem Cells" to "Mesenchymal Stromal Cells" to reflect a more precise understanding of their biological nature [6]. A robust flow cytometry panel is therefore not merely an analytical technique but a fundamental component of quality control, ensuring that MSC products comply with these standards and exhibit the required critical quality attributes (CQAs) for their intended clinical applications [16] [6]. This guide objectively compares methodologies and reagents central to designing such panels, focusing on fluorochrome selection and the implementation of proper compensation controls to ensure data accuracy and reproducibility.

Core Principles of Flow Cytometry Panel Design

The Foundation: ISCT Criteria for MSC Validation

A flow cytometry panel for MSC validation must be constructed to accurately assess the specific markers mandated by ISCT. The standards require that ≥95% of the MSC population express the positive markers CD73, CD90, and CD105, while ≤2% express negative markers, which must include the hematopoietic lineage marker CD45, among others [6] [9]. The 2025 ISCT update emphasizes quantitative reporting via flow cytometry, requiring the specification of positive identification thresholds and complete reporting of the percentage of positive cells for each marker [6]. Furthermore, the tissue origin of the MSCs must be specified, as cells from different sources (e.g., bone marrow, adipose tissue, umbilical cord) may have distinct phenotypic and functional properties that influence marker expression levels [31] [6] [9].

Strategic Fluorochrome Selection and Assignment

The selection and assignment of fluorochromes to specific cellular markers are the most critical steps in panel design, directly determining the resolution between positive and negative populations.

• Know Your Instrument Configuration: Before selecting fluorochromes, you must know the configuration of the flow cytometer, including the number of lasers, their excitation wavelengths, and the bandpass filters for each detector [32] [33]. This information is essential because a fluorochrome can only be used if its excitation peak aligns with an available laser and its emission peak falls within the range of a corresponding detector [32].
• Match Fluorochrome Brightness to Antigen Density: A fundamental strategy for optimizing resolution is to pair bright fluorochromes with low-abundance antigens and dim fluorochromes with highly expressed antigens [32] [33] [34]. The brightness of a fluorophore is a function of its quantum yield and extinction coefficient, but a more practical measure is the Stain Index (SI), which accounts for the separation between positive and negative populations and the spread of the negative peak [32]. For MSC panels, high-expression markers like CD90 and CD105 are well-suited to dimmer fluorophores, while markers of unknown or potentially low expression should be assigned the brightest available fluorophores.
• Minimize Spectral Overlap: Fluorochromes emit light across a broad spectrum, leading to spillover into detectors intended for other fluorochromes [33]. This spillover can be corrected mathematically through compensation, but excessive spillover, especially from bright fluorophores, causes spillover spreading error (the "Trumpet Effect"), which reduces the ability to distinguish dimly positive signals from negative populations [33]. To minimize this, select fluorochromes with minimal spectral overlap and spread your markers evenly across all available lasers [33] [34].

Table 1: Fluorochrome Brightness and Suitability for Key MSC Markers

Brightness Category	Fluorochrome Examples	Stain Index (Example)	Recommended for MSC Markers
High	APC, PE	200.31, 158.46 [32]	Low-abundance targets, critical negative markers (e.g., CD45)
Medium	PE-Cy7, Alexa Fluor 700, FITC	53.70, 24.85, 56.40 [32]	Mid-level expression markers
Low	Pacific Blue, Alexa Fluor 405, PerCP	14.61, 10.01, 8.75 [32]	High-abundance positive markers (e.g., CD73, CD90, CD105)

Panel Design Workflow

The following diagram illustrates the logical workflow for building a robust flow cytometry panel.

Experimental Protocols for Panel Validation

Protocol: Antibody Titration and Staining Index Calculation

Titrating every antibody-conjugate pair is essential for maximizing the signal-to-noise ratio and avoiding wasted reagents [32] [33].

• Prepare Staining Samples: Aliquot a constant number of MSC cells (e.g., 1x10^5 per tube) into several tubes.
• Serial Dilution: Prepare a series of doubling dilutions of the antibody conjugate, typically starting from the manufacturer's recommended concentration.
• Stain and Acquire: Stain the cell aliquots with the different antibody concentrations following standard protocols. Acquire data on the flow cytometer.
• Calculate Staining Index: For each dilution, calculate the Stain Index (SI) using the formula:
  • SI = (Median Fluorescence Intensity of Positive Population - Median Fluorescence Intensity of Negative Population) / (2 × Standard Deviation of the Negative Population) [32].
• Select Optimal Concentration: The optimal concentration is the one that provides the highest Stain Index before the median fluorescence intensity (MFI) of the positive population plateaus, indicating saturation without excessive background [33].

Protocol: Setting Up Compensation Controls

Accurate compensation is non-negotiable for resolving spectral overlap and generating high-quality data.

• Select Control Particles: Use either compensation beads (which bind antibodies uniformly) or cells from the same source as your experimental sample. Cells are often preferred as they account for cellular autofluorescence [33].
• Prepare Single-Stain Controls: For each fluorochrome in your panel, prepare a dedicated tube containing:
  • The same type of particles/cells as your experiment.
  • A single antibody conjugate. The antibody should be targeted to a highly expressed antigen (e.g., CD90 for MSCs) to ensure a strong signal.
  • Critical: The amount of antibody in the single-stain control must be at least as much as the amount used in the full-panel experimental stain.
• Include Unstained and Viability Dye Controls: Always run an unstained control. If using a viability dye, include a single-stain control for it as well. A viability dye is highly recommended to exclude dead cells, which can cause aberrant nonspecific binding [32] [33].
• Acquisition and Calculation: Acquire the single-stain controls using the same cytometer settings as your experiment. Modern flow cytometer software will use these files to automatically calculate a spillover matrix and apply compensation during analysis [33] [35].

Visualizing Spillover and Compensation

The following diagram illustrates the concepts of spectral spillover and the goal of compensation.

Comparison of Reagents and Tools

Research Reagent Solutions for MSC Flow Cytometry

The table below details essential materials and tools required for executing a validated MSC flow cytometry experiment.

Table 2: Essential Research Reagents and Tools for MSC Flow Cytometry

Item Category	Specific Examples	Function & Application Notes
Core Antibodies	Anti-human CD73, CD90, CD105, CD45 [6] [9]	Validates MSC identity per ISCT criteria. Clone selection should be based on published performance [33].
Viability Dye	LIVE/DEAD Fixable Stains [32]	Distinguishes live from dead cells; critical for excluding dead cells that cause nonspecific staining and inaccurate data [32] [33].
Panel Design Tools	Fluorescence SpectraViewer, EasyPanel, Fluorofinder [32] [34]	Online tools to visualize fluorochrome spectra, check for spectral overlap, and receive AI-assisted panel suggestions based on instrument configuration.
Reference Panels	Optimized Multicolor Immunophenotyping Panels (OMIPs) [33] [34]	Peer-reviewed panels providing a validated starting point, including information on antibody clones, titration, and gating strategies.
Instrument QC	Calibration Beads	Ensures the flow cytometer's performance and optical alignment are optimal before data acquisition [33].

Designing a robust flow cytometry panel for MSC validation is a deliberate process that integrates the latest ISCT standards with foundational principles of panel design. Success hinges on strategic fluorochrome selection guided by antigen density and instrument configuration, rigorous experimental validation through antibody titration and Stain Index calculation, and the uncompromising application of compensation controls. By adhering to these protocols and leveraging the available tools and reagents, researchers and drug developers can generate reliable, reproducible, and standardized data. This is paramount for advancing the field of MSC therapies, ensuring product quality, and ultimately addressing significant unmet clinical needs in autoimmunity and regenerative medicine [16] [6].

Accurate analysis of Mesenchymal Stromal Cells (MSCs) via flow cytometry is foundational to validating their identity according to International Society for Cell & Gene Therapy (ISCT) criteria. The principle of "garbage in, garbage out" applies profoundly to flow cytometry, where sample preparation quality directly dictates analysis accuracy and reliability [36]. For researchers and drug development professionals, standardizing pre-analytical procedures is particularly crucial following the 2025 ISCT standards, which introduced quantitative marker reporting requirements and clarified MSC terminology [6]. This guide systematically compares best practices in MSC sample preparation and staining, providing experimental protocols and data to optimize workflow consistency and data quality for MSC characterization.

Updated MSC Identification Standards: ISCT 2025 Revisions

The ISCT recently updated MSC standards, reflecting significant shifts in characterization requirements that directly impact flow cytometry practices:

Terminology and Criteria Updates

The most notable change formalizes MSCs as "Mesenchymal Stromal Cells" rather than "Mesenchymal Stem Cells," requiring experimental evidence of stem cell properties to use the "stem" terminology [6]. The 2006 standard's mandatory trilineage differentiation and plastic adherence criteria are no longer compulsory, acknowledging their limitations in distinguishing true stem cells from stromal populations [6].

Enhanced Flow Cytometry Requirements

The updated standards introduce stricter surface marker detection protocols requiring quantitative reporting rather than qualitative assessments [6]. Researchers must now specify the threshold percentage for positive identification via flow cytometry and report complete results for each marker, including the percentage of positive cells, to improve data transparency and comparability [6]. CD45 must be included as a negative marker to exclude hematopoietic contamination, and tissue origin must be specified acknowledging source-dependent phenotypic variations [6].

Table: ISCT 2006 vs. 2025 MSC Identification Standards Comparison

Standard Element	2006 Standard	2025 Standard
Cell Definition	Mesenchymal Stem Cells (MSCs)	Mesenchymal Stromal Cells (MSCs)
Stemness Requirement	Must demonstrate trilineage differentiation	Must provide evidence to use term "stem"
Marker Detection	Qualitative (positive/negative)	Quantitative (thresholds and percentages)
Tissue Origin	Not emphasized	Must be specified and considered
Critical Quality Attributes	Not required	Must assess efficacy and functional properties

MSC Sample Preparation Methods: Comparative Analysis

Tissue Dissociation Techniques

Solid tissues require optimized dissociation for high-viability single-cell suspensions essential for flow cytometry. The selection between mechanical and enzymatic methods involves trade-offs between cell yield, viability, and epitope preservation.

Table: Comparison of Tissue Dissociation Methods for MSC Isolation

Method	Procedure	Advantages	Limitations	Optimal Applications
Mechanical Dissociation	Tissue trimming, mortar/pestle or blender homogenization (GentleMax system) [36]	Rapid processing; works well on loosely associated tissues [36]	Inconsistent yields, variable viability, user-dependent results [36]	Spleen, bone marrow, lymph nodes [36]
Enzymatic Dissociation	Proteolysis using collagenase, trypsin, or commercial cocktails (Liberase, Blendzymes) with DNase [36]	Effective, efficient, reproducible for complex tissues [36]	Potential epitope damage, requires optimization and validation [36]	Complex tissues (e.g., skin, adipose) [36]

Mechanical dissociation works optimally for loosely associated tissues like mouse spleens, bone marrow, and lymph nodes, but results can vary widely between users [36]. Enzymatic dissociation employing collagenase, trypsin, or commercial protease cocktails like Liberase more effectively handles complex tissue structures but may damage cell surface epitopes critical for antibody binding [36]. For neural tissues with high myelin content, additional myelin removal steps using 30% Percoll gradients or anti-myelin beads are necessary before enzymatic dissociation [36].

Cell Line and Cultured MSC Preparation

For cultured MSCs, optimal freeze/thaw practices are imperative: thaw rapidly at 37°C and remove DMSO promptly [36]. When harvesting adherent cells, mechanical dislodging may be preferable to enzymatic methods using trypsin or EDTA if epitopes of interest are sensitive to these treatments [36]. However, mechanical harvesting risks cell damage and DNA release causing clumping [36]. Overnight post-thaw recovery often improves epitope expression, and standardizing harvest protocols is essential for reproducibility [36].

Viability Maintenance and Clump Prevention

Sample preparation with high cell viability is fundamental, as dead cells bind labeling reagents indiscriminately, increasing background signals and false positives [36]. Homogeneously suspended particles minimize clumping, reduce cell doublets, and ensure accurate signal detection [36]. For cell sorting applications, maintain harvested cells on ice in Ca++/Mg++-free PBS with 1mM EDTA or DNase + 5mM MgCl2 if clumping occurs [36]. Live/dead staining with PI, DAPI, or 7-AAD is essential, and filtration before analysis is mandatory for sorting protocols [36].

Staining Protocols and Panel Design for MSC Characterization

Fixation and Permeabilization Methods

Fixation stabilizes samples for delayed analysis and neutralizes infectious agents, but method selection significantly impacts staining quality. Aldehyde-based fixatives (e.g., formaldehyde) cross-link lysine residues and generally provide superior epitope preservation compared to alcohol-based fixatives that denature proteins [36]. For combined surface and intracellular staining, initial fixation with formamide followed by treatment with Triton X-100 or Tween-20 can improve antibody access for intracellular targets [36]. Always vortex samples while adding fixative to ensure good penetration and reduce clumping [36].

Fixation compatibility with fluorochromes is crucial; PE and APC are incompatible with ethanol fixation, while tandem dyes like APC-Cy7 and PE-Cy7 degrade upon fixation, emitting parent dye profiles [36]. Formamide-stable fluorophores (APC-H7) and synthetic dyes (Alexa Fluor, Brilliant Violet) perform better under fixation conditions [36].

Marker Selection and Panel Optimization

The ISCT-defined positive markers (CD73, CD90, CD105) and negative markers (CD45, CD34, CD11b, CD19, HLA-DR) provide the foundation for MSC panels [37]. However, advanced characterization requires additional markers to distinguish MSCs from fibroblasts and identify tissue-specific subsets.

Table: Discriminatory Markers for MSC Identification vs. Fibroblasts by Tissue Source

Tissue Source	Markers Higher in MSCs	Markers Higher in Fibroblasts	Research Evidence
Adipose Tissue	CD105, CD106, CD146, CD271 [38]	CD79a [38]	Flow cytometry analysis of MSCs vs. fibroblasts [38]
Bone Marrow	CD105, CD106, CD146 [38]	Not specified	Flow cytometry analysis of MSCs vs. fibroblasts [38]
Wharton's Jelly	CD105 [38]	CD14, CD56 [38]	Flow cytometry analysis of MSCs vs. fibroblasts [38]
Placental Tissue	CD105, CD146 [38]	CD14 [38]	Flow cytometry analysis of MSCs vs. fibroblasts [38]

Titrate all staining reagents to ensure optimal signal-to-noise ratios for specific cell types, and include counting beads to guarantee sufficient events for statistical significance [36]. For mechanical conditioning studies, panels incorporating vascular markers (PECAM-1, VE-Cadherin, CD146, PDGFR-β, Nestin) alongside standard MSC markers can characterize enhanced regenerative phenotypes [39].

Experimental Protocols for MSC Characterization

Standardized Staining Protocol for MSC Surface Markers

The following protocol, adapted from current research methods, ensures consistent staining for MSC characterization by flow cytometry [38] [39]:

• Cell Harvesting: Harvest subconfluent cells (≤80% confluence) at passage 3-5 using 0.25% trypsin or non-enzymatic dissociation reagents [38]. For adherent cells requiring trypsin, consider overnight recovery to restore epitopes [36].

• Cell Washing: Wash harvested cells with PBS containing 1% penicillin/streptomycin to remove residual enzymes and serum [38].

• Antibody Staining: Resuspend cell pellets in fluorophore-conjugated monoclonal antibody cocktails. Use manufacturer-recommended quantities and incubate for 20 minutes in the dark [38]. For intracellular staining, fix and permeabilize cells using commercial buffer systems (e.g., BD Pharmingen Transcription-Factor Buffer Set) before antibody addition [39].

• Wash and Resuspension: Centrifuge at 350-400g for 5 minutes, discard supernatant, and resuspend in PBS or stain buffer for analysis [38].

• Flow Cytometry Analysis: Analyze immediately or fix samples (1-4% paraformaldehyde) for delayed analysis. Include fluorescence minus one (FMO) and isotype controls for accurate gating and background determination [40].

Mechanical Conditioning Protocol for Enhanced MSC Phenotype

For functional MSC enhancement studies, this mechanical conditioning protocol augments vascular regenerative properties [39]:

• Plate Preparation: Assemble and sterilize custom stretch plates or use commercial systems (Flexcell FX-6000T) [39].

• Cell Seeding: Seed MSCs on fibronectin-coated stretch membranes at appropriate density (e.g., 50,000 cells/cm²) [39].

• Conditioning Regime: Apply specific mechanical loading regimes (e.g., physiological waveform mimicking brachial artery stretch) with or without pharmacological inhibitors (EGFR/ErbB-2/4 inhibitor) for 24-72 hours [39].

• Phenotype Validation: Analyze conditioned cells for endothelial and pericyte markers (PECAM-1, VE-Cadherin, CD146, PDGFR-β) alongside standard MSC markers using flow cytometry [39].

Research Reagent Solutions for MSC Flow Cytometry

Table: Essential Reagents for MSC Flow Cytometry Analysis

Reagent Category	Specific Examples	Function	Considerations
Dissociation Reagents	Trypsin-EDTA (0.25%), Collagenase (Type 3), TrypLE Select, Dispase II [36] [38] [39]	Tissue dissociation and cell harvesting	Epitope damage potential; requires validation for specific markers [36]
Viability Stains	Propidium Iodide (PI), DAPI, 7-AAD [36]	Dead cell exclusion	Compatibility with fixation and other fluorochromes [36]
Positive Marker Antibodies	CD73, CD90, CD105 [6] [37]	MSC identification	Require titration for optimal signal-to-noise [36]
Negative Marker Antibodies	CD45, CD34, CD14, CD19, HLA-DR [6] [37]	Exclusion of hematopoietic and lineage cells	CD45 essential for hematopoietic exclusion [6]
Fixation/Permeabilization	Paraformaldehyde, BD Pharmingen Transcription-Factor Buffer Set [36] [39]	Cell structure preservation and intracellular access	Aldehyde fixatives preferred for epitope preservation [36]
Advanced Characterization Antibodies	CD106, CD146, CD271, PECAM-1, VE-Cadherin [38] [39]	Fibroblast discrimination and functional phenotyping	Tissue-source dependent expression patterns [38]

Data Analysis and Visualization Tools

Advanced analysis tools extract maximum information from MSC flow cytometry data. FlowJo remains the predominant analysis platform, offering machine learning tools for clustering and population identification [41]. Open-source alternatives like FlowKit (Python-based), Floreada (web-based, no coding required), and Cytoflow (Jupyter Notebook-integrated) provide cost-effective solutions with specialized capabilities [42].

For multidimensional data visualization, dimensionality reduction techniques (t-SNE, UMAP) simplify complex datasets and identify patterns [41]. Automated clustering algorithms (SOM, partitioning algorithms) enable unbiased population identification within manually gated MSC populations [41].

Valid MSC characterization requires integrating optimized sample preparation with standardized staining protocols and analytical methods compliant with updated ISCT criteria. The 2025 standards emphasize quantitative reporting, tissue origin specification, and functional characterization alongside traditional marker expression. Success hinges on maintaining high cell viability, selecting dissociation methods that preserve target epitopes, implementing appropriate fixation protocols compatible with fluorochromes, and including discriminatory markers to distinguish MSCs from contaminating fibroblasts. By adopting these comprehensive best practices, researchers can generate reproducible, high-quality MSC characterization data that advances both basic research and clinical applications.

The accurate identification and isolation of rare cell populations, such as Mesenchymal Stem Cells (MSCs) and specific immune cell subsets, are critical for advancing research in regenerative medicine and disease diagnostics. Flow cytometry serves as a powerful tool for this purpose, but the analysis of rare events presents unique challenges, including the need for stringent gating strategies and potential pre-enrichment techniques. Within this context, the identification of cells with low CD45 expression (CD45low) is particularly relevant, as this phenotype is associated with various progenitor and tissue-resident cells. This guide objectively compares methodological approaches for rare event analysis, with a specific focus on strategies for validating MSC identity per International Society for Cellular Therapy (ISCT) criteria and for reliably detecting CD45low populations.

Comparative Analysis of Gating Strategies and Markers

Table 1: Gating Strategy Comparison for Rare Event Analysis

This table summarizes the core steps and considerations for a robust gating strategy, which forms the foundation for accurate rare cell population analysis [43].

Gating Step	Primary Objective	Key Parameters & Plots	Common Pitfalls	Solutions for Rare Populations
1. Debris Exclusion	Remove non-cellular particles and apoptotic bodies.	FSC-A vs. SSC-A	Gating out too tightly, losing rare cells.	Use biological references (e.g., lymphocyte cluster) to guide gate placement [43].
2. Singlet Selection	Exclude cell doublets/aggregates for accurate single-cell analysis.	FSC-A vs. FSC-W (or FSC-H vs. FSC-W)	Inadequate exclusion, leading to fluorescence intensity distortions.	Apply strict linear gating; use PI-W vs. PI-A for DNA content analysis [43].
3. Viability Gating	Focus analysis on live, intact cells.	Viability dye (e.g., PI, 7-AAD) vs. FSC-A	Dead cells causing non-specific antibody binding.	Use a viability dye as a mandatory negative selection marker in Boolean gating [43] [44].
4. Target Phenotyping	Identify the rare population of interest using specific markers.	Fluorescence scatter plots (e.g., CD45 vs. SSC)	False positives due to fluorescence spillover or autofluorescence.	Use Fluorescence Minus One (FMO) controls and recalibrate compensation with single-stained controls [43].

Table 2: Marker Expression Profiles for MSC and CD45low- Associated Cell Populations

This table compares the defining markers for MSCs against other rare cell types that exhibit low or negative CD45 expression, highlighting critical differentiation points [45] [9] [46].

Cell Population	Key Positive Markers	Key Negative Markers	Tissue Source / Context	Notes & Challenges
Mesenchymal Stem Cells (MSCs)	CD73, CD90, CD105, CD44 [14] [9]	CD45, CD34, CD11b, CD19, HLA-DR (with caveats) [9]	Bone Marrow, Adipose Tissue, Placenta	Adherence to plastic & trilineage differentiation are defining functional criteria [9].
Circulating Endothelial Cells (CECs)	CD34^(dim), CD31^(bright), vWF [44]	CD45	Peripheral Blood (Lysed Whole Blood)	Often senescent; may lack CD146 and nucleus, requiring secondary validation [45] [44].
Erythro-Myeloid Progenitors (EMPs)	CD31, CD45 (low or +) [46]	Lineage markers (Lin-)	Peripheral Blood (Lin- enriched)	Heterogeneous; includes subpopulations like CD31lowCD45low and CD31highCD45+ [46].
Retinal Microglia	CD11b/c+, CD4low	CD45high (but are CD45low) [47]	Retina	Defined as CD45lowCD11b/c+CD4low; distinct from MHC Class II+ perivascular cells [47].

Experimental Protocols for Key Applications

Protocol 1: Flow Cytometric Validation of MSC Identity per ISCT Criteria

This protocol is designed for the verification of human MSCs following the minimal criteria established by the ISCT [9] [18].

• Sample Preparation: Culture candidate MSCs under standard conditions. Harvest cells using standard trypsinization or non-enzymatic cell dissociation reagents. Wash cells with a cold FACS buffer (e.g., PBS with 1-2% FBS).
• Staining Panel Design: Prepare an antibody panel that includes:
  • Positive Markers: Fluorescently-conjugated antibodies against CD73, CD90, and CD105.
  • Negative Markers: Antibodies against CD45, CD34, CD11b (or CD14), and CD19. Inclusion of HLA-DR is advised, with the note that its expression may be induced [9].
  • Viability Stain: Incorporate a viability dye such as 7-AAD or propidium iodide (PI).
• Staining Procedure: Resuspend approximately 1x10^6 cells per tube in FACS buffer. Incubate with normal serum or Fc block to reduce non-specific binding. Add the pre-titrated antibody cocktail and viability dye. Incubate in the dark for 25-30 minutes at 4°C. Wash cells twice with FACS buffer to remove unbound antibody.
• Flow Cytometry Acquisition & Gating Strategy:
  • Acquisition: Acquire data on a flow cytometer, collecting a sufficient number of events (e.g., 50,000-100,000) for statistical analysis of the population.
  • Gating: a. Singlets: Gate on single cells using FSC-A vs. FSC-W. b. Live Cells: Select viability dye-negative cells. c. MSC Phenotype: Within the live, single cell population, gate on cells that are positive for CD73, CD90, and CD105, and negative for the hematopoietic lineage markers (CD45, CD34, CD11b/CD14, CD19) [9].
• Interpretation: A population can be considered MSCs if ≥95% of the cells express CD73, CD90, and CD105, while ≤2% express the negative markers [9]. This immunophenotype must be coupled with functional assays for adherence to plastic and demonstration of trilineage differentiation potential.

Protocol 2: Identification of CD45low Populations in Heterogeneous Samples

This protocol outlines an approach for resolving CD45low cells, such as microglia or certain progenitors, from CD45- and CD45+ cells [47] [44].

• Sample Preparation & Pre-enrichment (Optional): For very rare populations, consider pre-enrichment steps. For circulating cells, this may involve density gradient centrifugation (e.g., Ficoll) to isolate peripheral blood mononuclear cells (PBMCs) or lineage depletion (Lin-) to remove mature hematopoietic cells [46]. For tissue samples like retina or brain, mechanical and enzymatic dissociation followed by Percoll density gradient centrifugation can be effective for isolating specific cell subsets [47].
• Staining Panel Design:
  • Primary Marker: An antibody against CD45 is central. Use a high-quality, brightly conjugated antibody (e.g., APC, BV421) to best resolve low expression levels.
  • Population-Specific Markers: Include antibodies to define the population of interest (e.g., CD11b/c for microglia [47], CD31 for endothelial cells/EMPs [46] [44]).
  • Viability Stain: A mandatory viability dye to exclude dead cells.
• Staining and Controls: Follow a standard staining procedure as in Protocol 1. It is critical to include FMO controls for CD45 and other key markers to accurately set boundaries for negative, low, and positive expression populations [43].
• Flow Cytometry Acquisition & Gating Strategy:
  • Acquisition: Use a low flow rate to enhance sensitivity for rare events. Acquire a high number of total events to ensure a statistically significant number of the rare CD45low population is captured.
  • Gating: a. Singlets and Live Cells: As in Protocol 1. b. CD45 Expression: Plot the fluorescence intensity of CD45 against SSC. A typical plot will show a continuum from CD45-negative (e.g., MSCs, CECs), to CD45low (e.g., retinal microglia, some EMPs), to CD45-high (leukocytes) [47] [46] [44]. c. Backgating: Validate the gated CD45low population by backgating onto the FSC vs. SSC plot to confirm its expected location based on size and granularity [43].

Visualizing Gating and Experimental Workflows

Diagram 1: Hierarchical Gating for Rare CD45low Cells

Diagram 2: MSC Identity Verification Workflow

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Rare Event Flow Cytometry

This table details key reagents and their critical functions in ensuring the validity of rare population analysis.

Reagent / Material	Function / Purpose	Application Example
Viability Dyes (PI, 7-AAD)	Distinguish live from dead cells; reduces non-specific binding and false positives.	Mandatory for accurate CEC [44] and MSC immunophenotyping.
Fluorescence Minus One (FMO) Controls	Define accurate positive/negative boundaries and account for spectral spillover in multicolor panels.	Critical for defining low-expression markers like CD45 [43].
Reference Reagents	Standardize instrument setup and staining protocols across labs and over time.	WHO IRR for MSC identity aids in validating equipment and results [18].
Pre-enrichment Kits	Increase the relative frequency of rare cells prior to flow cytometry.	Lineage depletion kits to enrich for EMPs [46] or density gradients for microglia [47].
High-Quality Antibodies (Bright Conjugates)	Maximize signal-to-noise ratio for detecting low-abundance surface markers.	Using APC or BV421-conjugated anti-CD45 to resolve CD45low populations.
Compensation Beads	Create single-stained controls for accurate spectral overlap compensation.	Essential for any multicolor panel to ensure clean signal separation [43].

The identity and functional potency of Mesenchymal Stromal Cells (MSCs) are fundamentally defined by specific quantitative thresholds established by the International Society for Cell Therapy (ISCT). These criteria provide the essential framework for validating MSC identity in research and drug development, ensuring consistency and reproducibility across laboratories. For researchers and scientists engaged in MSC characterization, adherence to these thresholds is not merely advisory but constitutes a foundational requirement for credible experimental outcomes. The ISCT standards establish three cardinal principles: plastic adherence under standard culture conditions, specific surface marker expression profiles with defined percentage thresholds, and trilineage differentiation potential [1] [48]. This guide systematically compares the application of these criteria across experimental contexts, providing detailed methodologies and data analysis approaches to standardize MSC characterization workflows. As the field advances, emerging technologies like single-cell transcriptomics are revealing further distinctions between MSCs and true stem cells, highlighting the continued importance of rigorous quantitative standards [49].

Core ISCT Criteria: Quantitative Thresholds and Marker Profiles

Surface Marker Expression Standards

The ISCT has established precise quantitative thresholds for surface marker expression to define human MSCs. These standards require specific percentages of positive and negative markers analyzed through flow cytometry, creating a definitive framework for cell population identification.

Table 1: ISCT Minimum Criteria for Human MSC Surface Marker Expression

Category	Markers	Threshold	Method of Analysis
Positive Expression	CD105, CD73, CD90	≥95% positive	Flow cytometry or immunocytochemistry
Negative Expression	CD45, CD34, CD14, CD19, HLA-DR	≤2% positive	Flow cytometry or immunocytochemistry

These thresholds ensure population purity and identity, with the positive markers confirming mesenchymal lineage and the negative markers excluding hematopoietic contamination [48]. Adherence to these percentages is critical for validating MSC identity across different tissue sources and laboratory environments.

Functional Potency Standards

Beyond surface markers, the ISCT criteria mandate functional validation through demonstrated trilineage differentiation potential. This requirement confirms the multipotent capacity of MSCs and represents a crucial quality assessment.

Table 2: Trilineage Differentiation Assessment Methods

Lineage	Induction Factors	Staining Method	Output Measurement
Adipogenic	Dexamethasone, insulin, IBMX, indomethacin	Oil Red O	Lipid droplet visualization
Osteogenic	Dexamethasone, ascorbic acid, β-glycerophosphate	Alizarin Red S, Von Kossa	Calcium deposit quantification
Chondrogenic	Dexamethasone, TGF-β1	Toluidine Blue, Alcian Blue	Proteoglycan detection

The differentiation capacity must be demonstrated qualitatively through visual confirmation of staining, and increasingly through quantitative methods such as spectrophotometric analysis of extracted dyes or gene expression analysis of lineage-specific markers [12] [50].

Advanced Quantitative Methods for MSC Potency Assessment

Proliferation and Metabolic Assays

While the ISCT criteria define identity, additional quantitative assays are necessary to predict MSC functional potency. Several validated methods provide insight into proliferation capacity and metabolic health:

• Growth Kinetics Analysis: MSC proliferation capacity can be quantified by plating cells at 2,000 cells/cm² in 24-well plates and monitoring percent confluence every 3 hours using live-cell imaging systems. Growth rates below 30 hours/doubling indicate robust self-renewal capacity [50] [48].
• Bromodeoxyuridine (BrdU) Incorporation: This proliferation assay involves seeding 500 cells per well in 96-well plates, adding BrdU label for 18 hours, and measuring incorporation through anti-BrdU antibody detection and spectrophotometric analysis [12].
• Metabolic Viability Assessment: Cellular ATP concentration serves as a sensitive indicator of metabolic health. The Lumistem assay platforms enable quantification of ATP levels by measuring luminescence after seeding 5,000 cells per well in 96-well plates and adding ATP-MR reagent [12].

Clonogenic and Differentiation Potential Quantification

Advanced quantitative methods enable precise measurement of MSC stem-like properties and differentiation efficiency:

• Colony Forming Unit (CFU) Assay: This clonogenicity assessment involves plating 100 cells per 10-cm tissue culture dish, maintaining cultures for 14 days without media changes, then staining with 3% Crystal Violet and counting colonies >2 mm in diameter. The percentage of CFUs indicates stemness frequency within the population [50].
• Adipogenic Precursor Frequency by Limiting Dilution: For precise quantification of adipogenic potential, MSCs are plated at serial dilutions (32-1,000 cells/well) in 96-well plates, induced with adipogenic differentiation media for 21 days, then fixed and stained with Oil Red O. The precursor frequency is calculated from the inverse of the cell dose corresponding to 37% non-responding wells, providing a quantitative measure of differentiation capacity [50].
• Flow Cytometric Cytotoxicity Assay: To assess MSC susceptibility to immune cell-mediated lysis, a robust assay utilizes differential immunostaining with CD105 (MSC marker) and CD45 (PBMC marker) combined with 7AAD viability staining and absolute counting with fluorospheres. This approach overcomes limitations of dye-based methods and provides precise quantification of target cell loss [51].

MSC Characterization Workflow

The following diagram illustrates the integrated experimental workflow for comprehensive MSC characterization, from isolation to final validation:

Experimental Protocols for MSC Characterization

Flow Cytometry Analysis for ISCT Marker Validation

Protocol Objective: Quantify expression of positive and negative MSC markers according to ISCT thresholds [48].

Materials:

• Single-cell suspension of MSCs (passage 3-5)
• Antibodies: CD73-FITC, CD90-FITC, CD105-PE, CD14-FITC, CD19-FITC, CD45-ECD, HLA-DR
• Flow cytometry staining buffer (PBS + 2% FBS)
• Flow cytometer with appropriate laser configurations

Methodology:

• Harvest MSCs at 80% confluence using trypsin/EDTA and resuspend in staining buffer at 1×10⁶ cells/mL.
• Aliquot 100 μL cell suspension into flow cytometry tubes.
• Add fluorochrome-labeled antibodies according to manufacturer recommendations.
• Incubate for 30 minutes at 4°C in the dark.
• Wash cells twice with staining buffer and resuspend in 300-500 μL buffer.
• Acquire data on flow cytometer, collecting at least 10,000 events per sample.
• Analyze using flow cytometry software, gating on viable cells based on forward/side scatter properties.

Data Analysis:

• Calculate percentage of positive cells for each marker using appropriate isotype controls for background subtraction.
• Validate MSC identity if ≥95% express CD73, CD90, CD105 and ≤2% express CD14, CD19, CD34, CD45, HLA-DR.
• Report fluorescence intensity and distribution patterns in addition to percentage values [52].

Trilineage Differentiation Protocol

Protocol Objective: Demonstrate adipogenic, osteogenic, and chondrogenic differentiation capacity of MSCs [12] [48].

Materials:

• MSCs at passage 4-5
• Basal media: α-MEM with 10% FBS
• Adipogenic induction supplements: dexamethasone, insulin, IBMX, indomethacin
• Osteogenic induction supplements: dexamethasone, ascorbic acid, β-glycerophosphate
• Chondrogenic induction supplements: dexamethasone, TGF-β1
• Staining solutions: Oil Red O, Alizarin Red S, Alcian Blue

Adipogenic Differentiation Method:

• Plate MSCs at 8,000 cells per well in tissue culture slides.
• Culture in growth media for 8 days with media changes every 4 days.
• Switch to adipogenic differentiation media for 16 days, changing media every 4 days.
• Fix cells with 100% ethanol for 15 minutes at room temperature.
• Stain with 0.25% Oil Red O solution to visualize lipid droplets.
• Quantify differentiation through spectrophotometric analysis of extracted dye or image analysis of lipid droplet area.

Osteogenic Differentiation Method:

• Plate MSCs as for adipogenic differentiation.
• Induce with osteogenic media for 16 days with media changes every 4 days.
• Fix cells and stain with 0.25% Alizarin Red S solution to detect calcium deposits.
• Quantify mineralization through spectrophotometric analysis of extracted dye.

Chondrogenic Differentiation Method:

• Pellet 2.5×10⁵ MSCs in a 15 mL conical tube.
• Culture pellet in chondrogenic induction media for 28 days with media changes every 3-4 days.
• Fix micromass, embed in agar, section with microtome.
• Stain with Alcian Blue to detect proteoglycan-rich matrix.

Adipogenic Precursor Frequency by Limiting Dilution

Protocol Objective: Quantitatively determine the frequency of adipogenic precursors in MSC populations [50].

Materials:

• MSC single-cell suspension
• 96-well flat-bottom tissue culture plates
• Adipogenic differentiation media
• Oil Red O staining solution
• Inverted microscope

Methodology:

• Prepare serial dilutions of MSCs in expansion media: 1,000, 500, 250, 125, 63, and 32 cells per well.
• Plate 48 wells for each cell dilution in 96-well plates.
• After 24 hours of adhesion, replace expansion media with 100 μL/well adipogenic differentiation media.
• Culture for 21 days, supplementing with fresh differentiation media every 3-5 days.
• On day 21, fix cells with 10% formalin and stain with Oil Red O.
• Score wells visually: wells containing at least one differentiated cell (red-stained lipid droplets) are positive.

Data Analysis:

• Calculate fraction of non-responding wells at each cell dilution.
• Plot fraction of non-responding wells against cell dilution on semi-logarithmic plot.
• Determine the cell dose corresponding to 37% non-responding wells.
• Calculate precursor frequency as the inverse of this cell dose.

Data Reporting Standards and Threshold Interpretation

Flow Cytometry Reporting Guidelines

Comprehensive reporting of flow cytometry data extends beyond simple percentage values to provide complete experimental context:

• Patient and Sample Demographics: Include sample type (bone marrow, adipose tissue, etc.), viability, and date of analysis [52].
• Instrumentation and Reagents: Specify flow cytometer model, laser configurations, antibody clones, and fluorochromes used.
• Gating Strategy: Document initial gating to exclude debris and dead cells, followed by population-specific analysis.
• Percentage Reporting: For abnormal populations, report percentage relative to a defined population (e.g., lymphocytes, white blood cells, or all nucleated cells) [52].
• Interpretation Guidelines: Include qualitative description of fluorescence distribution (negative/positive/partial) and intensity for relevant markers rather than exhaustive numerical data for every antigen [52].

Troubleshooting Discrepant Results

When MSC characterization yields unexpected results, systematic troubleshooting is essential:

• Reduced Positive Marker Expression: Passage-induced senescence can cause decreased CD105 expression. Evaluate earlier passages (P3-P5) and assess proliferation rates.
• Elevated Negative Marker Expression: Hematopoietic contamination during initial isolation may cause CD45+ populations. Implement additional purification steps such as density gradient centrifugation or plastic adherence duration optimization.
• Variable Differentiation Capacity: Donor-specific differences significantly impact differentiation potential. Implement quantitative potency assays like limiting dilution analysis to precisely measure differentiation frequency [50].
• Size-Related Functionality: Increased cell diameter with passaging correlates with decreased clonogenicity. Monitor cell size distributions and sort subpopulations if consistent functionality is required [50].

MSC Marker Analysis and Validation

The following diagram illustrates the decision process for validating MSC surface marker expression against ISCT criteria:

Research Reagent Solutions for MSC Characterization

Table 3: Essential Reagents for MSC Characterization Workflows

Reagent Category	Specific Examples	Function	Application Notes
Flow Cytometry Antibodies	CD73-FITC, CD90-FITC, CD105-PE, CD45-ECD, HLA-DR	Surface marker quantification	Validate antibody clones for consistency; use same lot for comparative studies
Differentiation Kits	StemPro Adipogenesis, Osteogenesis, Chondrogenesis kits	Trilineage differentiation induction	Standardized formulations ensure reproducibility across experiments
Cell Viability Assays	Lumistem ATP assay, BrdU proliferation assay	Metabolic health and proliferation assessment	ATP levels more accurately reflect metabolic status than simple dye exclusion
Cell Culture Media	α-MEM with 16.5% FBS, platelet lysate supplements	MSC expansion and maintenance	Serum lot consistency critical for reproducible growth kinetics
Molecular Biology Kits	RNA sequencing kits, quantitative PCR assays	Gene expression analysis	Validate reference genes for MSC studies (GAPDH, β-actin)
Extracellular Matrix	Fibronectin, collagen I, collagen VI	Assessment of MSC matrisome production	Tissue-specific ECM profiles influence MSC behavior [53]

The validation of MSC identity through rigorous application of ISCT criteria remains foundational to reproducible research and successful therapeutic development. This guide has detailed the essential quantitative thresholds, experimental protocols, and data analysis methods required to standardize MSC characterization across laboratories. The integration of basic ISCT standards with advanced potency assays provides a comprehensive framework for predicting MSC functional capacity. As single-cell technologies reveal increasing heterogeneity within MSC populations [49], and proteomic analyses identify tissue-specific signatures [53], the need for standardized quantitative thresholds becomes ever more critical. By implementing these detailed methodologies and maintaining rigorous adherence to percentage thresholds, researchers can ensure the validity of their MSC characterization data, enabling meaningful comparisons across studies and accelerating the development of MSC-based therapies.

The development of robust potency assays for Mesenchymal Stromal Cell (MSC)-based therapies represents a critical bottleneck in the translation from research to clinical application. These assays must quantitatively demonstrate the biological activity of the product that is linked to its intended mechanism of action, in accordance with regulatory guidelines such as ICH Q2(R1). For MSC products, the International Society for Cell & Gene Therapy (ISCT) has established minimal criteria for defining human MSCs, which include adherence to plastic, specific surface marker expression, and multipotent differentiation potential [9]. Flow cytometry has emerged as a powerful analytical tool that can satisfy multiple regulatory requirements by simultaneously assessing product identity, purity, and potency through quantitative measurement of critical quality attributes.

The fundamental challenge in MSC potency assay development stems from the complex and often multifunctional mechanisms of action underlying MSC therapies. Unlike traditional pharmaceuticals with single, well-defined targets, MSCs exert therapeutic effects through multiple pathways including immunomodulation, trophic factor secretion, and direct differentiation [9] [1]. This complexity necessitates a strategic approach to validation that demonstrates the assay's ability to reliably measure biologically relevant attributes that correlate with clinical efficacy. The validation process must address precision, accuracy, specificity, range, linearity, and robustness as outlined in ICH Q2(R1), while also accommodating the inherent biological variability of living cell products.

Core Validation Parameters for Flow Cytometric Potency Assays

Alignment with ICH Q2(R1) Validation Characteristics

The validation of flow cytometric methods for MSC potency testing requires meticulous attention to the validation parameters defined in ICH Q2(R1). Each parameter must be addressed with specific experiments designed to generate quantitative data supporting the assay's reliability for its intended purpose. Specificity demonstrates that the assay accurately measures the intended analyte in the presence of other components, which for MSC flow cytometry involves using appropriate isotype controls and fluorescence minus one (FMO) controls to establish gating strategies that accurately identify target populations while excluding debris and non-viable cells [54].

Accuracy and precision present unique challenges for cell-based flow cytometry assays, as they must account for both technical variability (instrument performance, reagent lot variation) and biological variability (donor-to-donor differences, passage effects). Accuracy is typically established through comparison with reference standards or orthogonal methods, such as the WHO International Reference Reagent for MSC identity, which was shown in a collaborative study to "perform extremely well under all the different conditions" across 15 participants from 9 laboratories [18]. Precision encompasses repeatability (intra-assay), intermediate precision (inter-assay, inter-operator, inter-day), and reproducibility (inter-laboratory), with acceptance criteria often set at ≤15-20% coefficient of variation for quantitative flow cytometric measurements [54].

The validation of range and linearity establishes that the assay provides accurate and precise results across the entire continuum of expected values, which for MSC marker expression typically spans from 0% to 100% positive cells. Linearity is demonstrated through serial dilution experiments, while the validated range represents the interval over which acceptable linearity, accuracy, and precision are maintained. Robustness testing evaluates the method's capacity to remain unaffected by small, deliberate variations in method parameters, such as changes in antibody incubation time, temperature, or instrument settings, which helps establish standard operating procedures and system suitability criteria [54].

Quantitative Acceptance Criteria for MSC Flow Cytometry

Table 1: Validation Parameters and Typical Acceptance Criteria for MSC Flow Cytometric Potency Assays

Validation Parameter	Experimental Approach	Typical Acceptance Criteria	Reference Method/Standard
Specificity	Isotype controls, FMO controls, viability dye exclusion	Clear separation of positive and negative populations; ≥95% agreement with morphological assessment	WHO IRR for MSC identity [18]
Accuracy	Comparison with reference method or standard	Mean difference ≤10% from reference value	ISCT recommended markers [9]
Precision (Repeatability)	Intra-assay: 10 replicates of same sample	CV ≤15% for quantitative markers	Established internal control [54]
Precision (Intermediate Precision)	Inter-assay: 3 different days, 2 operators	CV ≤20% for quantitative markers	Established internal control [54]
Linearity	Serial dilution of MSC sample	R² ≥0.95 across 5 dilution points	Cell count standardization [54]
Range	Expression from 0% to 100% positive cells	Meets accuracy and precision criteria across range	Instrument dynamic range verification [54]
Robustness	Deliberate variation in incubation time, temperature	CV ≤20% across tested conditions	Established SOP parameters [54]

Implementing ISCT Criteria within a Regulatory Framework

Standardized Marker Panels and Gating Strategies

The ISCT minimal criteria for MSC definition provide a foundational framework for identity testing, requiring ≥95% expression of CD73, CD90, and CD105, and ≤2% expression of hematopoietic markers (CD45, CD34, CD14/CD11b, CD79α/CD19, and HLA-DR) [9]. Implementing these criteria within a validated potency assay requires standardized gating strategies that consistently identify the target population while excluding debris, dead cells, and non-MSC populations. The analytical workflow begins with light scatter gating to exclude debris and doublets, followed by viability dye exclusion to eliminate dead cells, and finally marker-specific gating to quantify positive and negative populations according to ISCT criteria [55].

A key advancement in standardizing MSC flow cytometry has been the development of the WHO International Reference Reagent (IRR) for MSC identity, which provides a benchmark for validating laboratory-specific methods and instruments. In a collaborative study involving 15 participants across 9 laboratories, the reference reagent "performed extremely well under all the different conditions," with mean values falling "very close to the ranges for % expression for each of the markers in the ISCT recommendations" [18]. This reagent serves as a critical tool for establishing accuracy and reproducibility across different laboratories and platforms, though it is important to note that it is "not a replacement for the ISCT values but a tool to help researchers to validate their equipment and results" [18].

The complexity of MSC biology necessitates that the standard ISCT criteria be viewed as a minimum baseline rather than a comprehensive identity profile. Emerging evidence suggests that additional markers may provide valuable information about functional potency. For instance, CD36, CD163, CD271, CD200, CD273, CD274, CD146, CD248, and CD140b have been identified as potentially discriminating adipose-derived MSCs from other cell types and may correlate with functional characteristics [14]. Furthermore, the expression of certain markers may vary based on tissue source, with CD34 expression observed in adipose-derived MSCs at the time of isolation but lost during culture [9]. These nuances highlight the importance of context-specific validation and the potential need for expanded marker panels that reflect the biological complexity and intended mechanism of action of specific MSC products.

Visualizing the MSC Validation Workflow

Diagram 1: Comprehensive workflow for validating MSC identity and potency using flow cytometry, incorporating ISCT criteria and additional potency markers within a regulatory framework.

Advanced Technical Considerations for Assay Validation

Instrument Qualification and Standardization

The validation of flow cytometric potency assays requires thorough instrument qualification to ensure analytical performance throughout method implementation and routine use. This process includes demonstration of optical alignment, fluidic stability, fluorescence sensitivity, and spectral compensation accuracy. Daily quality control using standardized fluorescent beads establishes instrument performance thresholds and validates that key parameters such as laser power, fluorescence detection efficiency, and background levels remain within specified ranges. This foundational qualification is essential for generating reliable, reproducible data that meets regulatory standards [54].

Multicenter validation studies have demonstrated that standardized protocols can yield highly consistent results across different instruments and laboratories when proper controls are implemented. The WHO collaborative study that evaluated the IRR for MSC identity noted that participants were asked "to run the reagent in their inhouse flow cytometry set-up as usual, and report back as if it was one of their own samples," with "no restrictions or recommendations given" [18]. Despite this methodological diversity, the reagent "performed extremely well under all the different conditions," suggesting that with appropriate biological standards, inter-laboratory reproducibility is achievable [18]. This finding supports the implementation of a controls-based approach to validation, where system suitability is demonstrated through the consistent performance of reference materials rather than absolute standardization of all method parameters.

Addressing MSC Heterogeneity and Source Variability

A significant challenge in MSC potency assay validation is accounting for the inherent heterogeneity of MSC populations, both between different tissue sources and between donors. While the ISCT criteria provide a universal definition, the biological and functional characteristics of MSCs can vary substantially based on their origin. Bone marrow-derived MSCs remain the most extensively characterized, but adipose tissue, umbilical cord, dental pulp, and other perinatal tissues have emerged as important alternative sources, each with potential distinctions in marker expression and functional capabilities [1]. For example, CD34 expression has been observed in freshly isolated adipose-derived MSCs but is typically absent in bone marrow-derived MSCs, creating potential misinterpretation if rigid application of ISCT criteria is followed without source-specific validation [9].

This biological variability necessitates that validation studies include MSC populations from multiple donors and tissue sources to demonstrate that the assay performs reliably across the expected spectrum of biological variation. The inclusion of additional markers beyond the core ISCT panel may enhance the ability to distinguish functional subpopulations or potency-relevant characteristics. Research has identified several "non-classical" markers that may provide valuable information about MSC quality, including CD36, CD163, CD271, CD200, CD273, CD274, CD146, CD248, and CD140b, which exhibit variability among different cell isolates and may be "informative when manufacturing cells" [14]. The validation of such extended marker panels should follow the same rigorous approach applied to core ISCT markers, with demonstrated link to product potency where possible.

Current Regulatory Landscape and Future Directions

Analysis of Approved Cellular Therapy Products

The regulatory approach to potency testing for cell therapies continues to evolve as regulatory agencies gain experience with increasingly diverse product types. An analysis of the 31 FDA-approved cell therapy products reveals important trends in potency testing strategies. Of these approved products, 61% utilize cell viability or cell count measurements as potency tests, while 65% employ some form of gene or protein expression analysis, frequently using flow cytometry [56]. On average, each approved product incorporates 3.4 potency tests, with a standard deviation of 2.0, reflecting the product-specific nature of potency testing strategies [56].

Table 2: Potency Test Categories for FDA-Approved Cell Therapy Products

Product Category	Number of Products	Average Number of Potency Tests	Most Frequently Used Test Types
Hematopoietic Stem Cell-Cord Blood	5	4.4	Viability, Cell Count, CD34+ Expression
CAR T-Cell Products	7	1.9	Viability, CAR Expression, Transduction Efficiency
Tissue Engineered Products	5	1.8	Viability, Histology
All Approved Cell Therapies	31	3.4	Viability (61%), Expression (65%)

This analysis demonstrates that flow cytometry-based tests play a crucial role in current potency testing paradigms, particularly for expression-based characterization. However, it also highlights that most products employ a matrix approach, combining multiple test methods to comprehensively assess potency. For MSC products specifically, this suggests that flow cytometry for identity and marker expression should be complemented with functional assays such as immunomodulation testing or differentiation potential to fully characterize product potency [56]. The limited use of bioassays as potency tests (only 7 of 31 products) may reflect the developmental and validation challenges associated with these typically more variable methods, though redaction of proprietary information may obscure their actual prevalence [56].

Emerging Trends and Methodological Advances

The field of MSC potency testing continues to advance with several emerging trends shaping future validation approaches. There is growing recognition that the traditional ISCT criteria, while necessary for product identity, may be insufficient for fully characterizing therapeutic potency. Consequently, research efforts are focusing on identifying novel markers that correlate with specific mechanisms of action or therapeutic outcomes. For example, the quantification of MSC-like cells in bone marrow has been investigated as a potential biomarker for disease progression in myelodysplastic syndrome, suggesting that specific MSC subpopulations may have diagnostic and potentially therapeutic relevance [55].

Methodologically, there is increasing emphasis on the development of analytical approaches that can simultaneously assess multiple critical quality attributes, with flow cytometry positioned as a versatile platform for such multiparameter assessment. Advances in high-parameter flow cytometry, automated analysis algorithms, and data integration platforms are enabling more comprehensive product characterization without corresponding increases in resource requirements. Additionally, the adoption of design-of-experiment approaches to method validation allows for more efficient characterization of method robustness and the interaction between multiple method parameters [54].

Looking forward, the field is moving toward mechanistic potency assays that specifically measure attributes linked to biological activity, with flow cytometry serving as a cornerstone technology in this evolution. As one review notes, flow cytometric assays are increasingly used "as surrogates of functional assays to allow comparison and release of cellular products for clinical use" [54]. This trend underscores the importance of thoroughly validated flow cytometric methods that not only satisfy regulatory requirements but also provide meaningful insight into product quality and biological function.

The Scientist's Toolkit: Essential Research Reagent Solutions

Table 3: Key Research Reagent Solutions for MSC Flow Cytometric Analysis

Reagent Category	Specific Examples	Function in MSC Validation	Considerations for Implementation
Reference Standards	WHO IRR for MSC identity [18]	Instrument and method qualification	Provides benchmark for inter-laboratory standardization
Core Antibody Panel	CD73, CD90, CD105, CD45, CD34, CD14/CD11b, HLA-DR [9]	ISCT criteria verification	Requires validation for each specific MSC source
Extended Characterization Panel	CD36, CD163, CD271, CD200, CD146 [14]	Potency-relevant subpopulation identification	Marker selection should link to mechanism of action
Viability Indicators	7-AAD, DAPI, propidium iodide [54]	Exclusion of non-viable cells from analysis	Must be validated with specific antibody combinations
Intracellular Staining Reagents	Fixation, permeabilization buffers, intracellular antibodies	Assessment of intracellular markers	Requires separate validation from surface staining
Compensation Controls	Capture beads, antibody compensation standards	Fluorescence compensation	Essential for multicolor panel accuracy
System Suitability Controls	Stable fluorescent cell lines, calibration beads	Daily instrument performance verification	Establishes baseline for longitudinal data comparison

Solving Common Challenges in MSC Flow Cytometry and Enhancing Assay Quality

The therapeutic potential of Mesenchymal Stromal Cells (MSCs) is significantly hampered by their inherent heterogeneity, which presents substantial challenges for clinical translation and reproducible research outcomes. This heterogeneity manifests across multiple dimensions: donor-specific characteristics, diverse tissue sources, and variable culture conditions, all of which profoundly influence the phenotypic and functional properties of these cells [57] [58]. The International Society for Cell & Gene Therapy (ISCT) has established baseline criteria for defining MSCs, requiring plastic adherence, trilineage differentiation potential, and expression of specific surface markers (CD73, CD90, CD105) while lacking hematopoietic markers [9]. However, research demonstrates that adherence to these minimum criteria alone is insufficient for predicting therapeutic potency or functional capacity [57]. A critical analysis of how biological and technical variables impact marker expression patterns is therefore essential for advancing MSC-based therapies from laboratory research to reliable clinical applications, enabling researchers to better stratify cell populations for specific therapeutic applications and improve experimental reproducibility.

Impact of Donor Characteristics on MSC Marker Expression

Donor-specific factors introduce significant variability in MSC populations, affecting both their surface marker profile and functional capabilities. Understanding these relationships is crucial for donor selection and experimental design in preclinical and clinical studies.

Age and Genetic Background: A 2025 bovine model study demonstrated that donor age and breed distinctly influence MSC characteristics [58]. MSCs isolated from fetal and calf Holstein Friesian (HF) animals showed superior proliferation capacity compared to adult donors. Furthermore, breed-specific differences were evident in osteogenic differentiation potential and immunophenotype; Belgian Blue (BB)-derived MSCs exhibited enhanced osteogenic capacity, while calf HF-MSCs contained a higher percentage of CD34+ cells, a marker correlated with both osteogenic potential and proliferation [58]. These findings highlight how intrinsic genetic factors interact with developmental stage to shape MSC properties.

Growth Capacity and Potency: Research on human bone marrow-derived MSCs revealed that cells from different age- and sex-matched donors could be stratified into high-growth and low-growth capacity groups based on their long-term expansion potential in vitro [57]. This functional distinction correlated with significant phenotypic differences. High-growth capacity MSCs were typically smaller, exhibited greater colony-forming efficiency, and expressed higher levels of the markers STRO-1 and platelet-derived growth factor receptor alpha (PDGFR-α), which were not discernible through the standard ISCT panel [57]. These findings underscore that donor-dependent functional potency is reflected in specific marker expression patterns beyond the conventional ISCT criteria.

Table 1: Impact of Donor Characteristics on MSC Properties

Donor Characteristic	Impact on MSC Properties	Key Markers Affected	Functional Consequences
Age (Fetal/Calf vs. Adult) [58]	Increased proliferation, variable differentiation potential	CD34 expression levels	Fetal/calf MSCs show higher proliferative capacity; age effects on differentiation are lineage-specific
Breed/Genetic Background [58]	Distinct differentiation potential, immunophenotype	CD34, breed-specific markers	Belgian Blue MSCs showed superior osteogenesis vs. Holstein Friesian
Inherent Growth Capacity [57]	Cell size, clonogenicity, telomere length	STRO-1, PDGFR-α, TWIST-1, DERMO-1	High-growth MSCs produced double the mineralized tissue volume in vivo

Influence of Tissue Source on MSC Phenotype

The anatomical origin of MSCs is a major determinant of their molecular signature and functional specialization, contributing significantly to heterogeneity in research and clinical applications.

Proteomic and Functional Distinctions: A comprehensive 2025 proteomic analysis comparing MSCs from different sources identified clear tissue-specific protein signatures [59]. The study demonstrated that while adipose-derived MSCs (AD-MSCs) and dental pulp stem cells (DPSCs) shared similar expression of classical surface markers (CD73, CD90, CD105), they exhibited distinct functional pathway activations. AD-MSCs showed a strong association with angiogenesis and vascularization pathways, while DPSCs displayed upregulated pathways involved in cell migration, adhesion, and Wnt signaling [59]. This suggests that tissue-specific MSCs may be preferentially suited for different regenerative applications—AD-MSCs for vascularized tissues and DPSCs for defect repair requiring robust cellular integration.

Discrimination from Fibroblasts: The challenge of distinguishing MSCs from fibroblasts, which can contaminate cultures, requires source-specific marker panels. A 2020 flow cytometry study identified unique combinations of surface markers that could discriminate MSCs of different origins from fibroblasts [60]:

• Adipose Tissue MSCs: CD79a, CD105, CD106, CD146, CD271
• Bone Marrow MSCs: CD105, CD106, CD146
• Wharton's Jelly MSCs: CD14, CD56, CD105
• Placental MSCs: CD14, CD105, CD146

This research highlights that no single universal marker cleanly separates all MSCs from fibroblasts; instead, authentication requires tissue-specific validation panels [60].

Table 2: Tissue-Specific Marker Expression and Functional Properties of MSCs

Tissue Source	Distinguishing Positive Markers	Key Functional Specializations	Research Applications
Adipose Tissue (AT) [14] [60]	CD36, CD163, CD273, CD274, CD106, CD146, CD271	High angiogenic potential; efficient immunomodulation	Vascular regeneration, immune modulation
Bone Marrow (BM) [57] [60]	STRO-1, PDGFR-α, CD106, CD146	Standard for osteogenesis; heterogeneous populations	Skeletal tissue regeneration, basic MSC biology
Dental Pulp (DPSC) [59]	Enhanced migration/adhesion pathways	Strong migration and adhesion capabilities	Defect repair models requiring tissue integration
Umbilical Cord/Wharton's Jelly [1] [60]	CD14, CD56, CD105	Perinatal source with high proliferative capacity	High-volume expansion, allogeneic therapy

Effects of Culture Conditions and Manufacturing Processes

The methods used to isolate, expand, and maintain MSCs create technical heterogeneity that can profoundly alter their phenotypic characteristics, potentially masking or modifying their innate biological properties.

Culture Media Composition: The choice of culture supplement can induce significant changes in the MSC surfaceome. Clinical-grade adipose-derived MSCs expanded in human platelet lysate (hPL) maintained homogeneity for classical markers but exhibited variable expression of non-classical markers including CD36, CD163, CD271, CD200, CD273, CD274, CD146, and CD248 across different donors [14]. This demonstrates that culture conditions can reveal or suppress specific marker expressions that may be relevant for therapeutic function.

Passaging and Cryopreservation: Manufacturing processes such as extended passaging and cryopreservation significantly impact MSC marker stability. Studies note that CD34 expression is rapidly lost in adipose-derived MSCs when placed in culture, suggesting that negative marker status may be a culture artifact rather than an innate characteristic [9] [58]. Furthermore, the state of cells (freshly prepared, previously frozen, or actively proliferating) affects the surface expression of many non-classical markers, necessitating careful documentation of cell handling procedures when interpreting flow cytometry data [14].

Experimental Protocols for Addressing Heterogeneity

Standardized experimental approaches are essential for meaningful interpretation of MSC marker expression across different studies and laboratory settings. Below are detailed methodologies for key characterization protocols.

Multicolor Flow Cytometry for Immunophenotyping

Objective: To comprehensively profile MSC surface markers, account for donor and tissue source heterogeneity, and distinguish MSCs from contaminating fibroblasts [55] [60].

Protocol Steps:

• Cell Preparation: Harvest subconfluent cells (P3-P5) using enzyme-free dissociation buffer to preserve surface epitopes. Pass single-cell suspension through a 70μm strainer.
• Antibody Staining: Incubate 1×10^5 cells in FACS buffer (DPBS with 1mM EDTA and 5% mouse serum) for 30 minutes at 4°C to block Fc receptors. Add fluorescently-conjugated antibody panels (Table 3) and incubate for 1 hour at 4°C in the dark [59] [60].
• Data Acquisition: Wash cells, resuspend in FACS buffer, and analyze on a flow cytometer (e.g., BD FACSArray or FACS Aria II). Acquire at least 10,000 events per sample with consistent gating based on unstained and isotype controls [57] [59].
• Analysis: Determine positive/negative populations using fluorescence-minus-one (FMO) controls. Report percentage positive cells and median fluorescence intensity (MFI) for quantitative comparisons [6].

Functional Potency Assays

Objective: To correlate marker expression profiles with functional potency, moving beyond minimal identification criteria [57].

In Vivo Bone Formation Assay:

• Implementation: Combine 4×10^6 MSCs with 40mg of hydroxyapatite/tricalcium phosphate ceramic particles in a diffusion chamber. Implant subcutaneously in immunocompromised mice for 8 weeks [57].
• Analysis: Process explants for histology (paraffin embedding, H&E staining). Quantify formed bone volume relative to total tissue volume using image analysis software. High-growth capacity MSCs typically produce approximately double the mineralized tissue volume compared to low-growth capacity MSCs [57].

Colony-Forming Unit Fibroblast (CFU-F) Assay:

• Implementation: Plate bone marrow mononuclear cells at 0.5-3.0×10^6 cells in T75 flasks. Culture for 14 days, then stain with 0.5% crystal violet [57].
• Analysis: Count colonies containing ≥50 cells not in contact with adjacent colonies. Calculate efficiency as colonies formed per 10^5 cells plated. High colony-forming efficiency correlates with stem cell enrichment [57].

Visualization of Experimental Workflows and Marker Relationships

MSC Characterization Workflow

Marker Expression Relationships

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagent Solutions for MSC Characterization

Reagent Category	Specific Examples	Research Application	Considerations
Flow Cytometry Antibodies	CD73, CD90, CD105, CD45, CD34, CD14, CD19, HLA-DR [9]	ISCT minimum criteria verification	Include isotype controls; validate antibody clones
Extended Characterization Antibodies	STRO-1, PDGFR-α, CD146, CD271, CD106, CD36 [57] [14] [60]	Potency assessment and tissue source identification	STRO-1 requires special sourcing [57]
Culture Media Supplements	Fetal Bovine Serum (FBS), Human Platelet Lysate (hPL) [14]	MSC expansion	hPL reduces zoonotic risks but affects marker expression [14]
Enzymatic Dissociation Reagents	Collagenase (Type I), Liberase, TrypLE [14] [58]	Tissue digestion and cell harvesting	Enzyme choice affects surface epitope preservation
Functional Assay Kits	OsteoMAX-XF, StemPro Adipogenesis Kit [59]	Trilineage differentiation assessment	Standardize differentiation protocols for comparisons

The heterogeneity of MSCs, driven by donor characteristics, tissue source, and culture conditions, presents both a challenge and an opportunity for the field. While the ISCT minimum criteria provide a essential foundation for MSC identification, they are insufficient alone for predicting therapeutic potency or fully characterizing these complex cell populations [57]. The research community is moving toward more nuanced characterization strategies that incorporate quantitative flow cytometry, tissue-specific marker panels, and functional potency assays correlated with phenotypic profiles [6] [14]. Successfully navigating MSC heterogeneity requires rigorous reporting of donor metadata, tissue source, and culture conditions alongside standardized functional assays. By adopting these comprehensive characterization approaches, researchers can transform heterogeneity from a confounding variable into a stratifiable parameter, ultimately advancing the development of more reliable and effective MSC-based therapies. The future of MSC research lies not in eliminating heterogeneity, but in understanding and leveraging it to match specific MSC profiles with appropriate therapeutic applications.

The International Society for Cell and Gene Therapy (ISCT) has established minimal criteria for defining mesenchymal stromal cells (MSCs), including plastic adherence, multipotent differentiation potential, and specific surface marker expression patterns [9] [61]. According to these standards, MSCs must demonstrate ≥95% expression of CD73, CD90, and CD105 while showing ≤2% expression of hematopoietic markers including CD34, CD45, CD11b, CD14, CD19, and HLA-Class II [9]. However, recent research has revealed significant complexities and contextual variations in the expression of CD34 and HLA-Class II molecules that challenge these rigid classifications. This guide objectively compares standard interpretations against emerging evidence, providing researchers with a framework for navigating these complexities in experimental design and data interpretation.

The CD34 Controversy: Negative Marker or Tissue-Resident Marker?

Established ISCT Criteria Versus Emerging Evidence

The ISCT position designating CD34 as a negative marker for MSCs primarily reflects the phenotype of culture-adapted, plastic-adherent cells [9]. However, substantial evidence indicates this classification represents an artifact of in vitro expansion rather than the true nature of tissue-resident MSCs.

Table 1: Comparative Analysis of CD34 Expression in MSCs

Aspect	Traditional ISCT View	Emerging Evidence
Expression Status	CD34 is a negative marker (≤2% expression) [9]	Freshly isolated MSCs from bone marrow and adipose tissue express CD34 [62] [63]
Technical Basis	Analysis of cultured, plastic-adherent MSCs [9]	Analysis of uncultured, tissue-resident MSCs [63]
Temporal Pattern	Consistent negative expression	Dynamic expression: positive in tissue, lost during culture [62] [63]
Functional Association	Distinguishes MSCs from HSCs	CD34+ fraction contains majority of colony-forming unit fibroblasts (CFU-F) [63]
Tissue Specificity	Uniform across tissues	Varies by tissue source (e.g., strongly expressed in adipose-derived MSCs) [62]

Experimental Evidence Challenging the CD34 Dogma

Multiple studies have demonstrated that CD34+ bone marrow cells give rise to the majority of fibroblast colonies (CFU-F), with one study reporting growth in 19 of 87 wells from the CD34+ fraction versus no growth from the CD34- fraction [63]. Similarly, freshly isolated adipose-derived MSCs (ADSCs) consistently show CD34 positivity at isolation, with disappearance of expression during culture propagation [62] [63].

The historical context reveals that the Stro-1 antibody, widely used for MSC isolation, was generated using CD34+ bone marrow cells as immunogen, further supporting the connection between CD34 and primitive stromal precursors [63].

Recommended Experimental Approaches for CD34 Investigation

For accurate CD34 characterization, researchers should:

• Analyze freshly isolated cells from target tissues prior to plastic adherence and culture expansion [63]
• Implement time-course studies tracking CD34 expression from isolation through successive passages using flow cytometry [62]
• Perform functional correlation between CD34 expression patterns and CFU-F efficiency or differentiation potential [63]
• Include appropriate controls accounting for tissue-specific variations (adipose vs. bone marrow vs. umbilical cord) [62]

HLA-Class II Induction: From Negative Marker to Activation Signal

Context-Dependent Expression and Regulatory Mechanisms

While the ISCT criteria classify HLA-Class II as a negative marker for MSCs, this reflects only the basal state of unstimulated cells. Upon exposure to inflammatory stimuli, particularly interferon-gamma (IFN-γ), MSCs significantly upregulate HLA-Class II expression [61]. This induction represents a critical functional adaptation rather than a deviation from MSC identity.

Table 2: HLA-Class II Expression in MSCs Under Different Conditions

Condition	HLA-Class II Expression	Functional Significance	Therapeutic Implications
Basal State (Unstimulated)	Low or absent (≤2%) [9]	Default immunophenotype	Compliance with ISCT release criteria
IFN-γ Licensing	Significantly upregulated [61]	Enhanced immunomodulatory capacity; antigen presentation potential	Improved therapeutic efficacy for inflammatory conditions
Post-Licensing In Vivo	Context-dependent persistence	May trigger host immune recognition	Potential reduced persistence in allogeneic settings

Molecular Mechanisms of HLA-Class II Induction

The IFN-γ-mediated induction of HLA-Class II occurs through the JAK-STAT signaling pathway, where IFN-γ binding to its receptor activates JAK kinases, leading to phosphorylation of STAT1 transcription factors [61]. Activated STAT1 translocates to the nucleus and drives expression of class II transactivator (CIITA), the master regulator of HLA-Class II genes [61].

Experimental evidence indicates that protein kinase C (PKC) activity is required throughout the signaling events leading to HLA-Class II expression [64]. When PKC inhibitors were added up to 20 hours after IFN-γ stimulation, they effectively prevented further HLA-Class II expression [64].

Methodologies for Investigating HLA-Class II Dynamics

To properly characterize HLA-Class II expression:

• Implement IFN-γ licensing protocols using concentrations ranging from 10-50 ng/mL for 24-96 hours [61]
• Employ flow cytometry with viability dyes to distinguish true expression from artifactual uptake by dead cells [61]
• Utilize molecular techniques (RT-PCR, Western blotting) to confirm transcriptional and translational regulation [65]
• Consider functional correlates including IDO activity, PDL-1 expression, and T-cell modulation capacity [61]

Research Reagent Solutions for Marker Validation

Table 3: Essential Reagents for Investigating MSC Marker Expression

Reagent Category	Specific Examples	Research Application	Technical Considerations
Flow Cytometry Antibodies	CD73, CD90, CD105, CD34, CD45, HLA-DR [9]	Immunophenotyping per ISCT criteria	Include viability dyes; establish compensation controls
Cell Isolation Kits	Enzymatic digestion cocktails; density gradient media [1]	Tissue-specific MSC isolation	Optimization required for different tissue sources
Cell Culture Media	Specific MSC expansion media; serum-free formulations [1]	In vitro expansion	Serum lots may affect marker expression
Differentiation Kits	Osteogenic, adipogenic, chondrogenic induction media [9]	Multipotency verification	Include appropriate staining protocols
Cytokines/Activators	Recombinant IFN-γ; PKC inhibitors [61] [64]	HLA-Class II induction studies	Titrate concentrations; optimize timing

The characterization of MSCs requires moving beyond rigid adherence to marker checklists toward a more nuanced understanding of contextual expression patterns. The CD34 controversy highlights that what we define as "MSC markers" largely reflects culture-adapted cells rather than tissue-resident populations, with potentially significant functional implications. Similarly, HLA-Class II induction represents a biologically meaningful response to inflammatory cues rather than a deviation from MSC identity.

For research and therapeutic applications, we recommend:

• Reporting detailed methodological context including tissue source, passage number, and culture conditions
• Implementing complementary validation approaches that correlate marker expression with functional potency
• Developing tissue-specific characterization frameworks that account for source-dependent variations
• Considering dynamic marker modulation as a feature of MSC biology rather than a quality concern

This refined approach to MSC characterization will enhance experimental reproducibility, facilitate appropriate clinical translation, and ultimately advance our understanding of MSC biology in health and disease.

The transition of Mesenchymal Stromal Cells (MSCs) from research tools to clinically approved therapeutics hinges on demonstrating consistent product quality, safety, and efficacy. According to the International Society for Cellular Therapy (ISCT), defining MSC identity requires a trifecta of criteria: adherence to plastic, specific surface marker expression (CD73, CD90, CD105 ≥95%; CD34, CD45, CD14, CD19, HLA-DR ≤2%), and trilineage differentiation potential [4]. However, these identity criteria alone are insufficient for predicting therapeutic efficacy, particularly for immunomodulatory applications. The functional potency of MSC products—their specific biological activity—can vary substantially based on tissue origin, donor characteristics, and production methods [66] [67]. Consequently, regulatory frameworks for advanced therapy medicinal products mandate the development of robust potency assays that quantitatively link MSC phenotype to immunomodulatory function [29]. The Mixed Lymphocyte Reaction (MLR) has emerged as a leading functional assay that directly measures the capacity of MSCs to suppress alloreactive T-cell responses, providing a critical bridge between MSC identity and their therapeutic mechanism of action in immune-mediated diseases.

MLR Fundamentals: Physiological Relevance and Technical Implementation

The Mixed Lymphocyte Reaction exploits the natural alloreactivity that occurs when immune cells from genetically distinct donors are co-cultured. This physiological relevance makes it particularly valuable for predicting how MSCs will perform in clinical settings involving immune activation, such as graft-versus-host disease (GVHD) and autoimmune disorders. In a standard MLR potency assay, responder Peripheral Blood Mononuclear Cells (PBMCs) from multiple donors are combined to create a robust alloreactive response, and the test MSC product is evaluated for its ability to suppress the resulting T-cell proliferation [66] [67].

Table 1: Key Components of MLR Potency Assays for MSC Immunomodulation

Component	Function in Assay	Optimization Parameters	Research Reagent Solutions
Responder PBMCs	Source of alloreactive T-cells	Donor combination (4+ donors recommended), cryopreservation method, viability >90%	Fresh or cryopreserved PBMCs from healthy donors; CryoStor CS10 for GMP-compliant cryopreservation [67] [68]
MSC Test Article	Immunomodulatory agent being evaluated	Passage number, confluency, viability, MSC:PBMC ratio	MSCs expanded under GMP conditions; characterized per ISCT criteria [4]
Culture Conditions	Microenvironment for immune cell interaction	Medium formulation, serum source, plating density, duration	RPMI-1640 + 10% FBS; 96-well round-bottom plates; 5-7 day culture [69] [67]
Proliferation Readout	Quantification of T-cell response	Flow cytometry (CFSE dilution), 3H-thymidine incorporation, ELISA for cytokine production	CFSE staining (5μM); anti-CD3/CD28 beads as positive control [66] [67]

The MLR assay's superiority over mitogen-based approaches lies in its physiological relevance. While phytohemagglutinin (PHA) and anti-CD3/CD28 stimulation generate more robust and reproducible proliferation signals, they represent artificial activation pathways that bypass normal immune recognition mechanisms [66]. In contrast, the MLR models the actual alloreactive T-cell responses that MSCs would encounter in clinical applications involving HLA-mismatched donors or recipients. However, this physiological relevance comes with technical challenges, particularly the relatively low frequency of alloreactive T-cells compared to polyclonally-activated T-cells, which can result in variable proliferation signals [66].

Comparative Analysis: MLR Versus Alternative Potency Assays

Evaluating the performance of MLR against other common immunomodulatory assays reveals a landscape of complementary strengths and limitations. While no single assay fully captures the multifaceted immunomodulatory capacity of MSCs, the MLR occupies a unique niche with high physiological relevance for T-cell-mediated applications.

Table 2: Comparison of MLR with Alternative Immunomodulatory Potency Assays

Assay Type	Mechanism of Action	Key Readouts	Advantages	Limitations
Mixed Lymphocyte Reaction (MLR)	Alloreactive T-cell activation	T-cell proliferation inhibition; cytokine secretion profile	High physiological relevance; predictive for GVHD [66] [70]	Donor-to-donor variability; lower dynamic range [66]
Mitogen-Stimulated Proliferation	Polyclonal T-cell activation (PHA, ConA, anti-CD3/CD28)	T-cell proliferation inhibition; flow cytometry analysis	High robustness and dynamic range; minimal donor variation [66] [67]	Artificial stimulation; less physiologically relevant [66]
Macrophage Co-culture Systems	MSC modulation of macrophage polarization	IL-1RA secretion; TNF-α reduction; surface marker expression	Relevant for macrophage-driven diseases; robust readouts [29]	Limited to monocyte/macrophage interactions [29]
NK Cell Cytotoxicity	MSC inhibition of NK cell activity	NK-mediated killing assays; activation marker expression	Important for innate immunity assessment [69] [70]	Does not address adaptive immune responses [70]
Cytokine Secretion Profiling	MSC response to inflammatory cues	Multiplex cytokine analysis (IL-6, MCP-1, PGE2, IDO)	Definitive molecular mechanisms; quantifiable [69] [70]	May not reflect functional immune cell modulation [70]

The data from comparative studies indicates that MLR consistently demonstrates the immunomodulatory capacity of MSCs across various tissue sources. For instance, urine-derived stem cells (USCs) suppressed PBMC proliferation in MLR by 68.4% ± 7.2% compared to controls, comparable to the inhibition observed with bone marrow-derived MSCs (72.1% ± 6.5%) [69]. Similarly, human fetal cartilage progenitor cells (hFCPCs) inhibited concanavalin A-stimulated peripheral blood lymphocyte proliferation in a dose-dependent manner, with maximum suppression exceeding 70% at higher cell ratios [70]. These findings across diverse MSC sources highlight the utility of MLR as a standardized platform for comparing immunomodulatory potency.

Advanced MLR Protocol: Technical Optimization and Standardization

PBMC Preparation and Quality Control

Robust MLR assays begin with optimized PBMC procurement and handling. Current best practices recommend combining PBMCs from four or more donors to maximize alloreactive responses while minimizing individual donor variability [66]. PBMCs should be isolated using density gradient centrifugation (LymphoPrep) within 8 hours of blood collection, with careful attention to minimize platelet contamination through multiple washing steps [67]. Cryopreservation represents a critical juncture in assay standardization; while traditional cryomedium (90% FBS + 10% DMSO) remains effective, GMP-compliant alternatives like CryoStor CS10 provide defined composition and better post-thaw viability [67]. Validated thawing procedures including rapid warming (37°C water bath), gradual dilution in pre-warmed medium, and 1-hour recovery incubation before assay setup are essential for maintaining immune cell functionality [67] [68].

MLR Experimental Setup and Controls

A properly configured MLR includes critical controls that ensure assay validity and interpretability:

Diagram 1: MLR experimental workflow and controls.

The standard MLR setup employs PBMCs at 1×10^5 cells per well in 96-well round-bottom plates, with MSC:PBMC ratios typically ranging from 1:10 to 1:100 [66] [69]. Co-cultures are maintained for 5-7 days in RPMI-1640 supplemented with 10% FBS, L-glutamine, and antibiotics at 37°C with 5% CO2 [67]. For proliferation quantification, flow cytometric analysis of CFSE dilution provides superior information content compared to radioactive thymidine incorporation, enabling simultaneous assessment of viability and immunophenotyping of responding cells [66] [68]. CFSE staining at 5μM concentration prior to cryopreservation has been demonstrated to maintain fluorescence intensity without compromising cell viability or function [67].

Analytical Measurements and Acceptance Criteria

Assay validation requires predefined acceptance criteria that ensure consistent performance. For the MLR, positive control wells (PBMCs without MSCs) should typically demonstrate at least a 5-fold increase in proliferation compared to negative controls (unstimulated PBMCs) [66]. The coefficient of variation for replicate wells should not exceed 15-20%, and viability staining should confirm that suppression is not merely due to cytotoxicity [68]. MSC potency is typically expressed as percentage inhibition normalized to the positive control proliferation, with dose-response curves providing the most robust quantification [66] [70]. Advanced implementations incorporate multiplex cytokine analysis (IFN-γ, TNF-α, IL-10, IL-6) to provide mechanistic insights alongside functional readouts [69] [70].

MSC Immunomodulatory Mechanisms in MLR: Linking Function to Molecular Pathways

The suppression of T-cell proliferation in MLR assays results from integrated molecular mechanisms deployed by MSCs in response to inflammatory cues. The immunological synapse formed between activated T-cells and MSCs triggers a sophisticated immunomodulatory response involving both cell-contact-dependent mechanisms and soluble factor secretion.

Diagram 2: MSC immunomodulatory mechanisms in MLR.

The molecular machinery depicted in Diagram 2 manifests differently across MSC sources. Bone marrow-derived MSCs typically employ indoleamine 2,3-dioxygenase (IDO) as a primary mechanism, catalyzing tryptophan depletion in the microenvironment [70]. Adipose-derived stromal cells (ASC) strongly express both IDO and prostaglandin E2 (PGE2), while urine-derived stem cells (USCs) show distinctive secretion patterns of IL-6, IL-8, MCP-1, RANTES, GROα, and GM-CSF, particularly when in direct contact with PBMCs [66] [69]. Human fetal cartilage progenitor cells (hFCPCs) employ a different strategy, expressing LIF, TGF-β1, TSG-6, and sHLA-G5, but notably lacking IDO and HGF expression [70]. This mechanistic diversity highlights why MLR assays that measure integrated functional outcomes often provide more clinically relevant potency assessments than reductionistic measurements of individual molecules.

Implementation Framework: Integrating MLR into MSC Product Development

Successful integration of MLR potency testing requires careful consideration of its position in the overall product development pipeline. The assay serves different purposes at various stages, from early donor screening to final product release testing.

Table 3: MLR Application in MSC Product Development Pipeline

Development Stage	Assay Objective	Acceptance Criteria	Regulatory Considerations
Donor Screening	Identify donors with potent immunomodulatory capacity	Comparison to reference MSC population; minimum 50% inhibition at 1:10 ratio	Establishment of donor eligibility criteria [66]
Process Development	Evaluate impact of expansion methods, culture conditions, cryopreservation	Consistency across multiple batches (CV ≤ 20%)	Demonstration of manufacturing process control [67]
Product Characterization	Define dose-response relationship and mechanism of action	Linear range of inhibition from 20% to 80%	Comprehensive understanding for regulatory submissions [29]
Batch Release Testing	Confirm potency of final product meets specifications	Predefined minimum inhibition percentage	Validation per ICH guidelines; GMP-compliant execution [68] [29]
Stability Studies	Monitor potency throughout shelf life	No significant decline from baseline potency	Real-time and accelerated stability data [29]

For batch release testing, the MLR must undergo rigorous validation demonstrating accuracy, precision, specificity, and robustness [68] [29]. This includes determining the assay's linear range, limit of quantification, and intermediate precision (typically ≤15% CV) [68]. For products targeting specific clinical indications, the MLR conditions may be tailored to better model the disease environment. For instance, MSCs intended for macrophage-driven diseases might benefit from complementary macrophage co-culture assays measuring IL-1RA secretion [29], while products for GVHD would prioritize MLR as the primary potency assay.

The Mixed Lymphocyte Reaction represents a robust, physiologically relevant platform for assessing the immunomodulatory potency of MSC-based therapeutics. When properly optimized and validated, the MLR provides critical functional data that complements phenotypic characterization per ISCT criteria, creating a comprehensive identity and potency profile essential for regulatory approval and clinical success. The assay's particular strength lies in modeling alloreactive T-cell responses relevant to key clinical applications like GVHD while accommodating the mechanistic diversity across MSC sources. As the field advances, standardized MLR protocols incorporating multi-donor PBMC pools, defined cryopreservation methods, and flow cytometric readouts will enable more meaningful cross-study comparisons and accelerate the development of consistently potent MSC therapies for immune-mediated diseases.

The validation of Mesenchymal Stromal Cell (MSC) identity according to International Society for Cellular Therapy (ISCT) criteria has traditionally relied on conventional flow cytometry for surface marker profiling. However, the field is now advancing toward more sophisticated technologies that provide deeper biological insights. Imaging flow cytometry merges the high-throughput capabilities of conventional flow cytometry with detailed morphological information, enabling simultaneous quantification of marker expression and visualization of its subcellular distribution. When combined with novel fluorescent dyes designed for specific cellular structures and functions, these advanced tools offer unprecedented resolution for MSC characterization. This technological evolution is critical for addressing MSC heterogeneity and developing robust potency assays that can predict therapeutic performance, moving beyond minimal criteria to functional validation [71] [72] [9].

Comparative Performance of Advanced Cytometry Methods

The transition from conventional to advanced flow cytometric methods provides significant advantages for in-depth MSC analysis. The table below compares the core technologies, their applications, and key experimental findings from recent studies.

Table 1: Comparison of Flow Cytometry Methods in MSC Research

Technology	Key Features	Documented Applications in MSC Research	Reported Experimental Findings
Conventional Flow Cytometry	High-speed multiparametric analysis; quantifies surface and intracellular markers [73].	Immunophenotyping (CD73, CD90, CD105 positivity; CD34, CD45, CD11b, CD19, HLA-DR negativity) [9].	Standard for ISCT minimal criteria; detects population averages but misses intracellular detail and morphological context [9].
Imaging Flow Cytometry	Combines high-throughput flow analysis with digital imagery of individual cells; quantifies fluorescence intensity and provides spatial context [72].	Single-cell analysis of intracellular protein accumulation (e.g., FABP4 in adipogenesis) [71]; analysis of co-culture systems with immune cells [72].	Revealed increasing intra-culture heterogeneity during adipogenic differentiation; identified that more granular cells accumulated more FABP4 protein [71].
Spectral Flow Cytometry	Captures full emission spectrum for each fluorophore; uses spectral deconvolution to resolve dye overlaps [74].	High-dimensional immunophenotyping (40+ markers); designed for complex panel analysis of mixed cell populations [74].	Enables use of dyes with closer emission spectra, increasing panel size and improving resolution of complex MSC-immune cell interactions [74].

Experimental Protocols for Advanced MSC Analysis

Protocol 1: Quantifying Adipogenic Differentiation via Flow Cytometry

This protocol, adapted from a study validating adipogenesis assays, uses Nile red and FABP4 staining to quantify differentiation at the single-cell level [71].

• Step 1: Cell Seeding and Differentiation: Plate Bone Marrow-MSCs (BM-MSCs) at a constant density of 4.0 × 10⁴ cells per cm² in multi-well plates. Induce adipogenesis using a defined medium (e.g., DMEM supplemented with 10% FBS, 10% horse serum, 0.5 mM IBMX, 0.06 mM indomethacin, and 50 pM hydrocortisone). Change half of the medium twice weekly for a 21-day period [71].
• Step 2: Cell Harvest and Staining: Harvest cells at desired time points (e.g., day 7, 14, 21) using trypsin/EDTA.
  • For FABP4 Protein Detection: Fix and permeabilize cells. Stain with a fluorescently conjugated antibody against FABP4 for analysis by flow cytometry or imaging flow cytometry [71].
  • For Lipid Content Detection: Stain live or fixed cells with Nile red dye (e.g., 0.5 µg/mL) to label neutral lipid droplets. A nuclear counterstain like DAPI can be added to normalize for cell number [71].
• Step 3: Data Acquisition and Analysis:
  • Conventional Flow Cytometry: Acquire a minimum of 10,000 events per sample. Use forward-scatter (FSC) and side-scatter (SSC) to gate on single, viable cells. Analyze the fluorescence intensity of FABP4 and Nile red. A reported ~5-fold increase in Nile red fluorescence is typical in day-21 MSCs compared to undifferentiated controls [71].
  • Imaging Flow Cytometry: Use brightfield and fluorescence channels to confirm the intracellular localization of FABP4 and the punctate staining pattern of Nile red within lipid vesicles, distinguishing true adipogenic differentiation from non-specific staining.

Protocol 2: Analyzing MSC Immunomodulation via Multicolor Co-culture Assay

This protocol outlines a direct co-culture system to study the context-dependent immunomodulatory effects of MSCs on specific leukocyte subsets, analyzed by multicolor flow cytometry [72].

• Step 1: Cell Preparation:
  • Isulate and label MSCs (e.g., adipose-derived) with a fluorescent cell tracker.
  • Isulate peripheral blood mononuclear cells (PBMCs) or whole leukocytes from blood. Optionally, activate leukocytes with stimuli such as Concanavalin A (ConA) for mild activation or Phorbol 12-myristate 13-acetate (PMA) combined with Ionomycin for strong activation [72].
• Step 2: Co-culture Setup: Establish direct co-cultures of labeled MSCs and leukocytes at a predefined ratio (e.g., 1:10 MSC:leukocyte) in multi-well plates. Include controls for leukocytes alone and MSCs alone. Culture for 24-72 hours [72].
• Step 3: Intracellular Staining and Flow Cytometry:
  • Add a protein transport inhibitor (e.g., Brefeldin A) for the final 4-6 hours of culture to accumulate cytokines intracellularly.
  • Harvest cells and stain surface markers (e.g., CD3 for T cells, CD14 for monocytes, CD19 for B cells) to define leukocyte subsets.
  • Fix, permeabilize, and stain for intracellular cytokines (e.g., IFN-γ, TNF-α, IL-1) and markers like FoxP3 in regulatory T cells.
  • Acquire data on a high-parameter flow cytometer, saving a statistically valid number of events (e.g., 100,000 leukocyte events) [72] [74].
• Step 4: Data Interpretation: Use a sequential gating strategy to identify leukocyte subsets and quantify the frequency of cytokine-producing cells within each subset. Compare co-culture conditions with controls to identify MSC-mediated suppressive or stimulatory effects. The production of soluble factors like PGE2 can be measured in the supernatant via ELISA to correlate with cellular observations [72].

The following diagram illustrates the logical workflow and key analysis points of this co-culture assay.

The Scientist's Toolkit: Essential Reagents for Advanced MSC Analysis

Successful implementation of these advanced protocols requires a carefully selected set of reagents and tools.

Table 2: Key Research Reagent Solutions for Advanced MSC Flow Cytometry

Reagent / Tool	Function in MSC Analysis	Specific Examples & Notes
Novel Lipid Dyes	Staining of neutral lipid droplets during adipogenic differentiation [71].	Nile Red: A vital dye that becomes fluorescent in a hydrophobic environment. Superior for quantitative microplate assays and flow cytometry compared to Oil Red O [71].
Intracellular Antibodies	Detection of lineage-specific proteins and cytokines for functional potency assessment [71] [72].	FABP4 (Fatty Acid Binding Protein 4): A specific marker for adipogenic commitment [71]. Cytokines (IFN-γ, TNF-α, IL-1): Used to assess immunomodulatory effects on leukocyte subsets [72].
Cell Viability Markers	Exclusion of dead cells from analysis to reduce non-specific antibody binding and autofluorescence [73] [74].	DAPI or proprietary viability dyes. Critical for data quality, especially in co-culture assays where cell death may occur [74].
Cell Tracking Dyes	Labeling of MSCs in co-culture systems to distinguish them from immune cells during analysis [72].	Fluorescent cytoplasmic membrane labels (e.g., CFSE). Allows for precise identification of MSC population in a mixed culture for downstream gating [72].
Flow Cytometry Panel Design Tools	Planning complex multicolor panels to minimize spectral overlap and ensure data quality [74].	Software tools from instrument manufacturers or third parties. Essential for high-dimensional panels targeting MSC markers and immune cell subsets simultaneously [74].

The integration of imaging flow cytometry and novel dyes represents a significant leap forward in MSC validation. These technologies provide the resolution necessary to dissect MSC heterogeneity, visualize key biological processes like differentiation in real time, and generate high-quality, quantitative data for potency assays. As the field moves toward more complex, high-dimensional analysis, the adoption of these advanced tools, coupled with robust experimental protocols, will be crucial for deepening our understanding of MSC biology and ensuring the consistent quality and efficacy of MSC-based therapies [71] [72] [9].

Controlling for Senescence and Genetic Stability During Long-Term Culture Expansion

In cell-based therapies, mesenchymal stem cells (MSCs) are ideal seed cells due to their strong regenerative capacity, multi-directional differentiation abilities, and immunomodulatory effects [75]. For widespread clinical application, a massive in vitro expansion is necessary to furnish sufficient material for transplantation [76] [77]. However, this essential process introduces a significant therapeutic dilemma: as the number of cell divisions increases during in vitro expansion, MSCs exhibit replicative senescence and genomic instability [75] [76]. This phenomenon poses a substantial barrier to the development of safe and effective cellular therapies, particularly for autologous treatments in elderly patients, whose cells are already predisposed to age-related dysfunction [75] [78]. The efficacy of autologous MSCs transplantation is limited because the quantity and quality of MSCs decline during aging, both in the donor and during necessary in vitro expansion [75]. This article provides a comparative analysis of strategies for monitoring and controlling senescence and genetic stability, framed within the essential context of validating MSC identity according to International Society for Cellular Therapy (ISCT) criteria.

MSC Senescence: Morphological, Functional, and Genetic Hallmarks

Defining Senescence Phenotypes

During long-term culture, MSCs undergo specific, measurable changes that define the senescent state. Morphologically, characteristic spindle-like shapes are lost, replaced by enlarged, flat, and broad cells [75] [78]. Functionally, proliferative and migratory capacities are significantly reduced [75]. The table below summarizes the key hallmarks of MSC senescence and the corresponding methods for their detection.

Table 1: Hallmarks of MSC Senescence and Associated Detection Methods

Category	Specific Hallmark	Detection Method	Reference
Morphology	Enlarged, flat, fried-egg morphology; Constrained nuclei; Granular cytoplasm	Phase-contrast microscopy; Cell size analysis via flow cytometry (FSC/SSC)	[75] [78]
Proliferation	Increased population doubling time; Prolonged G1/G0 phase; Decreased S phase; Reduced CFU-F efficiency	Cell counting; Cell cycle analysis (e.g., PI staining); Colony-forming unit (CFU) assay	[76] [78]
Differentiation	Reduced tri-lineage potential; Shift toward adipogenesis over osteogenesis	In vitro differentiation and staining (Oil Red O, Alizarin Red, Alcian Blue)	[75] [78]
Genetic Stability	Increased DNA double-strand breaks; Chromosomal instability (micronuclei)	γH2AX/53BP1 foci assay; Micronucleus assay	[76] [77]
Secretome	Pro-inflammatory SASP (e.g., increased IL-6, IL-8, MCP-1)	ELISA; Multiplex immunoassays	[75]
Epigenetic	Senescence-associated DNA-methylation (SA-DNAm) changes	DNA methylation sequencing	[78]

Quantifying Senescence in Culture

The progression of senescence is directly correlated with in vitro passaging. Imaging analyses indicate that MSCs begin to enlarge significantly by passage 5 (p5), resulting in a 4.8-fold increase in size compared to passage 1 (p1) [75]. Concurrently, telomeres shorten at a constant rate during culture [75]. Research on murine bone-marrow-derived MSCs has demonstrated that long-term expansion (up to 8-12 weeks) gradually impairs the DNA damage response (DDR). This impairment is quantified by a decrease in the number of γH2AX/53BP1 DNA double-strand break (DSB) repair foci, slower DNA repair kinetics, and a significantly increased number of residual DSBs post-irradiation [76] [77]. In parallel, chromosomal instability increases, evidenced by a higher frequency of micronuclei, both spontaneously and after genotoxic stress like gamma-irradiation [76] [77].

Foundational Identity: Adherence to ISCT Criteria as a Baseline

The ISCT's minimal criteria establish a essential baseline for defining MSCs, but they are insufficient alone for guaranteeing therapeutic potency or genetic stability [79] [9] [57]. These criteria mandate that MSCs must be plastic-adherent under standard culture conditions, express specific surface markers (≥95% positive for CD105, CD73, CD90; ≤2% positive for CD45, CD34, CD14/CD11b, CD79a/CD19, and HLA-DR), and retain multipotent differentiation potential into osteocytes, adipocytes, and chondrocytes in vitro [79] [9].

Beyond the Minimum Criteria

Crucially, adherence to these criteria does not distinguish between MSCs with high-growth capacity and those with low-growth capacity, the latter being less therapeutically potent [57]. Studies show that high-growth capacity MSCs are smaller, have greater colony-forming efficiency, longer telomeres, and preferentially express markers like STRO-1 and PDGFR-α [57]. Furthermore, these cells exhibited approximately double the volume of mineralized tissue in ectopic bone-forming assays compared to low-growth capacity MSCs from age- and sex-matched donors, despite both groups meeting the basic ISCT criteria and demonstrating multilineage differentiation in vitro [57]. This highlights that while ISCT criteria are necessary for establishing cell identity, they must be supplemented with more sensitive potency and stability assays.

Experimental Protocols for Monitoring Senescence and Genomic Integrity

Protocol 1: Flow Cytometry for MSC Identity and Beyond

Purpose: To verify MSC identity per ISCT criteria and assess additional markers correlated with potency and senescence. Workflow:

• Cell Preparation: Harvest MSCs at various passages (e.g., P2, P5, P8) using a non-enzymatic cell dissociation solution or accutase to preserve surface markers. Create a single-cell suspension.
• Staining: Aliquot cells and incubate with fluorochrome-conjugated antibodies against the ISCT panel (CD105, CD73, CD90, CD45, CD34, CD14/CD11b, CD19/CD79a, HLA-DR). Include antibodies for additional markers like STRO-1, PDGFR-α, and senescence-associated markers (e.g., CD146 may decrease with age). Use isotype-matched controls for each antibody.
• Analysis: Analyze stained cells on a flow cytometer. Acquire at least 20,000 events per sample. Gate on the live cell population based on forward and side scatter, excluding apoptotic cells (Annexin V+). The population must meet ISCT thresholds. Monitor the expression levels of STRO-1 and PDGFR-α as indicators of a potent, less senescent population [57].

Protocol 2: Micronucleus Assay for Chromosomal Instability

Purpose: To quantify chromosomal instability, a key indicator of genotoxic stress and senescence, in MSCs during long-term culture [76] [77]. Workflow:

• Culture and Treatment: Culture MSCs from different passages (e.g., early vs. late). Seed cells onto coverslips in multi-well plates. Optionally, expose cells to a sub-lethal dose of gamma-irradiation (e.g., 0.5 Gy) to challenge genomic integrity, alongside non-irradiated controls.
• Cytokinesis Block: Before harvesting, add cytochalasin-B to the culture medium to prevent cytoplasmic division, resulting in binucleated cells.
• Fixation and Staining: After a suitable incubation period (e.g., 28-72 hours), harvest cells, fix with methanol or formaldehyde, and stain nuclei with a DNA-specific dye like DAPI or Giemsa.
• Scoring and Analysis: Using fluorescence or bright-field microscopy, score the frequency of micronuclei exclusively in binucleated cells. A micronucleus is a small, round DNA-containing body in the cytoplasm, separate from the main nuclei. Count a minimum of 1000 binucleated cells per sample. An increase in micronucleus frequency with passage number or post-irradiation indicates rising chromosomal instability [76] [77].

Protocol 3: DNA Damage Response (DDR) Foci Assay

Purpose: To evaluate the functional capacity of MSCs to recognize and repair DNA double-strand breaks, a mechanism that becomes impaired with in vitro aging [76] [77]. Workflow:

• Induction and Fixation: Irradiate MSCs from different passages with a low dose of gamma-radiation (e.g., 0.2 Gy). Include a non-irradiated control. At specific time points post-irradiation (e.g., 0.5h, 7h), fix cells with paraformaldehyde.
• Immunofluorescence Staining: Permeabilize cells and incubate with primary antibodies against DNA damage response markers, specifically a combination of γH2AX (marks DSB sites) and 53BP1 (a key repair protein). After washing, incubate with fluorescently-labeled secondary antibodies. Counterstain nuclei with DAPI.
• Imaging and Quantification: Acquire images using a fluorescence microscope. The number of discrete nuclear γH2AX/53BP1 co-localizing foci corresponds to the number of DSBs. Quantify foci per cell in at least 50 cells per condition. Senescent MSCs show a decrease in initial foci formation (impaired recognition) and a significant increase in residual foci at later time points (e.g., 7h), indicating slower, less efficient repair [76] [77].

Diagram: DNA Damage Response Pathway Impairment in Senescent MSCs. The pathway from DNA damage to successful repair is impaired in senescent MSCs, leading to the accumulation of residual damage and genomic instability.

Comparative Analysis of Culture Management Strategies

Managing senescence requires a multi-faceted approach, from optimizing process parameters to targeted interventions. The table below compares key strategies.

Table 2: Comparison of Strategies for Controlling Senescence and Genetic Stability

Strategy Category	Specific Approach	Key Experimental Findings	Impact on Senescence/Stability
Process Optimization	Model-based Design Space (Seeding Density, Harvest Time)	A seeding density of 1500-4500 cells/cm² and controlled harvest time maintained confluency <80% and stable growth rate [80].	Moderate. Reduces stress from over-confluence but does not fundamentally halt replicative senescence.
Monitoring & QC	DDR Foci & Micronucleus Assays	Long-term cultured murine MSCs showed ~40% fewer γH2AX/53BP1 foci post-irradiation and ~3x increase in micronuclei [76] [77].	High for risk assessment. Enables direct monitoring of genomic instability for safety thresholds.
Marker Enhancement	STRO-1+/PDGFR-α+ Enrichment	High-growth MSCs with STRO-1+/PDGFR-α+ expression had longer telomeres and 2x greater bone volume in vivo [57].	High. Identifies a potent subpopulation with inherently better growth and stability.
Rejuvenation Strategies	3D Culture Systems	3D spheroids enhance cell-cell contact, reduce ROS, and improve paracrine function [81].	Promising. Shown to reverse some aged phenotypes and enhance immunomodulation.
Rejuvenation Strategies	Small Molecule Pre-treatment	Molecules targeting oxidative stress, autophagy, and metabolic pathways can inhibit senescence [81].	Promising. Can delay senescence and restore differentiation potential, but requires careful optimization.

The Scientist's Toolkit: Essential Research Reagents

A robust workflow for controlling senescence relies on specific, high-quality reagents.

Table 3: Essential Reagents for Senescence and Stability Research

Reagent / Tool	Critical Function	Application Example
CD105, CD73, CD90 Antibodies	Confirm MSC identity per ISCT positive criteria.	Flow cytometry verification at each new lot or passage [79] [9].
STRO-1 & PDGFR-α Antibodies	Identify and isolate a potent, high-growth MSC subpopulation.	Enrichment via FACS or MACS to improve culture quality [57].
Phospho-Histone H2AX (γH2AX) & 53BP1 Antibodies	Detect and quantify DNA double-strand breaks and repair efficiency.	Immunofluorescence staining for the DDR Foci Assay [76] [77].
Cytochalasin-B	Inhibits cytokinesis, enabling micronucleus scoring in binucleated cells.	Essential for the cytokinesis-block micronucleus (CBMN) assay [76] [77].
Senescence-associated β-galactosidase (SA-β-gal) Kit	Detects lysosomal β-galactosidase activity at pH 6.0, a common senescence biomarker.	Histochemical staining to quantify the proportion of senescent cells in a culture [78].
Tri-lineage Differentiation Kits	Functional validation of multipotency, which declines with senescence.	Confirm osteogenic, adipogenic, and chondrogenic potential per ISCT criteria [79] [78].

Diagram: Integrated Workflow for MSC Expansion with Senescence Monitoring. A proposed workflow integrating traditional expansion with critical control points for continuous monitoring of senescence and genetic stability.

Controlling for senescence and genetic stability is not an optional quality control step but a fundamental requirement for the safety and efficacy of MSC-based therapies. While adherence to the ISCT's minimal criteria provides a necessary foundation for defining MSCs, it is insufficient for predicting long-term culture performance or therapeutic potency. A comprehensive strategy must integrate rigorous process control, using design spaces to minimize extrinsic stress, with direct functional assays for genomic integrity (e.g., DDR and micronucleus assays). Furthermore, going beyond the ISCT panel to include potency-associated markers like STRO-1 and PDGFR-α can help select for more robust cell populations from the outset. As the field advances, the development and standardization of these enhanced monitoring and rejuvenation protocols will be paramount to ensuring that clinically expanded MSCs are not only identifiable but also functionally competent and genomically sound for patient administration.

Ensuring Reproducibility: Correlating Phenotype with Function and Navigating International Standards

The therapeutic application of Mesenchymal Stem Cells (MSCs) has emerged as a highly promising strategy in regenerative medicine due to their self-renewal, pluripotency, and immunomodulatory properties [4]. However, a significant challenge persists: the inconsistent therapeutic efficacy observed in both clinical trials and animal studies [82]. This inconsistency is largely attributed to the complex disconnect between in vitro characterization and in vivo performance, where cells that meet standard in vitro criteria often demonstrate variable therapeutic outcomes in living systems [57]. This article explores the current methodologies and emerging approaches for building predictive correlations between in vitro assays and in vivo performance, providing researchers with a framework for enhancing the reliability and effectiveness of MSC-based therapies.

The fundamental challenge stems from multiple sources of variability, including heterogeneous cell populations, differences in culture conditions, varied delivery methods, and diverse recipient conditions [82]. Moreover, the conventional criteria for defining MSCs, while essential for basic characterization, have proven insufficient for predicting therapeutic success [57]. Consequently, the field is increasingly moving toward multidimensional assessment strategies that integrate traditional in vitro assays with advanced computational models to create more robust predictions of in vivo efficacy. This evolution is critical for establishing potency assays that truly reflect therapeutic potential and ultimately improve clinical outcomes for a wide range of human diseases [57] [4].

Establishing Foundational MSC Identity: The ISCT Criteria Framework

The International Society for Cellular Therapy (ISCT) established minimal criteria for defining human MSCs, which serve as the foundational basis for any correlation studies between in vitro characterization and in vivo performance [4] [83]. These criteria provide a standardized framework that enables consistent comparison of MSCs across different laboratories and studies, forming the essential first step in quality assurance before advancing to more complex predictive modeling.

Core ISCT Characterization Criteria

According to ISCT guidelines, MSCs must fulfill three fundamental criteria [83]:

• Plastic Adherence: When maintained under standard culture conditions, MSCs must adhere to plastic surfaces, which serves as a basic functional property distinguishing them from hematopoietic cells.

• Specific Surface Marker Expression: MSCs must demonstrate a characteristic immunophenotype analyzed by flow cytometry, with ≥95% of the population expressing CD105, CD73, and CD90, while ≤2% of cells express hematopoietic markers (CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR).

• Trilineage Differentiation Potential: Under standard in vitro induction conditions, MSCs must demonstrate the capacity to differentiate into osteoblasts, adipocytes, and chondrocytes, confirming their multipotent mesenchymal lineage capability.

Table 1: Essential Markers for MSC Characterization by Flow Cytometry

Marker Category	Specific Markers	Expression Requirement	Biological Significance
Positive Markers	CD105	≥95%	Type I membrane glycoprotein essential for cell migration and angiogenesis
	CD73	≥95%	5'-exonuclease catalyzing AMP hydrolysis; role in bone marrow cell signaling
	CD90	≥95%	N-glycosylated GPI-anchored protein mediating cell-cell and cell-ECM interactions
Negative Markers	CD45	≤2%	Marker for white blood cells
	CD34	≤2%	Biomarker for hematopoietic stem cells and endothelial cells
	CD14/CD11b	≤2%	Expressed on monocytes and macrophages
	CD79α/CD19	≤2%	Markers of B cells
	HLA-DR	≤2%	MHC class II molecule with strong immunogenic properties

Experimental Protocol: Flow Cytometry for MSC Characterization

The following protocol provides detailed methodology for flow cytometric analysis of MSC surface markers, a critical component of ISCT criteria validation [83]:

• Sample Preparation: Create single-cell suspensions using enzymatic digestion (e.g., 0.125% trypsin/Versene) from passage 4 or earlier cultures to maintain representative cell populations.

• Cell Staining: Aliquot approximately 1×10^6 cells per tube and incubate with phycoerythrin- or fluorescein isothiocyanate-conjugated antibodies against target markers (CD105, CD73, CD90, CD45, CD34, CD14, CD19, HLA-DR) and appropriate isotype-matched controls (IgG1κ, IgG2aκ, IgG2bκ, IgM, IgG3).

• Analysis Setup: Resuspend stained cells in appropriate buffer (e.g., MACS buffer: 2 mM EDTA, 0.5% BSA in PBS, pH 7.2) and analyze using a flow cytometer (e.g., FACSArray Bioanalyzer). For each marker and isotype control, acquire 20,000 events to ensure statistical significance.

• Gating Strategy: First gate out non-viable cells (e.g., Annexin V+ populations), then apply quadrant gates to the live population. The expression threshold for each marker is set at 2% of the isotype control, with the final population requiring ≥95% positivity for CD105, CD73, CD90 and ≤2% expression for negative markers.

This standardized protocol ensures consistent assessment of MSC immunophenotype, forming the baseline for subsequent correlation with functional potency.

Advanced Characterization: Beyond Minimum Criteria

While ISCT criteria establish fundamental MSC identity, research demonstrates that these minimum standards alone are insufficient predictors of in vivo therapeutic efficacy [57]. Consequently, investigators have identified additional characterization parameters that show stronger correlation with functional potency in living systems, enabling more reliable prediction of therapeutic performance.

Enhanced Phenotypic Markers

Studies comparing MSCs with different growth capacities and in vivo performance have revealed several markers that correlate with enhanced potency beyond the basic ISCT criteria [57]:

• STRO-1: This cell-surface antigen is preferentially expressed on MSCs with high-growth capacity and has been associated with enhanced ectopic bone-forming ability in vivo, demonstrating approximately double the volume of mineralized tissue compared to STRO-1 low populations.

• Platelet-Derived Growth Factor Receptor Alpha (PDGFR-α): Expression of CD140a (PDGFR-α) has been identified as a distinguishing marker for MSCs with superior expansion potential and in vivo bone formation capacity.

• Transcriptional Markers: Elevated expression of mRNA transcripts TWIST-1 and DERMO-1 has been correlated with high-growth capacity MSCs, providing potential molecular targets for potency assessment.

• Cell Size Characteristics: High-growth capacity MSCs consistently demonstrate smaller cell size as measured by forward scatter/side scatter (FSC/SSC) parameters in flow cytometry, with the fraction of low FSC/SSC events serving as a useful indicator of potency.

Functional Potency Assays

Functional assays that measure biological activities beyond basic trilineage differentiation provide critical insights into potential in vivo performance [57]:

• Clonogenic Assays: Colony-forming unit fibroblastic (CFU-F) efficiency strongly correlates with in vivo bone-forming capacity. The assay involves plating mononuclear cells at low density (0.5-3.0×10^6 cells in T75 flasks), allowing adherence and colony formation for 14 days, then staining with 0.5% crystal violet. Colonies containing ≥50 cells are quantified, with efficiency calculated as colonies formed per 10^5 cells plated.

• Growth Kinetics and Telomere Length: Cumulative population doublings and telomere length analysis provide measures of replicative capacity, with high-growth capacity MSCs demonstrating longer telomeres and sustained proliferation through multiple passages (13-15 passages until senescence).

• Secretory Profile Analysis: Quantification of trophic factors (VEGF, HGF, IGF-1, EGF) involved in tissue repair and immunomodulation offers insights into paracrine-mediated therapeutic mechanisms, which may be more relevant for certain applications than differentiation capacity.

Table 2: Advanced Characterization Parameters Correlated with In Vivo Efficacy

Parameter Category	Specific Assays	Measurement Output	Correlation with In Vivo Efficacy
Enhanced Surface Markers	STRO-1 expression	Flow cytometry quantification	High expression correlates with doubled bone formation volume
	PDGFR-α (CD140a) expression	Flow cytometry quantification	Associated with superior expansion potential and in vivo performance
Molecular Markers	TWIST-1 and DERMO-1 expression	mRNA quantification by RT-PCR	Elevated in high-growth capacity MSCs
Cellular Properties	Cell size analysis	Forward/side scatter by flow cytometry	Smaller cells show enhanced potency
	Telomere length	Genomic DNA analysis	Longer telomeres correlate with sustained growth capacity
Functional Assays	CFU-F efficiency	Colony counts after crystal violet staining	Strong correlation with in vivo bone formation
	Growth kinetics	Cumulative population doublings	Predicts expansion potential in therapeutic contexts
	Secretory profile	Multiplex analysis of VEGF, HGF, IGF-1, EGF	Indicates paracrine-mediated therapeutic capacity

Predictive Modeling Approaches: From Correlation to Prediction

The integration of in vitro characterization data with in vivo outcomes through computational modeling represents the cutting edge of predictive efficacy assessment for MSC therapies. These approaches range established pharmaceutical modeling frameworks adapted for cell therapies to emerging machine learning methods that handle complex multivariate relationships.

In Vitro-In Vivo Correlation (IVIVC) Framework

The In Vitro-In Vivo Correlation (IVIVC) concept, well-established in pharmaceutical development for dosage forms, provides a valuable framework for MSC therapeutic characterization [84] [85]. IVIVC is defined as a predictive mathematical model describing the relationship between an in vitro property and a relevant in vivo response, which for MSCs could translate to correlating in vitro potency assays with in vivo therapeutic outcomes [84].

IVIVC models are categorized into three levels with distinct characteristics and applications [85]:

• Level A Correlation: Point-to-point relationship between in vitro release/activity and in vivo absorption/response, representing the highest category of correlation with strong predictive power for full response profiles. This approach has been successfully applied to establish in vivo bioequivalence from in vitro studies for pharmaceutical formulations [86].

• Level B Correlation: Utilizes statistical moment analysis comparing mean in vitro dissolution time to mean in vivo residence or absorption time, providing moderate predictive value but unable to predict individual response curves.

• Level C Correlation: Represents a single-point relationship between an in vitro parameter (e.g., release at a specific time point) and a pharmacokinetic parameter (e.g., AUC or Cmax), offering limited predictive capability suitable mainly for early development screening.

The development of a robust IVIVC model involves three key stages: (1) establishing a functional relationship between input (in vitro assay) and output (in vivo response); (2) constructing a structural model using collected data; and (3) parameterizing unknown variables in the structural model [84]. For MSC therapies, this approach could correlate in vitro potency measurements (e.g., secretory profiles, immunomodulatory activity) with in vivo therapeutic outcomes (e.g., tissue repair scores, reduction in inflammation markers).

Machine Learning and Neural Network Applications

Emerging computational approaches leverage machine learning to predict MSC therapeutic outcomes based on multidimensional input parameters, offering powerful tools for addressing the complex, multivariate nature of MSC efficacy [82]:

• Neural Network Architecture: A specialized neural network formalism with unique capacity to handle missing data by learning correlations across multiple properties and recursively imputing precise estimates has demonstrated significant promise in predicting cartilage repair outcomes following MSC therapy, achieving a coefficient of determination (R2) of 0.637 ± 0.005 in cross-validation tests [82].

• Critical Property Identification: Through machine learning analysis, key parameters influencing therapeutic outcomes have been identified, including defect area percentage, defect depth percentage, implantation cell number, body weight, tissue source, and cartilage damage type, enabling focused optimization of therapy protocols [82].

• Dosage Optimization: Machine learning models have revealed non-linear relationships between cell dosage and therapeutic outcomes, identifying an optimal range of 17-25 million MSCs for cartilage repair, beyond which additional cells provide diminishing returns [82].

• Uncertainty Quantification: Advanced neural network implementations compute prediction uncertainty arising from experimental variability and computational extrapolation, allowing the model to weight its predictions based on confidence levels, a crucial feature for clinical decision support [82].

The following diagram illustrates the experimental workflow for developing predictive models of MSC therapeutic efficacy:

Diagram Title: Workflow for Predictive Model Development

Research Reagent Solutions for MSC Characterization

The following table details essential research reagents and their specific functions in MSC characterization and predictive model development, compiled from experimental protocols across multiple cited studies:

Table 3: Essential Research Reagents for MSC Characterization and Predictive Modeling

Reagent Category	Specific Examples	Experimental Function	Application Context
Culture Media	Dulbecco's Modified Eagle's Medium (DMEM-low glucose) with 10% fetal calf serum	Maintenance media for MSC expansion	Basic cell culture and propagation [57]
	Serum-free/xeno-free PromoCell Growth Medium DXF	Defined culture conditions for standardized expansion	Reduction of batch-to-batch variability [83]
Characterization Antibodies	CD105 (266), CD73 (AD2), CD90 (5E10)	Positive marker identification by flow cytometry	ISCT criteria validation [57] [83]
	CD45 (H130), CD34 (RAM34), CD14 (MфP9)	Negative marker identification by flow cytometry	ISCT criteria validation [57] [83]
	STRO-1, PDGFR-α (CD140a, αR1)	Enhanced potency marker detection	Identification of high-growth capacity MSCs [57]
Differentiation Reagents	Dexamethasone, 1,25-dihydroxyvitamin D3	Osteogenic differentiation induction	Trilineage differentiation capacity [4]
	Insulin, IBMX, indomethacin	Adipogenic differentiation induction	Trilineage differentiation capacity [4]
	TGF-β, ascorbate, proline	Chondrogenic differentiation induction	Trilineage differentiation capacity [4]
Analysis Reagents	Crystal violet (0.5%)	Colony staining for CFU-F assays	Clonogenic potential assessment [57]
	Alcian Blue, Alizarin Red S	Histological staining of chondrocytes and osteocytes	Differentiation confirmation [83]

Integrated Workflow: From Characterization to Prediction

The integration of traditional characterization methods with advanced predictive modeling creates a comprehensive framework for correlating in vitro assays with in vivo performance. The following diagram illustrates the signaling pathways and biological processes that connect MSC characteristics with therapeutic mechanisms:

Diagram Title: Biological Pathways Linking MSC Properties to Outcomes

This integrated approach demonstrates how specific MSC characteristics influence molecular pathways and secretory profiles, which subsequently modulate immune interactions and ultimately drive tissue repair processes that determine therapeutic efficacy. The dashed lines represent direct relationships that bypass intermediate steps, reflecting the complexity of MSC mechanisms of action.

The correlation between in vitro assays and in vivo performance represents a critical frontier in advancing MSC-based therapies from promising experimental approaches to reliable clinical interventions. While the ISCT minimum criteria provide an essential foundation for MSC identification, they alone are insufficient predictors of therapeutic efficacy [57] [87]. The integration of enhanced characterization parameters—including functional potency assays, secretory profiling, and advanced marker expression—with computational modeling approaches creates a powerful framework for predicting in vivo performance.

The emerging applications of IVIVC principles and machine learning in MSC therapeutics demonstrate significant potential for addressing the persistent challenge of inconsistent clinical outcomes [82] [85]. By leveraging multivariate analysis and pattern recognition across complex datasets, these approaches can identify critical property thresholds and optimal therapeutic windows, ultimately enabling more precise patient-specific treatment strategies. Furthermore, the capacity to quantify prediction uncertainty provides clinicians with valuable guidance for evaluating the reliability of efficacy forecasts.

As the field progresses, the development of standardized, validated predictive models that incorporate both established characterization parameters and novel potency indicators will be essential for realizing the full potential of MSC-based therapies. This evolution toward predictive efficacy assessment will not only enhance therapeutic consistency but also accelerate the rational design of next-generation MSC products optimized for specific clinical applications, ultimately transforming the landscape of regenerative medicine.

Within regenerative medicine, Mesenchymal Stromal Cells (MSCs) have emerged as a cornerstone for therapeutic development. The International Society for Cell & Gene Therapy (ISCT) has established minimal criteria to define human MSCs, requiring plastic adherence, specific surface marker expression (≥95% positive for CD105, CD73, CD90; ≤2% positive for CD45, CD34, CD14, CD19, HLA-DR), and trilineage differentiation potential into adipocytes, osteoblasts, and chondrocytes [88]. While MSCs can be isolated from various tissues, Bone Marrow-derived MSCs (BM-MSCs) and Umbilical Cord Tissue-derived MSCs (UC-MSCs, specifically from Wharton's Jelly, hence MSC-WJ) represent two of the most prevalent sources. This guide provides an objective, data-driven comparison of these sources to inform research and development strategies.

Source Characterization and Isolation

BM-MSCs were the first discovered and remain the most extensively studied source. Isolation typically involves density gradient centrifugation of bone marrow aspirates to obtain mononuclear cells, followed by plating and selection based on plastic adherence [89] [1]. UC-MSCs are isolated from the Wharton's Jelly of the umbilical cord, a perinatal tissue often considered medical waste. Primary isolation methods include enzymatic digestion of the cord tissue or explant culture where migrating cells are harvested [1] [90]. UC-MSCs are notably obtained through a non-invasive collection procedure without ethical concerns [91].

Table 1: Fundamental Characteristics of MSC Sources

Characteristic	Bone Marrow (BM-MSC)	Umbilical Cord (UC-MSC)
Isolation Method	Density gradient centrifugation, plastic adherence [89] [1]	Enzymatic digestion or explant culture [1] [90]
Tissue Invasiveness	Invasive collection procedure [91]	Non-invasive collection, minimal ethical concerns [91]
Primary Cell Yield	Lower yield [89]	Higher yield and isolation efficiency [89]
Proliferation Capacity	Moderate; subject to donor age-related decline [92]	High; faster population doubling, "younger" phenotype [89] [90]

Comparative Functional Potency: Experimental Data

Direct comparative studies reveal significant differences in the functional potency of BM-MSCs and UC-MSCs across various therapeutic domains. The following table synthesizes quantitative findings from key experiments.

Table 2: Summary of Comparative Experimental Outcomes

Therapeutic Model	Key Metric	BM-MSC Performance	UC-MSC Performance	Source
Bronchopulmonary Dysplasia (BPD) Model	Alveolar simplification improvement	Significant improvement	Greater improvement in alveolarization metrics	[89]
	Lung macrophage infiltration	Reduced	Significantly greater reduction	[89]
	Lung epithelial wound healing	Baseline	Better-wound healing in scratch assay	[89]
Tendon Regeneration Model	Tenogenic gene expression (Scleraxis)	Baseline	3.12-fold upregulation vs. BM-MSC	[93]
	Tendon-like matrix formation	Baseline	4.22-fold increase vs. BM-MSC	[93]
Heart Failure Clinical Trials	LVEF improvement at 6 months	No significant effect	Significant improvement (+5.08%)	[91]
In Vitro Migration	Migration toward activated lymphocytes	Moderate	Superior migration ability	[90]
In Vitro Proliferation	Proliferation index (Ki-67)	Lower	Higher proliferation index	[89]

Analysis of Key Comparative Studies

• Lung Regeneration: In a hyperoxia-induced BPD model, both MSC types improved alveolar structure, angiogenesis, and vascular remodeling. However, UC-MSCs demonstrated superior performance in specific morphometric measures of alveolarization and were more effective at reducing lung macrophage infiltration. In vitro, lung epithelial cells showed better wound healing when incubated with UC-MSC conditioned media [89].
• Tendon Repair: Under tensioned 3D conditions mimicking the tendon environment, UC-MSCs significantly outperformed BM-MSCs in tenogenic differentiation and the formation of a well-organized tendon-like matrix. This was evidenced by marked upregulation of key tendon-related genes and histology [93].
• Cardiac Function: A meta-analysis of randomized controlled trials for heart failure treatment found that UC-MSCs significantly improved the Left Ventricular Ejection Fraction (LVEF) at 6 and 12 months, whereas BM-MSCs showed no significant effect compared to controls [91].
• Migration Potential: A critical step for in vivo efficacy is homing to injury sites. UC-MSCs exhibit significantly faster and higher migration potency toward activated lymphocytes in a mixed lymphocyte reaction (MLR) compared to BM-MSCs and adipose-derived MSCs. This was associated with distinct secretion profiles of chemokines like CCL2, CCL7, and CXCL2 [90].

Detailed Experimental Protocols

To ensure reproducibility, this section outlines standard methodologies for key experiments cited in this comparison.

In Vitro Wound Healing (Scratch) Assay

Purpose: To assess the ability of MSC-conditioned media to promote lung epithelial cell migration and wound closure [89]. Methodology:

• Cell Culture: Culture lung epithelial cells (e.g., BEAS-2B or primary cells) in standard growth medium until confluent.
• Conditioned Media Preparation: Culture BM-MSCs and UC-MSCs in serum-free medium for 48 hours. Collect the supernatant (conditioned media) and centrifuge to remove cells and debris.
• Scratch Formation: Create a uniform scratch in the monolayer of lung epithelial cells using a sterile pipette tip.
• Wash and Add Test Media: Wash cells to remove debris and add either conditioned media from BM-MSCs, UC-MSCs, or fresh serum-free media (control).
• Imaging and Quantification: Capture images of the scratch immediately (0 hours) and at regular intervals (e.g., 12, 24 hours). Measure the remaining cell-free area using image analysis software (e.g., ImageJ). The percentage of wound closure is calculated as: [(Area at 0h - Area at t=h) / Area at 0h] * 100.

In Vivo Hyperoxia-Induced BPD Model

Purpose: To evaluate the regenerative efficacy of MSCs in a rodent model of lung injury mimicking Bronchopulmonary Dysplasia [89]. Methodology:

• Animal Grouping: Newborn rat pups are randomly assigned to normoxia control, hyperoxia placebo, hyperoxia + BM-MSC, and hyperoxia + UC-MSC groups.
• Hyperoxia Exposure: Pups in the injury and treatment groups are exposed to high oxygen levels (85% O₂) from postnatal day (P)1 to P21. Normoxia controls are kept in room air.
• Cell Administration: On P3, a single dose of either BM-MSCs or UC-MSCs (e.g., 1×10⁶ cells in 50 µL) is administered via intra-tracheal instillation. The placebo group receives an equal volume of vehicle solution.
• Tissue Harvesting and Analysis: On P21, lungs are harvested for histological and molecular analysis.
  • Alveolarization: Assessed by mean linear intercept (Lm) and radial alveolar count (RAC) on lung sections.
  • Inflammation: Scored by counting infiltrating immune cells (e.g., macrophages) in lung sections via immunostaining.
  • Vascular Remodeling: Quantified by measuring the thickness of the pulmonary artery walls.

Transwell Migration Assay

Purpose: To compare the migration capacity of different MSCs toward an inflammatory stimulus [90]. Methodology:

• Chemoattractant Preparation: Stimulate peripheral blood mononuclear cells (PBMCs) in a mixed lymphocyte reaction (MLR) to create a conditioned medium containing inflammatory chemokines. This is placed in the lower chamber of a transwell system.
• Cell Seeding: Serum-starve BM-MSCs and UC-MSCs, then seed them into the upper chamber of a transwell insert with a porous membrane (e.g., 8 µm pores).
• Incubation: Incubate the plates for a set period (e.g., 6-24 hours) to allow cells to migrate through the pores toward the chemoattractant in the lower chamber.
• Quantification: Non-migrated cells on the upper surface of the membrane are carefully removed with a cotton swab. Cells that have migrated to the lower surface are fixed, stained (e.g., with crystal violet), and counted under a microscope or using image analysis software.

MSC Characterization Workflow

The following diagram outlines the standard pathway for isolating and validating MSCs from bone marrow and umbilical cord tissue, based on ISCT criteria, as described across multiple experimental protocols [89] [1] [88].

The Scientist's Toolkit: Key Research Reagents

Successful isolation and characterization of MSCs require specific reagents and tools. The following table details essential solutions for these procedures.

Table 3: Essential Reagents for MSC Isolation and Characterization

Research Reagent	Function/Purpose	Example Protocol Usage
Lymphocyte Separation Medium / Percoll	Density gradient medium for isolating mononuclear cells from bone marrow aspirates.	Isolation of BM-MNCs from bone marrow [89] [1].
Collagenase Type II	Enzyme for digesting umbilical cord tissue to release stromal cells from the extracellular matrix.	Enzymatic digestion of umbilical cord tissue for UC-MSC isolation [89].
TrypLE Select / Trypsin-EDTA	Enzyme solution for detaching adherent cells from culture plastic during subculturing.	Passaging and harvesting of both BM-MSCs and UC-MSCs [89] [90].
Fetal Bovine Serum (FBS)	Critical supplement for standard cell culture media, providing growth factors and nutrients.	Standard expansion medium (e.g., αMEM + 10-20% FBS) for MSC growth [89] [90].
Flow Cytometry Antibodies (CD105, CD73, CD90, CD45, CD34, CD14, CD19, HLA-DR)	Fluorescently-labeled antibodies for detecting surface markers to confirm MSC phenotype per ISCT criteria.	Immunophenotyping of MSCs to validate identity before experiments [88] [90].
Trilineage Differentiation Kits	Pre-formulated media cocktails containing inducers for adipogenic, osteogenic, and chondrogenic differentiation.	Functional validation of MSC multipotency [94] [88].

Both BM-MSCs and UC-MSCs fulfill the ISCT criteria for MSCs and hold significant therapeutic promise. The choice between them, however, is not trivial. BM-MSCs benefit from decades of research and well-understood biology. In contrast, UC-MSCs present distinct advantages for future clinical applications, including superior proliferation, enhanced migration to inflammatory sites, and more robust performance in select disease models like lung injury, tendon repair, and heart failure. Their non-invasive sourcing and potentially lower immunogenicity further bolster their appeal for "off-the-shelf" therapies. Researchers must weigh these comparative functional potencies, alongside practical and logistical considerations, when selecting an MSC source for specific regenerative medicine applications.

The field of mesenchymal stromal cell (MSC) research requires rigorous standardization to ensure biological material and associated data collections are of appropriate quality for research and development. International standards provide the critical framework for competence, impartiality, and consistent operation of biobanks, with the International Society for Cell and Gene Therapy (ISCT) playing a pivotal role in shaping these guidelines. The rapidly growing field of MSC basic and translational research demands standardization of terminology and functional characterization to advance therapeutic development responsibly. These standards represent an evolving-but-important first step in standardizing MSC biobanking and characterization for research use, creating essential consensus on MSC identity, definition, and characterization across the global scientific community.

The collaboration between ISO and ISCT has yielded specific documentation for biobanking of MSCs from different tissue sources. ISO/TC 276 on Biotechnology, working with extensive input from ISCT, has published ISO standardization documents focused on biobanking of MSCs from two tissue sources: Wharton's Jelly (MSC(WJ)) and Bone Marrow (MSC(M)). These international-consensus documents were developed through a rigorous multi-stage process involving voting experts from numerous countries and extensive liaison with professional societies like ISCT to ensure comprehensive expert input [95].

ISO Biobanking Standards: Framework and Specifications

Core Requirements for Biobanking Competence

The ISO 20387:2018 standard establishes general requirements for biobanking, specifying fundamental requirements for the competence, impartiality, and consistent operation of biobanks. This document applies to all organizations performing biobanking of biological material from multicellular organisms and microorganisms for research and development. Crucially, it includes quality control requirements to ensure biological material and data collections are of appropriate quality, though it explicitly does not apply to biological material intended for therapeutic use, which falls under different regulatory frameworks [96].

The standard emphasizes that biobanks must establish a quality management system to ensure consistent operations and reliable results. This includes requirements for documentation control, personnel competence, internal audits, and corrective actions. For biological material collections, the standard mandates appropriate collection procedures, processing methods, storage conditions, and distribution protocols to maintain material quality and integrity throughout the biobanking lifecycle [96].

MSC-Specific Technical Specifications

The ISO standardization documents for MSCs contain both requirements and recommendations for functional characterization using a matrix of assays. For MSC(WJ), the Technical Standard ISO/TS 22859 has been established, while for MSC(M), the full ISO Standard 24651 applies. These documents are aligned with ISCT's MSC committee position and recommendations on nomenclature because there was active input and incorporation of ISCT MSC committee recommendations during their development [95].

These MSC-specific standards have a carefully defined scope and are specifically meant for research use of culture-expanded MSC(WJ) and MSC(M). The standards represent international consensus on MSC identity, definition, and characterization, and are rigorous in detailing multivariate characterization of MSCs. As living documents, they can be updated in a revision process and will be systematically reviewed after 3–5 years as scientific insights grow and evolve [95].

Table 1: Key ISO Standards Relevant to MSC Biobanking and Characterization

Standard Number	Focus Area	Scope	Status
ISO 20387:2018	Biotechnology - Biobanking - General requirements	General requirements for competence, impartiality and consistent operation of biobanks	Published (2018), Stage: To be revised
ISO/TS 22859	MSC(WJ) - Biobanking	Technical specifications for biobanking of umbilical cord tissue-derived MSCs	Published
ISO 24651	MSC(M) - Biobanking	Full standard for biobanking of bone marrow-derived MSCs	Published

ISCT Committee Perspectives and Evolving Standards

Historical Development and Nomenclature Evolution

The ISCT Mesenchymal Stromal Cell Committee has been instrumental in developing international consensus standards through close collaboration with ISO/TC 276. This partnership has been essential for helping develop and refine ISO standardization documents for biobanking and research and development of MSCs [95]. The commitment to standardization reflects the field's maturation to a point where consensus is both possible and necessary for continued advancement.

The ISCT has provided crucial leadership in standardizing MSC nomenclature, recommending the term "Mesenchymal Stromal Cells" instead of "Mesenchymal Stem Cells" unless researchers provide experimental evidence of actual stem cell properties such as self-renewal and multi-lineage differentiation potential. This terminology clarification addresses longstanding issues of reproducibility caused by naming confusion and represents a significant shift from the 2006 position statement [6]. The updated standards also no longer mandate two key identification criteria from the 2006 standard: "trilineage differentiation in vitro" and "adherence to plastic under standard conditions," acknowledging the limitations of traditional "stemness" assays in distinguishing true stem cells from more specialized stromal cell populations [6].

Implementation and Practical Application

From the ISCT perspective, the dissemination of ISO standards follows the ISO business model of providing standards that are copyrighted by ISO and available for purchase. While this copyright protection has not previously posed an undue burden on the scientific community's ability to access and implement standards, it does represent a consideration for researchers seeking to implement these guidelines [95]. The ISCT emphasizes that as voluntary standards, implementation requires commitment from the research community but is essential for advancing the field.

The ISCT also addresses limitations of the ISO Biobanking Standards, noting they are carefully limited in scope to research and development use. This intentional limitation was established after several rounds of debate and discussion, as well as comprehensive consideration of input from various stakeholders. The standards specifically exclude clinical use, which remains governed by separate regulatory frameworks [95].

MSC Characterization: Methodologies and Protocols

Flow Cytometry for MSC Identification and Validation

Flow cytometry represents the gold standard for verifying MSC identity according to ISCT criteria, requiring specific positive and negative marker profiles. The standard mandates that ≥95% of the MSC population must express CD105 (Endoglin), CD73 (5'-Nucleotidase), and CD90 (Thy1) as measured by flow cytometry. Conversely, ≤2% of the population must express hematopoietic markers CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA Class II [9] [97].

The new standards introduce stricter and more detailed requirements for surface marker detection. While CD73, CD90, and CD105 are still recognized as basic positive markers, researchers must now specify the threshold percentage for positive identification via flow cytometry. CD45 must be included as a critical negative marker to ensure the cell population isn't contaminated by hematopoietic lineages, and complete results for each marker must be reported to improve data transparency and comparability [6].

Validation of Flow Cytometry Methods

Implementing validated flow cytometry methods is essential for MSC characterization. The validation process should assess multiple parameters to ensure reliable results. According to established guidelines, including ICH Q2(R1) and ISO 15189 standards, the following validation parameters should be addressed [98]:

• Accuracy: Closeness of the measured result to the true value
• Precision: Degree of agreement among individual test results
• Linearity and Range: Ability to obtain results proportional to analyte concentration
• Sensitivity: Lowest amount of analyte that can be detected
• Robustness: Capacity to remain unaffected by small variations
• Specificity: Ability to measure the analyte in the presence of components

For flow cytometry-based methods for cell therapy products, qualification protocols should be designed based on ICH Q2(R1) guidelines, including assessment of accuracy, precision, linearity, range, specificity, robustness, and carryover with pre-defined acceptance criteria for all parameters [99].

Experimental Workflow for MSC Characterization

The following diagram illustrates the core experimental workflow for comprehensive MSC characterization aligned with international standards:

Diagram 1: MSC characterization workflow

Critical Quality Attributes and Functional Characterization

Expanding Beyond Minimal Criteria

Contemporary MSC characterization extends beyond minimal criteria to encompass Critical Quality Attributes (CQAs) that better predict therapeutic functionality. The new standards incorporate efficacy and functional characterization into CQAs, emphasizing the need to describe these attributes to define the clinical functionality of MSCs. This shift reflects the growing demand for translational research and ensures that MSC products not only meet phenotypic standards but also deliver expected therapeutic outcomes [6].

The standards also emphasize specifying the tissue origin of MSCs, acknowledging that cells from different sources may have distinct phenotypic and functional properties. With advances in single-cell omics technologies, it's theoretically possible to isolate MSCs from any tissue, but their clinical potential must be independently verified for each source [6].

Quality Control and Reporting Requirements

For quality control, the standards propose comprehensive requirements that include standardization of culture conditions with detailed reporting on medium components, passaging methods, and culture environment parameters. Enhanced safety testing for microbial contamination (bacteria, fungi, mycoplasma) is mandated, along with specific efficacy tests designed based on the intended clinical application [6].

The ISCT emphasizes that standardization in reporting of clinical trials using MSCs for autoimmune disorders is essential so readers can interpret data correctly and ensure meta-analyses are generated from comparable datasets. This provides meaningful knowledge and guidelines for professionals working in the field and supports the successful transition of MSC therapies to market, addressing significant unmet clinical needs [16].

Table 2: Comparison of MSC Characterization Standards: Evolution from 2006 to 2025

Standard Element	2006 ISCT Standard	2025 ISCT Standard
Cell Definition	Mesenchymal Stem Cells (MSCs)	Mesenchymal Stromal Cells (MSCs)
Stemness Requirement	Must demonstrate trilineage differentiation	Must provide evidence to use the term "stem"
Marker Detection	Qualitative (positive/negative)	Quantitative (thresholds and percentages)
Tissue Origin	Not emphasized	Must be specified and considered
Critical Quality Attributes	Not required	Must assess efficacy and functional properties
Culture Conditions	No standard reporting requirement	Detailed parameter reporting required

Research Reagent Solutions for Standardized MSC Characterization

Implementing international standards requires specific research reagents and materials designed for consistent, reproducible MSC characterization. The following essential materials represent core solutions for researchers aligning with ISO and ISCT guidelines:

• Flow Cytometry Antibody Panels: Comprehensive kits including CD73, CD90, CD105 positive markers and CD45, CD34, CD14, CD19, HLA-DR negative markers with appropriate isotype controls and viability dyes (e.g., 7-AAD) for standardized immunophenotyping [9] [97].

• Trilineage Differentiation Kits: Qualified differentiation media for adipogenic, osteogenic, and chondrogenic lineages with appropriate staining solutions (Oil Red O for adipocytes, Alizarin Red for osteocytes, Alcian Blue for chondrocytes) to demonstrate multipotency [97].

• Serum-Free Culture Media: Defined, xeno-free media systems that maintain MSC phenotype and functionality across multiple passages while ensuring reproducibility and reducing batch-to-batch variability for standardized expansion [6] [97].

• Cell Counting Beads: Precision counting beads (e.g., 123count eBeads) for absolute cell counting via flow cytometry, essential for quantitative assessment and standardization across laboratories [99].

• GMP-Grade Cytokines and Supplements: Manufacturing-grade reagents including IL-2, IL-15, and other cytokines for functional potency assays, ensuring consistency in critical quality attribute assessment [99].

Alignment with international ISO biobanking guidelines and ISCT committee perspectives represents a critical foundation for advancing MSC research toward reproducible, therapeutic applications. The collaboration between standardization organizations and professional societies has created a robust framework for characterizing MSCs that continues to evolve with scientific advancements. Implementation of these standards requires meticulous attention to methodological details, comprehensive reporting, and adoption of standardized reagents and protocols across the research community. As the field progresses, these international standards provide the necessary foundation for developing safe, efficacious MSC-based therapies that can address significant unmet medical needs through rigorously characterized and quality-controlled cellular products.

This case study examines the validation of a flow cytometry-based Mixed Lymphocyte Reaction (MLR) assay for assessing the immunomodulatory potency of Mesenchymal Stromal Cells (MSCs). The assay was developed and validated according to the International Council for Harmonisation (ICH) Q2(R1) guidelines, providing a robust and standardized method for quality control of MSC-based therapies. We present a comprehensive comparison with alternative potency methods, detailed experimental protocols, and key validation parameters including precision, linearity, and robustness. The validated MLR assay effectively addresses the critical need for functional potency testing that reflects the mechanism of action of MSCs, supporting their advancement in clinical applications.

The therapeutic potential of Mesenchymal Stromal Cells (MSCs) largely stems from their immunomodulatory properties, which are harnessed in clinical trials for conditions like graft-versus-host disease [100]. However, the transition of MSC therapies from research to clinical application faces a significant challenge: the lack of standardized and validated potency assays that reflect their biological activity [101]. Potency, defined as the quantitative measure of a biological product's specific ability to effect a given result, is a critical quality attribute required by regulatory agencies for product release [101].

The International Society for Cellular Therapy (ISCT) established minimal criteria for defining MSCs, including plastic adherence, specific surface marker expression (CD73, CD90, CD105), absence of hematopoietic markers, and trilineage differentiation potential [9]. While these criteria verify cell identity, they do not sufficiently address functional potency [57]. The flow cytometry-based MLR assay fills this gap by quantitatively measuring the ability of MSCs to suppress T-cell proliferation, a key immunomodulatory mechanism [100]. This case study details the validation of this potency assay according to ICH Q2(R1) standards, providing a framework for reliable quality control in MSC manufacturing.

Experimental Comparison: MLR Assay Formats and Alternatives

Flow Cytometry-Based MLR Assay

The validated flow cytometry-based MLR measures MSC-mediated inhibition of T-cell proliferation using fluorescent proliferation tracking. Peripheral Blood Mononuclear Cells (PBMCs) are labeled with cytoplasmic dyes like CellTrace Violet or VPD450. As cells divide, the dye dilutes proportionally, allowing quantification of proliferation generations via flow cytometry [100] [102]. MSCs are co-cultured with stimulated PBMCs at varying ratios, and T-cell proliferation inhibition is calculated by comparing division percentages with and without MSCs. The area under the curve of inhibition percentage versus co-culture ratios represents MSC immunosuppressive capacity [100].

Alternative Potency Assay Methods

Several alternative methods exist for assessing MSC immunomodulatory function, each with distinct advantages and limitations:

• Thymidine Incorporation Assays: Measure DNA synthesis using radioactive (³H-thymidine) or non-radioactive analogs (BrdU, EdU). These assays provide quantitative proliferation data but lack information on division kinetics and may involve hazardous materials [103].
• Metabolic Activity Assays: Utilize tetrazolium salts (MTT, XTT) that form formazan products in metabolically active cells. While simple and colorimetric, they cannot differentiate between cell types and may misinterpret toxicity as non-proliferation [103].
• Cytokine Secretion Profiling: Quantifies immunomodulatory factors (IL-2, IFN-γ) in supernatant via ELISA or multiplex arrays. This provides additional functional data but may not fully capture the complex cellular interactions [103].
• T-Cell Activation Marker Analysis: Measures surface activation markers (CD25, CD69, CD71) upregulated on stimulated T-cells using flow cytometry. This offers early activation insights but requires careful timing due to dynamic expression patterns [103] [104].

Table 1: Comparison of MSC Potency Assay Methods

Assay Method	Measured Endpoint	Advantages	Limitations
Flow Cytometry MLR	T-cell proliferation inhibition via dye dilution	Quantifies division generations, multiparametric analysis, high resolution	Requires specialized equipment, complex validation
Thymidine Incorporation	DNA synthesis during proliferation	Highly sensitive, quantitative	Radioactive hazard (³H-thymidine), no kinetic information
Metabolic Activity	Cellular metabolic rate	Simple protocol, colorimetric readout	Cannot differentiate cell types, viability-dependent
Cytokine Secretion	Cytokine production levels	Specific soluble factor measurement	May not capture full mechanism of action
Activation Markers	Surface marker expression	Early activation detection, flow cytometry compatible	Dynamic expression requires precise timing

Experimental Protocols

PBMC Preparation and Staining

PBMC Isolation and Cryopreservation:

• Collect peripheral blood from healthy donors (buffy coats) with appropriate consent [105] [106].
• Isolate PBMCs using density gradient centrifugation with LymphoPrep or similar medium [105] [106].
• Wash PBMCs twice with PBS and count viable cells using trypan blue exclusion or automated cell counters [102].
• For assay standardization, pool PBMCs from multiple donors (4-10 donors) to minimize individual immune response variability [106].
• Cryopreserve PBMCs at 1×10⁷ cells/mL in standard cryomedium (90% FBS + 10% DMSO) using controlled-rate freezing, then transfer to liquid nitrogen for long-term storage [105] [106]. PBMC banks remain stable for up to 509 days [100].

Fluorescent Labeling:

• Thaw PBMCs rapidly at 37°C and incubate for 1 hour in complete medium (RPMI-1640 + 10% FBS) for recovery [105].
• Resuspend PBMCs at 2×10⁷ cells/mL in PBS with 2.5% FBS.
• Label with CellTrace Violet (5 μM) or VPD450 for 10 minutes at 37°C with constant shaking [105] [102].
• Quench staining with 5 volumes of complete medium and wash twice [105].
• Count cells and adjust to appropriate concentration for co-culture.

MSC Preparation and Co-Culture

MSC Culture and Qualification:

• Culture MSCs under standardized conditions using human platelet lysate instead of fetal bovine serum for clinical compliance [106].
• Verify MSC identity according to ISCT criteria: ≥95% expression of CD73, CD90, CD105; ≤2% expression of CD34, CD45, CD11b, CD19, and HLA-DR [9] [107].
• For safety, mitotically inactivate MSCs using gamma irradiation (30 Gy) while maintaining immunomodulatory function [106] [102].
• Harvest MSCs using standard detachment methods and quantify viable cells before co-culture.

MLR Co-Culture Setup:

• Seed irradiated MSCs in tissue culture-treated plates at varying ratios with PBMCs (typically 1:1 to 1:0.01 MSC:PBMC) [102].
• Add 3×10⁵ labeled PBMCs per well to MSC cultures [106].
• Stimulate T-cell proliferation using:
  • Mitogenic stimulation: Anti-CD3/CD28 antibodies (0.4 μg/mL each) [102] or PHA-L (5 μg/mL) [105] [106].
  • Allogeneic stimulation: Mixed PBMCs from multiple unmatched donors to create a one-way MLR [106].
• Include controls: unstimulated PBMCs (background), stimulated PBMCs without MSCs (maximum proliferation), and MSC-only wells.
• Incubate co-cultures for 4-7 days at 37°C, 5% CO₂ [106] [102].

Flow Cytometry Analysis and Data Interpretation

Sample Harvesting and Staining:

• After incubation, harvest cells and stain with viability dye (7-AAD or similar) to exclude dead cells from analysis [106] [102].
• Add surface marker antibodies (anti-CD3-APC for T-cell identification) for 15-30 minutes at 4°C [106].
• Wash cells and resuspend in PBS for flow cytometry analysis.

Data Acquisition and Analysis:

• Acquire data using flow cytometer (Gallios, Attune NxT, or similar), collecting ≥20,000 events per sample [106] [104].
• Gate on viable, single cells, then on CD3+ T-cells [106].
• Analyze proliferation using dye dilution in the FL1/Violet channel, quantifying division index or percentage of divided cells [100].
• Calculate percentage inhibition using the formula: % Inhibition = (Control % division - Test % division) / Control % division × 100 [100].
• Generate dose-response curves using multiple MSC:PBMC ratios and calculate area under the curve for overall potency assessment [100].

Diagram 1: Experimental workflow for flow cytometry-based MLR potency assay, showing key steps from cell preparation through analysis and validation.

Validation Data and Performance Metrics

Analytical Validation Parameters

The flow cytometry-based MLR assay was systematically validated according to ICH Q2(R1) guidelines, with critical parameters summarized in Table 2 [100] [102].

Table 2: MLR Assay Validation Parameters According to ICH Q2(R1)

Validation Parameter	Experimental Design	Results	Acceptance Criteria
Precision	Repeatability (n=10) and intermediate precision (n=30 donor pairs)	Repeatability: 6.1% SD [100]Intermediate precision: <10-15% variation [102]	SD <10% for repeatabilitySD <15% for intermediate precision
Linearity & Range	Serial dilution of MSCs (PBMC:MSC ratios 1:1 to 1:0.01)	Linear range established from 1:1 to 1:0.01 ratios [102]	R² > 0.95Linearity across working range
Robustness	Testing with 3 adjacent PBMC concentrations; different PBMC donors	No statistical differences with PBMC concentration variations; low inter-donor variability [100] [102]	p > 0.05 for variationsConsistent results across donors
Specificity	Comparison with non-compendial reference method (BrdU)	Linear correlation r = 0.9021 with reference method [102]	Significant correlation with reference method
Measurement Range	Testing MSC samples with different inhibition activities	Able to differentiate MSC with varying potency levels [100]	Distinguishes high vs. low potency MSCs

Comparative Performance Data

Studies directly comparing the flow cytometry MLR with alternative methods demonstrate its superior performance characteristics:

• Donor Variability Management: Pooling PBMCs from multiple donors (4-10) significantly reduced individual response variability, with maximum proliferation achieved when combining ≥4 donors [105] [106].
• Stimulation Efficiency: Antibody-mediated CD3/CD28 stimulation and PHA produced substantial lymphocyte proliferation that was effectively inhibited by MSCs, while concanavalin A and pokeweed mitogen showed less consistent results [105].
• Assay Sensitivity: The flow cytometry method detected significant donor-dependent variation in MSC immunomodulatory capacity, with some MSCs showing potent suppression of mitogen-induced proliferation but less efficacy in allogeneic MLR settings [106].
• Impact of MSC Source: MSCs from different tissue origins (bone marrow, adipose tissue, umbilical cord) displayed varying immunosuppressive potency in the MLR assay, highlighting the importance of source characterization [106].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for Flow Cytometry-Based MLR Potency Assay

Reagent Category	Specific Examples	Function in Assay
Cell Separation	LymphoPrep, Ficoll-Paque	PBMC isolation via density gradient centrifugation [105] [106]
Fluorescent Proliferation Dyes	CellTrace Violet, VPD450, CFSE	Track cell division generations via dye dilution [100] [102]
T-Cell Stimulants	Anti-CD3/CD28 antibodies, PHA-L	Activate T-cell proliferation pathways [105] [102]
Flow Cytometry Antibodies	Anti-CD3, CD4, CD8, CD25, CD69	Identify T-cell populations and activation status [106] [103]
Viability Markers	7-AAD, Annexin V, viability dyes	Distinguish live/dead cells for accurate analysis [106] [102]
Cell Culture Media	RPMI-1640, DMEM with supplements	Maintain cell viability and function during co-culture [105] [102]
Serum Replacements	Human platelet lysate, FBS, HSA	Support cell growth while reducing xenogenic components [105] [106]

MSC Immunomodulatory Mechanisms and Signaling Pathways

MSCs employ multiple mechanisms to suppress T-cell proliferation, which are captured in the MLR potency assay [102] [104]:

Diagram 2: MSC immunomodulatory mechanisms measured in MLR potency assay, showing multiple pathways leading to T-cell suppression.

The validation of flow cytometry-based MLR according to ICH Q2(R1) guidelines provides a robust, standardized potency assay for MSC-based therapies. This method effectively addresses regulatory requirements for quantitative functional assessment that reflects the mechanism of action of MSCs. Compared to alternative methods, the flow cytometry MLR offers superior resolution of proliferation kinetics, multiparametric analysis capabilities, and robust performance metrics with precision values <15% variability. The assay demonstrates excellent linearity across relevant MSC:PBMC ratios, effectively distinguishes between MSC batches of varying potency, and shows minimal inter-bank PBMC variability when properly standardized. As MSC therapies advance through clinical development, this validated potency assay provides an essential quality control tool for ensuring consistent product quality and predicting clinical performance.

Implementing Critical Quality Attributes (CQAs) for Clinical-Grade MSC Products

For researchers and drug development professionals, the transition of Mesenchymal Stromal Cell (MSC) therapies from research to clinical application demands rigorous quality control systems. The framework of Critical Quality Attributes (CQAs)—defined as physical, chemical, biological, or microbiological properties that must be within appropriate limits to ensure desired product quality—is fundamental to this process [108]. The biological complexity and inherent variability of MSCs present unique challenges that traditional small-molecule pharmaceuticals do not face. Establishing well-defined CQAs aligned with the International Council for Harmonisation (ICH) Q8 Quality by Design (QbD) principles provides a systematic approach to ensure that MSC-based Advanced Therapy Medicinal Products (ATMPs) are safe, potent, and consistent from batch to batch [109] [110]. This guide objectively compares the implementation of CQAs against traditional methods, providing the experimental protocols and data frameworks essential for clinical translation.

Core CQAs for MSC Products: From Minimal Criteria to Clinically Relevant Attributes

The establishment of CQAs begins with the foundational criteria set by the International Society for Cell & Gene Therapy (ISCT) and expands to include attributes critically linked to clinical safety and efficacy.

Identity and Purity: Evolving Beyond Minimal Markers

Identity testing ensures the manufactured cells match the intended cell type. The ISCT's minimal criteria have historically provided a baseline, but recent updates in 2025 have refined these requirements to enhance reproducibility and clinical relevance [6].

Key Changes in MSC Identification Standards (2006 vs. 2025)

Standard Element	ISCT 2006 Standard [9]	ISCT 2025 Standard [6]
Cell Definition	Mesenchymal Stem Cells	Mesenchymal Stromal Cells (MSCs)
Stemness Requirement	Must demonstrate trilineage differentiation	Must provide evidence to use the term "stem"
Marker Detection	Qualitative (positive/negative)	Quantitative (thresholds and percentages)
Mandatory Negative Marker	Not explicitly emphasized	CD45 (to exclude hematopoietic contamination)
Tissue Origin	Not emphasized	Must be specified and considered
Critical Quality Attributes	Not formally required	Must assess efficacy and functional properties

Experimental Protocol for Identity and Purity by Flow Cytometry:

• Method: Flow Cytometry immunophenotyping [9] [108].
• Sample Preparation: Create a single-cell suspension. Use viability stains (e.g., 7-AAD) to exclude dead cells from analysis [108].
• Antibody Panel: Incubate cells with conjugated antibodies against positive markers (CD73, CD90, CD105) and negative markers (CD45, CD34, CD11b, CD19, HLA-DR) [9] [108].
• ISCT 2025 Compliance: For the 2025 standard, researchers must report complete results for each marker, including the percentage of positive cells, to improve data transparency and comparability [6].
• Gating Strategy: Acquire a minimum of 20,000 events per sample. First, gate on live, single cells based on forward and side scatter properties. Then, analyze the expression of positive and negative markers on this gated population [108].
• Acceptance Criteria: For a pure MSC population, ≥95% of cells must express CD73, CD90, and CD105, while ≤2% of cells may express the negative markers [9].

Potency: Linking Product Function to Clinical Mechanism of Action

Potency is a fundamental CQA confirming the product's biological function relevant to the intended condition. Unlike identity markers, potency assays must be tailored to the specific therapeutic mechanism of action (MoA) [108] [110].

Comparison of Potency Assays for Different Therapeutic Indications

Therapeutic Indication	Proposed MoA	Example Potency Assay	Measurable Output
Graft vs. Host Disease (GvHD)	Immunomodulation [109]	T-cell proliferation suppression assay [110]	Percentage of inhibition of T-cell growth
Neurological/Cardiovascular Diseases	Trophic factor secretion [31]	Angiogenic cytokine secretion profile [110]	Concentration of VEGF, HGF, IGF-1 via ELISA [57]
Bone/Cartilage Repair	Tissue regeneration & differentiation	Trilineage differentiation potential [9]	Quantitative analysis of calcium deposits (osteogenesis) or lipid droplets (adipogenesis)

Experimental Protocol for Trilineage Differentiation (Historical CQA):

• Osteogenic Differentiation: Culture MSCs to confluence and switch to osteo-inductive media containing dexamethasone, ascorbic acid, and β-glycerophosphate. Culture for 2-4 weeks, replacing media twice weekly. Differentiated osteoblasts can be confirmed by staining for mineralized calcium phosphate deposits with Alizarin Red S [9].
• Adipogenic Differentiation: Culture MSCs to confluence and switch to adipogenic induction media. After 2-3 weeks, intracellular lipid vacuoles can be stained with Oil Red O [9].
• Chondrogenic Differentiation: Pellet culture in chondrogenic media containing TGF-β3 for 21 days. Pellet sections can be stained for sulfated proteoglycans with Alcian Blue [9].

Limitation Note: While trilineage potential has been a cornerstone of MSC definition, the ISCT 2025 standard no longer mandates it as a universal CQA, acknowledging its limitations in predicting in vivo therapeutic function [6]. The field is shifting towards MoA-relevant potency assays.

Safety CQAs: Ensuring Patient Safety

Safety CQAs are critical and relatively standardized across cell therapy products. They ensure the product is free from harmful contaminants [108] [110].

Experimental Protocols for Key Safety CQAs:

• Sterility Testing: Per USP <71>, the product is inoculated into aerobic and anaerobic culture media and incubated for 14 days to detect bacteria and fungi [108].
• Mycoplasma Testing: Use PCR-based assays to detect this common cell culture contaminant. Mycoplasma is difficult to eliminate and often introduced via human handling [108].
• Endotoxin Testing: Use the Limulus Amebocyte Lysate (LAL) assay to ensure bacterial endotoxins are within safe limits for human administration [108].
• Viability Testing: Assess post-thaw viability using Trypan Blue exclusion or flow cytometry with 7-AAD/Annexin V staining. Viability should typically be >70% at the time of infusion [108].

The Scientist's Toolkit: Essential Reagents for CQA Assessment

Successful implementation of CQAs relies on a suite of specialized reagents and tools. The following table details key solutions required for the experiments described in this guide.

Research Reagent Solutions for MSC CQA Analysis

Reagent / Kit	Function in CQA Assessment	Application Note
Flow Cytometry Antibody Panel (CD73, CD90, CD105, CD45, CD34, HLA-DR)	Identity and Purity testing via immunophenotyping	Titrate antibodies to optimal dilution; include isotype and fluorescence-minus-one (FMO) controls [108].
Trilineage Differentiation Media Kits	Assess differentiation potential (a traditional potency attribute)	Use serum-free, defined media components for clinical-grade production to avoid variability [108] [6].
Serum-Free, Xeno-Free MSC Culture Media	Expansion of MSCs under defined conditions for CQA consistency	Essential for clinical applications to minimize serum variability and risk of xenogeneic contamination [108] [6].
ELISA Kits (e.g., for VEGF, HGF, IDO)	Quantification of secreted factors for potency assessment	Align secreted factor profile with the proposed mechanism of action for the target disease [57] [110].
Rapid Sterility Testing Systems (e.g., BacT/ALERT)	Microbiological safety testing	Provides faster results than the 14-day compendial method, enabling quicker product release [108].

Advanced Implementation: Quality by Design and Process Development

The inherent biological variability of MSCs means that "the product is the process." Consequently, controlling the manufacturing process is paramount to ensuring consistent CQAs [110].

The Role of Critical Process Parameters

Critical Process Parameters (CPPs) are process variables that directly impact CQAs. For MSC expansion, key CPPs identified in bioreactor systems include the cultivation system (bioreactor type, media composition), and physiochemical properties like pH and dissolved oxygen (DO) [109]. Modern approaches use kinetic models and statistical design of experiments to establish a "design space"—a multidimensional combination of CPPs (e.g., seeding density and harvesting time) proven to ensure that CQAs (e.g., target cell number and confluency) are met [111]. Operating within this validated design space ensures process robustness and product consistency.

Navigating Regulatory Expectations

Regulatory agencies require a clear scientific rationale linking potency measurements to the product's biological activity. The case of Mesoblast's remestemcel-L highlights this critical point. The FDA issued a Complete Response Letter requesting "further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity" [110]. This underscores the necessity of developing clinically relevant, mechanism-based potency assays early in product development.

Implementing a robust CQA framework is non-negotiable for the successful development of clinical-grade MSC products. The field is evolving from adherence to basic phenotypic criteria (ISCT 2006) toward a more nuanced, mechanism-driven approach (ISCT 2025) that prioritizes clinically relevant potency and comprehensive quality control [6]. While challenges remain—particularly in developing sensitive, predictive potency assays—the integration of QbD principles, advanced modeling for process control, and standardized reagent systems provides a clear path forward [110] [111]. For researchers and drug developers, a deep understanding of these requirements and a commitment to rigorous, data-driven CQA implementation is the key to advancing safe and effective MSC therapies from the bench to the bedside.

Conclusion

The precise validation of MSC identity through flow cytometry is a critical pillar for advancing reproducible research and successful clinical translation. The field has matured from the foundational 2006 ISCT criteria to a more nuanced framework that integrates quantitative phenotyping with mandatory functional potency assessments, as underscored by the latest 2025 perspectives. Success hinges on a holistic approach that navigates technical challenges, acknowledges cellular heterogeneity, and rigorously correlates surface marker profiles with therapeutic mechanisms. Future directions will involve deeper integration of omics technologies for biomarker discovery, the development of universally accepted reference materials, and the refinement of standardized, clinically relevant potency assays. By adhering to these evolving international standards, the scientific community can ensure the consistent quality, safety, and efficacy of MSC-based therapies, ultimately fulfilling their significant promise in regenerative medicine and the treatment of autoimmune diseases.

References

• 1. Validated methods for isolation and qualification of ... [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06972-8]
• 2. Why are MSCs called Mesenchymal Stem Cells? ... [https://www.atlantisbioscience.com/blog/why-are-mscs-called-mesenchymal-stem-cells-nomenclature-terminology-evolution/?srsltid=AfmBOoq_8Fte5PgI3i972_Jc_oNBLnSkSeDrMwF_UEsPGE4zGm9bwp4f]
• 3. Mesenchymal stem cell [https://en.wikipedia.org/wiki/Mesenchymal_stem_cell]
• 4. Mesenchymal stem cells in treating human diseases [https://www.nature.com/articles/s41392-025-02313-9]
• 5. From “stem” to “stromal”: Reframing the nomenclature of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12553919/]
• 6. MSC Renamed? From "Stem Cells" to "Stromal Cells" [https://yoconcelltherapy.com/msc-renamed-from-stem-cells-to-stromal-cells-three-major-shifts-to-note/]
• 7. Minimal criteria for defining multipotent mesenchymal ... [https://pubmed.ncbi.nlm.nih.gov/16923606/]
• 8. Committee Spotlight: Updates from the ISCT MSC Committee [https://www.isctglobal.org/telegrafthub/blogs/lauren-reville/2023/06/14/committee-spotlight-press-release-from-the]
• 9. Methods to Validate Mesenchymal Stem Cell Quality [https://www.rndsystems.com/resources/articles/markers-and-methods-verify-mesenchymal-stem-cell-identity-potency-and-quality]
• 10. Mesenchymal Stem Cell Characterization [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/imaging-analysis-and-live-cell-imaging/mesenchymal-stem-cell-characterization?srsltid=AfmBOopukn9_4I0fVDJbP02mB2Sv2tiSaLJF5whZ3SQgy-8x4CdK-FO-]
• 11. Mesenchymal Stem Cell (MSC) Markers [https://www.novusbio.com/research-areas/stem-cells/mesenchymal-stem-cell-markers?srsltid=AfmBOopwnytWbaR_nRZZw__aRxGR6JRb8J9vmxvTI3A3M9Xy1h-uB9HV]
• 12. Human Mesenchymal Stromal Cells: Identifying Assays to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3659751/]
• 13. Validation of an ICH Q2 Compliant Flow Cytometry-Based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10047294/]
• 14. Identification and validation of multiple cell surface markers of ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-016-0370-8]
• 15. Immunological characterization of multipotent ... [https://www.sciencedirect.com/science/article/abs/pii/S1465324913004118]
• 16. Defining minimal criteria for peer-reviewed reporting of ... [https://www.sciencedirect.com/science/article/pii/S1465324925007443]
• 17. Download ISCT 2025 Poster [https://www.accellix.com/isct-2025-poster/]
• 18. WHO/BS/2019.2376 Collaborative Study to assess the ... [https://www.who.int/publications/m/item/WHO-BS-2019.2376]
• 19. From the Editors — Cell Therapy Regulation in 2025 [https://www.isctglobal.org/telegrafthub/blogs/isct-head-office1/2025/10/07/from-the-editors-cell-therapy-regulation-in-2025-a]
• 20. Mesenchymal Stem Cell Characterization [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/imaging-analysis-and-live-cell-imaging/mesenchymal-stem-cell-characterization?srsltid=AfmBOorLwvSHbURY5Y0rLwGmnNIlgqcGKhJs8pacMey6CnMh3jF5d1Z8]
• 21. In Vitro Cell Surface Marker Expression on Mesenchymal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11319515/]
• 22. Cell surface markers for mesenchymal stem cells related to ... [https://www.sciencedirect.com/science/article/pii/S2405844023006710]
• 23. Guidelines for the use of flow cytometry and cell sorting in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9165548/]
• 24. Spectral Flow Cytometry: The Current State and Future of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12193525/]
• 25. Blog Post - Seeing in Full Color – Selecting the Right ... [https://www.cerbaresearch.com/article/blog-post-seeing-in-full-color-selecting-the-right-reagents-and-instrumentation-for-your-flow-cytometry-assay/]
• 26. Potency Analysis of Mesenchymal Stromal Cells Using a ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5855117/]
• 27. Pooled mesenchymal stromal cells do not reflect average ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12519293/]
• 28. Rationale for Determining the Functional Potency of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5442793/]
• 29. Potency assay to predict the anti-inflammatory capacity of a ... [https://www.sciencedirect.com/science/article/pii/S1465324924000501]
• 30. Comparison of production methods for mesenchymal stem ... [https://www.nature.com/articles/s41598-025-21218-9]
• 31. Validated methods for isolation and qualification of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12403454/]
• 32. Flow Cytometry Panel Design: The Basics [https://www.thermofisher.com/us/en/home/references/newsletters-and-journals/bioprobes-journal-of-cell-biology-applications/bioprobes-71/bioprobes-71-flow-cytometry-panel-design.html]
• 33. Guide to Flow Cytometry Panel Building [https://www.ptglab.com/news/blog/guide-to-flow-cytometry-panel-building/?srsltid=AfmBOop_LRmHZZmbQlZIt2eiPuLtZaKhF_qNLAVPFJIBQhyrdxNFQR1T]
• 34. Traditional Flow Cytometry Panel Design - UChicago Voices [https://voices.uchicago.edu/ucflow/project/traditional-panel-design/]
• 35. Flow cytometry data standards - PMC - PubMed Central [https://pmc.ncbi.nlm.nih.gov/articles/PMC3060130/]
• 36. Flow Cytometry Sample Preparation: Best Practices [https://kcasbio.com/blogs/sample-preparation-for-flow-cytometry-best-practices/]
• 37. Mesenchymal Stem Cell (MSC) Markers [https://www.novusbio.com/research-areas/stem-cells/mesenchymal-stem-cell-markers?srsltid=AfmBOoqclt7H_tNDZk4ufZyliMy3Yel8FSyGzqPKQUHE7ehdLJILzCDe]
• 38. Flow cytometric characterization of cell surface markers to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10507789/]
• 39. Mechanical conditioning of human mesenchymal stem ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9929623/]
• 40. How to Interpret Flow Cytometry Data [https://www.fortislife.com/resources/antibody-resources/how-to-interpret-flow-cytometry-data]
• 41. Advanced flow cytometry data analysis ... [https://www.flowjo.com/advanced_analysis.html]
• 42. 7 tools to take your flow cytometry data visualizations to the ... [https://blog.ganymede.bio/seven-tools-for-flow-cytometry-data-visualization/]
• 43. Comprehensive Guide to Gating Strategies in Flow Cytometry [https://www.bosterbio.com/blog/post/comprehensive-guide-to-gating-strategies-in-flow-cytometry?srsltid=AfmBOooZyZM0ExEw8XlR2zQmWwE44E8gX0IztRQAeTwVlxZfV5sc638c]
• 44. Isolation of a circulating CD45−, CD34dim cell population ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4988526/]
• 45. Flow Cytometric Determination of Circulating Progenitor Cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11925724/]
• 46. Identification of circulating CD31+CD45+ cell populations with ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02311-y]
• 47. Flow cytometric identification of a minority population ... [https://pubmed.ncbi.nlm.nih.gov/7488603/]
• 48. Mesenchymal Stem Cell Characterization [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/imaging-analysis-and-live-cell-imaging/mesenchymal-stem-cell-characterization?srsltid=AfmBOoq74Hq-6z44kfd-YcU-bxNzm3JlJNQRC-DDQf7AU5gDJ-hOu45_]
• 49. Unveiling distinctions between mesenchymal stromal cells ... [https://www.sciencedirect.com/science/article/pii/S2405844025006917]
• 50. Quantitative Approaches to Detect Donor and Passage ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3483050/]
• 51. A flow cytometric assay for the quantification of MSC lysis ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7856420/]
• 52. Ask an Expert [https://www.cytometry.org/web/q_view.php?id=112&filter=General]
• 53. Quantitative proteomic characterization of lung-MSC and ... [https://www.nature.com/articles/s41598-017-09127-y]
• 54. Flow cytometric assays for identity, safety and potency of ... [https://pubmed.ncbi.nlm.nih.gov/30240161/]
• 55. Flow Cytometry Analysis of Mesenchymal Stem Cells [https://pmc.ncbi.nlm.nih.gov/articles/PMC12118590/]
• 56. Analysis of the measurements used as potency tests for the 31 ... [https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-025-06253-4]
• 57. Establishing Criteria for Human Mesenchymal Stem Cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5363381/]
• 58. Donor age and breed determine mesenchymal stromal cell ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04236-2]
• 59. Proteomic Study Revealed a Distinction Between Human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12408728/]
• 60. Flow cytometric characterization of cell surface markers to ... [https://www.archivesofmedicalscience.com/Flow-cytometric-characterization-of-cell-surface-markers-to-differentiate-between,131088,0,2.html]
• 61. The Impact of IFN-γ Licensing on Mesenchymal Stromal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12525040/]
• 62. Concise Review: Evidence for CD34 as a Common Marker ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4260088/]
• 63. Is CD34 Truly a Negative Marker for Mesenchymal Stem ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3846603/]
• 64. Transduction of the IFN-gamma signal for HLA-DR ... [https://pubmed.ncbi.nlm.nih.gov/1934072/]
• 65. Dysregulation of the expression of HLA-DR, costimulatory ... [https://www.sciencedirect.com/science/article/abs/pii/S156757691830540X]
• 66. Optimizing an immunomodulatory potency assay for ... [https://pubmed.ncbi.nlm.nih.gov/36578497/]
• 67. Optimizing an immunomodulatory potency assay for ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1085312/full]
• 68. Validation of a flow cytometry-based method to quantify ... [https://pubmed.ncbi.nlm.nih.gov/32718876/]
• 69. Functional characterization of the immunomodulatory ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8511544/]
• 70. Immunophenotype and Immune-Modulatory Activities of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6719489/]
• 71. Assay validation for the assessment of adipogenesis of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3539160/]
• 72. A novel direct co-culture assay analyzed by multicolor flow ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218949]
• 73. Data analysis in flow cytometry [https://www.abcam.com/en-us/technical-resources/guides/flow-cytometry-guide/data-analysis-in-flow-cytometry]
• 74. Ten Tips for Successful Flow Cytometry [https://www.biotechniques.com/cell-and-tissue-biology/how-to-10-tips-for-successful-flow-cytometry/]
• 75. Mesenchymal Stem Cell Senescence during Aging:From ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10529739/]
• 76. Long-term culture of mesenchymal stem cells impairs ATM ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6664790/]
• 77. Long-term culture of mesenchymal stem cells impairs ATM ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-019-1334-6]
• 78. Mesenchymal Stem Cell Senescence and Rejuvenation [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00364/full]
• 79. Mesenchymal Stem Cell Characterization [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/imaging-analysis-and-live-cell-imaging/mesenchymal-stem-cell-characterization?srsltid=AfmBOooYbbZ-PO6VkqzxTjOPVoBSoUsAw0sn5Uj7paLicBzMncdp8cR5]
• 80. Determination and validation of design space for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12062477/]
• 81. Preventing MSC aging and enhancing immunomodulation [https://www.sciencedirect.com/science/article/pii/S2352320425000902]
• 82. Machine learning to predict mesenchymal stem cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7571701/]
• 83. Mesenchymal Stem Cell Characterization [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/imaging-analysis-and-live-cell-imaging/mesenchymal-stem-cell-characterization?srsltid=AfmBOopE2UTpLFAyrbaaRMYsq1M9kOTRz3mDCD9Y0IdNbeRiw0Nl9CH7]
• 84. In vitro-In vivo Correlation: Perspectives on Model Development [https://pmc.ncbi.nlm.nih.gov/articles/PMC3099258/]
• 85. CMC Perspectives of In Vitro / In Vivo Correlation (IVIVC) ... [https://premier-research.com/perspectives/cmc-perspectives-of-in-vitro-in-vivo-correlation-ivivc-in-drug-development/]
• 86. In vitro-in vivo correlation (IVIVC) population modeling for ... [https://www.page-meeting.org/default.asp?abstract=8581]
• 87. versus stromal Mesenchymal : International Society for stem ... cells Cell [https://pubmed.ncbi.nlm.nih.gov/31526643/]
• 88. Mesenchymal Stem Cell Characterization [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/imaging-analysis-and-live-cell-imaging/mesenchymal-stem-cell-characterization?srsltid=AfmBOopeH0bK1EweXGdeLnZVwwYsjA-K19PnBmBS0hAaSy4Vm3QU0XvK]
• 89. Comparative Effects of Bone Marrow-derived Versus ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8929420/]
• 90. Superior migration ability of umbilical cord-derived ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2024.1329218/full]
• 91. Umbilical cord mesenchymal stem cells vs bone marrow ... [https://pubmed.ncbi.nlm.nih.gov/39734819/]
• 92. Mesenchymal Stem Cell Review: Research and Future ... [https://saieyecarecentre.com/mesenchymal-stem-cell-review-2025-latest-research-uses-and-future-directions/]
• 93. Comparison of mesenchymal stem cells from bone marrow, ... [https://www.sciencedirect.com/science/article/pii/S2405580823000675]
• 94. Comparative analysis of mesenchymal stem cells derived from ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-1104-x]
• 95. An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone marrow-MSCs and umbilical cord tissue–derived MSCs for research purposes - ScienceDirect [https://www.sciencedirect.com/science/article/abs/pii/S1465324923001007]
• 96. ISO 20387:2018 - Biotechnology — Biobanking — General requirements for biobanking [https://www.iso.org/standard/67888.html]
• 97. Mesenchymal Stem Cell Characterization [https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/cell-culture-and-cell-culture-analysis/imaging-analysis-and-live-cell-imaging/mesenchymal-stem-cell-characterization]
• 98. Validation of a flow cytometry-based method to quantify ... [https://www.sciencedirect.com/science/article/abs/pii/S1465324920307817]
• 99. Qualification of a flow cytometry-based method for the ... - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10830575/]
• 100. validation of mixed lymphocyte reaction assay using flow ... [https://pubmed.ncbi.nlm.nih.gov/33004063/]
• 101. Potency testing of cell and gene therapy products - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10196484/]
• 102. Validation of an ICH Q2 Compliant Flow Cytometry-Based ... [https://www.mdpi.com/2073-4409/12/6/850]
• 103. Mixed Lymphocyte Reaction Readouts [https://xenodiagnostics.com/mixed-lymphocyte-reaction-readouts/]
• 104. Mixed Lymphocyte Reaction (MLR) Analysis by Flow ... [https://www.marinbio.com/mixed-lymphocyte-reaction-mlr-analysis-by-flow-cytometry-a-high-resolution-assay-for-immunogenicity-testing-and-drug-development/]
• 105. Optimizing an immunomodulatory potency assay for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9791065/]
• 106. A robust potency assay highlights significant donor variation of ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-015-0233-8]
• 107. Mesenchymal Stem Cell (MSC) Markers [https://www.novusbio.com/research-areas/stem-cells/mesenchymal-stem-cell-markers?srsltid=AfmBOoo7I5a5musSkR6y6PGSqygKNH8WL1tJPh3WBpKBmHC6oPjJ_-aL]
• 108. Understanding Critical Quality Attributes (CQAs) in T-Cell ... [https://www.atlantisbioscience.com/blog/understanding-critical-quality-attributes-cqas-in-t-cell-and-msc-therapy/?srsltid=AfmBOorXmPqVCWitIUAFCk_D5XUnHlcqtQPo6KvEHo2ndWQ_eQXUCw-4]
• 109. Identification of critical process parameters and quality ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12408662/]
• 110. Critical Quality Attributes (CQAs): Know Their Importance & ... [https://www.roosterbio.com/blog/critical-quality-attributes-cqas-know-their-importance-limitations-in-product-process-development/]
• 111. Determination and validation of design space for ... [https://www.nature.com/articles/s42003-025-08063-2]